
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="utf-8"?-->


     <title></title>
<meta http-equiv="Content-Type" content="text/html">

<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_MAAQ_manacapital.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20210519_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001870144 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->

<div style="display: none">
<ix:header>
 <ix:hidden>
  <span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityCentralIndexKey" inside-table="false" id="fact-identifier-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001870144</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag" inside-table="false" id="fact-identifier-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:DocumentFiscalYearFocus" inside-table="false" id="fact-identifier-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:DocumentFiscalPeriodFocus" inside-table="false" id="fact-identifier-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0089" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0129" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0141" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0142" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0143" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0144" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0145" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0147" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0149" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0151" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0154" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0159" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0162" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0167" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0168" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0170" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0173" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0175" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0176" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0178" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0181" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0182" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0184" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0187" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0190" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0195" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0198" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0201" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0202" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0203" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0204" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0205" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0209" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0210" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0212" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0215" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0218" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0223" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0224" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0225" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0229" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0235" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0281" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0538" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0546" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0573" unitref="USD" xs:nil="true"></ix:nonfraction>
  </ix:hidden>
 <ix:references>
  <link:schemaref xlink:href="maaq-20211231.xsd" xlink:type="simple">
  </link:schemaref></ix:references>
 <ix:resources>
    <xbrli:context id="From2021-05-19to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_custom_UnitsEachConsistingOfOneShareOfCommonStockParValue0.00001Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">MAAQ:UnitsEachConsistingOfOneShareOfCommonStockParValue0.00001Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_custom_CommonStockParValue0.00001Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">MAAQ:CommonStockParValue0.00001Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">MAAQ:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_custom_RightsEachToReceiveOneseventh17OfOneShareOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">MAAQ:RightsEachToReceiveOneseventh17OfOneShareOfCommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-18_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-18_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-18_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-18_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-26_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-26</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-26_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-26_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-26</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-26_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_custom_UnderwritingAgreementMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TransactionTypeAxis">MAAQ:UnderwritingAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_custom_UnderwritingAgreementMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TransactionTypeAxis">MAAQ:UnderwritingAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-26_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-26</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember1582076484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-22_custom_FounderSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">MAAQ:FounderSharesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-06-01</xbrli:startdate>
        <xbrli:enddate>2021-06-22</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30_custom_FounderSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">MAAQ:FounderSharesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-09-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_custom_FounderSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">MAAQ:FounderSharesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_FounderSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">MAAQ:FounderSharesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_custom_FounderSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">MAAQ:FounderSharesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-11_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">MAAQ:SponsorMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TransactionTypeAxis">MAAQ:UnderwritingAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_us-gaap_IPOMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_custom_PublicWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">MAAQ:PublicWarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_custom_PrivateWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">MAAQ:PrivateWarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_custom_RedeemableCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">MAAQ:RedeemableCommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-192021-12-31_custom_NonRedeemableCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001870144</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">MAAQ:NonRedeemableCommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-19</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitnumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitnumerator>
        <xbrli:unitdenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitdenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 5pt Times New Roman, Times, Serif; margin: 0; text-indent: 302pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_900_edei--DocumentType_c20210519__20211231_zukVcTGq9TT2"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:DocumentType" inside-table="false" id="fact-identifier-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Mark One)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--DocumentAnnualReport_c20210519__20211231_zYH674LiLTUj"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport" inside-table="false" id="fact-identifier-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></span>
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the fiscal year ended <span id="xdx_90A_edei--DocumentPeriodEndDate_c20210519__20211231_zErzkDFEZWvh"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" inside-table="false" id="fact-identifier-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span id="xdx_907_edei--CurrentFiscalYearEndDate_c20210519__20211231_zPYd3pPPNnIc"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" inside-table="false" id="fact-identifier-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December 31</ix:nonnumeric></span></span>, 2021</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--DocumentTransitionReport_c20210519__20211231_zpAqjOAqUWxj"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" inside-table="false" id="fact-identifier-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></span>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the transition period from <span style="text-decoration: underline">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;to
<span style="text-decoration: underline">	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Commission File No. <span id="xdx_905_edei--EntityFileNumber_c20210519__20211231_zkLj5tod7WZi"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityFileNumber" inside-table="false" id="fact-identifier-9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">001-41097</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityRegistrantName_c20210519__20211231_zF3cOUIfY1L"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityRegistrantName" inside-table="false" id="fact-identifier-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">MANA CAPITAL ACQUISITION CORP.</ix:nonnumeric></span></span></span></b></p>

<p style="font: 5pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 52%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20210519__20211231_zp9NrtjcEWsg"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" inside-table="true" id="fact-identifier-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Delaware</ix:nonnumeric></span></span></b></span></td>
    <td style="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 46%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20210519__20211231_zcOePfjjt8O2"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityTaxIdentificationNumber" inside-table="true" id="fact-identifier-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87-0925574</ix:nonnumeric></span></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.45pt; padding-right: 5.75pt; padding-left: 5.75pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">State or Other Jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Incorporation or Organization</p></td>
    <td style="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-top: 1.45pt; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><span style="font-size: 10pt">I.R.S. Employer Identification No.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20210519__20211231_zdzpsQsFsbfg"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityAddressAddressLine1" inside-table="true" id="fact-identifier-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8 The Green</ix:nonnumeric></span></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20210519__20211231_zLj09kKJc3Rl"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityAddressAddressLine2" inside-table="true" id="fact-identifier-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Suite 12490</ix:nonnumeric></span></span>, <span id="xdx_909_edei--EntityAddressCityOrTown_c20210519__20211231_z0zp4dPxHSEg"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityAddressCityOrTown" inside-table="true" id="fact-identifier-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Dover</ix:nonnumeric></span></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20210519__20211231_zlnMT4jSNjdg"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" inside-table="true" id="fact-identifier-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Delaware</ix:nonnumeric></span></span></b></span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressPostalZipCode_c20210519__20211231_zPHxJE4bZqE5"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityAddressPostalZipCode" inside-table="true" id="fact-identifier-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19901</ix:nonnumeric></span></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.45pt; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><span style="font-size: 10pt">Address of Principal Executive Offices</span></td>
    <td style="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-top: 1.45pt; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><span style="font-size: 10pt">Zip Code</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-decoration: underline">Issuer’s telephone number, including area
code (<span id="xdx_903_edei--CityAreaCode_c20210519__20211231_zKJYnrdQmyAg"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:CityAreaCode" inside-table="false" id="fact-identifier-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">302</ix:nonnumeric></span></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20210519__20211231_z8XGz1caBskk"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:LocalPhoneNumber" inside-table="false" id="fact-identifier-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">281-2147</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(b) of
the Exchange Act</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 45%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 21%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%; text-align: center">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 31%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--UnitsEachConsistingOfOneShareOfCommonStockParValue0.00001Member_zeJq24J5sUrj"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_UnitsEachConsistingOfOneShareOfCommonStockParValue0.00001Member" name="dei:Security12bTitle" inside-table="true" id="fact-identifier-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Units, each consisting of one share of common stock, par value $0.00001,</ix:nonnumeric></span></span><br>
one-half of one redeemable warrant and one right to acquire 1/7<sup>th</sup>&nbsp;of one share of common stock</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--UnitsEachConsistingOfOneShareOfCommonStockParValue0.00001Member_z9wBYNjN0Bwb"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_UnitsEachConsistingOfOneShareOfCommonStockParValue0.00001Member" name="dei:TradingSymbol" inside-table="true" id="fact-identifier-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">MAAQU</ix:nonnumeric></span></span></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">The <span id="xdx_903_edei--SecurityExchangeName_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--UnitsEachConsistingOfOneShareOfCommonStockParValue0.00001Member_zvK6IuU11yZ9"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_UnitsEachConsistingOfOneShareOfCommonStockParValue0.00001Member" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" inside-table="true" id="fact-identifier-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nasdaq</ix:nonnumeric></span></span> Stock Market LLC</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_edei--Security12bTitle_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.00001Member_z86JQvRbe1oc"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_CommonStockParValue0.00001Member" name="dei:Security12bTitle" inside-table="true" id="fact-identifier-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common Stock, par value $0.00001</ix:nonnumeric></span></span></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.00001Member_zf4ncTbe2tm7"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_CommonStockParValue0.00001Member" name="dei:TradingSymbol" inside-table="true" id="fact-identifier-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">MAAQ</ix:nonnumeric></span></span></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">The <span id="xdx_909_edei--SecurityExchangeName_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.00001Member_zKW1ckQIbmr8"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_CommonStockParValue0.00001Member" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" inside-table="true" id="fact-identifier-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nasdaq</ix:nonnumeric></span></span> Stock Market LLC</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember_zuHo1bAZr8gc"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember" name="dei:Security12bTitle" inside-table="true" id="fact-identifier-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Redeemable warrants, each whole warrant exercisable for one share of common stock</ix:nonnumeric></span></span></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember_zsZH6yK3tgok"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember" name="dei:TradingSymbol" inside-table="true" id="fact-identifier-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">MAAQW</ix:nonnumeric></span></span></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">The <span id="xdx_90B_edei--SecurityExchangeName_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember_zN9Ye0rouATc"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" inside-table="true" id="fact-identifier-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nasdaq</ix:nonnumeric></span></span> Stock Market LLC</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--RightsEachToReceiveOneseventh17OfOneShareOfCommonStockMember_zVI8rjbTQjlf"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_RightsEachToReceiveOneseventh17OfOneShareOfCommonStockMember" name="dei:Security12bTitle" inside-table="true" id="fact-identifier-29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Rights, each to receive one-seventh (1/7) of one share of common stock</ix:nonnumeric></span></span></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--RightsEachToReceiveOneseventh17OfOneShareOfCommonStockMember_zu7XFClo77B9"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_RightsEachToReceiveOneseventh17OfOneShareOfCommonStockMember" name="dei:TradingSymbol" inside-table="true" id="fact-identifier-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">MAAQR</ix:nonnumeric></span></span></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">The <span id="xdx_90D_edei--SecurityExchangeName_c20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--RightsEachToReceiveOneseventh17OfOneShareOfCommonStockMember_zK1YQ8qgjKmk"><span><ix:nonnumeric contextref="From2021-05-192021-12-31_custom_RightsEachToReceiveOneseventh17OfOneShareOfCommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" inside-table="true" id="fact-identifier-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nasdaq</ix:nonnumeric></span></span> Stock Market LLC</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(g) of
the Securities Exchange Act: NONE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;Yes&nbsp;&nbsp;☐&nbsp;&nbsp;<span id="xdx_90A_edei--EntityWellKnownSeasonedIssuer_c20210519__20211231_zewoFyc5dHOg"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" id="fact-identifier-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span>&nbsp;&nbsp;☒</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is not required
to file reports pursuant to Section 13 or 15 (d) of the Securities Exchange Act.&nbsp;Yes&nbsp;&nbsp;<span style="font-family: Times New Roman, Times, Serif">☐</span>&nbsp;&nbsp;<span id="xdx_905_edei--EntityVoluntaryFilers_c20210519__20211231_zNhEEtmbJzm6"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityVoluntaryFilers" inside-table="false" id="fact-identifier-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span>&nbsp;&nbsp;<span style="font-family: Times New Roman, Times, Serif">☒</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.&nbsp;<span id="xdx_90D_edei--EntityCurrentReportingStatus_c20210519__20211231_z7K0gKV2KSoi"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityCurrentReportingStatus" inside-table="false" id="fact-identifier-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span>&nbsp;<span style="font-family: Times New Roman, Times, Serif">☒</span> &nbsp;No&nbsp;<span style="font-family: Times New Roman, Times, Serif">☐</span>&nbsp;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;<span id="xdx_907_edei--EntityInteractiveDataCurrent_c20210519__20211231_z3qfV3bYjKAj"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:EntityInteractiveDataCurrent" inside-table="false" id="fact-identifier-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span>&nbsp;<span style="font-family: Times New Roman, Times, Serif">☒</span> &nbsp;No&nbsp;<span style="font-family: Times New Roman, Times, Serif">☐</span>&nbsp;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 4pt 0 6pt; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="width: 52%; padding-top: 4pt; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">Large&nbsp;accelerated&nbsp;filer&nbsp;☐</span></td>
    <td style="vertical-align: top; width: 48%; padding-top: 4pt; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">Accelerated&nbsp;filer&nbsp;☐</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 4pt; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><span id="xdx_90E_edei--EntityFilerCategory_c20210519__20211231_z8CmdcweZgh1"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" inside-table="true" id="fact-identifier-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span></span>&nbsp;<span style="font-family: Times New Roman, Times, Serif">☒</span></span></td>
    <td style="padding-top: 4pt; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">Smaller&nbsp;reporting&nbsp;company&nbsp;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--EntitySmallBusiness_c20210519__20211231_z9MtikllG2wc"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" inside-table="true" id="fact-identifier-37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 4pt; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding-top: 4pt; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">Emerging growth company&nbsp;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20210519__20211231_zjWfPctYzI8d"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" inside-table="true" id="fact-identifier-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></span></span></td></tr>
  </tbody></table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--EntityExTransitionPeriod_c20210519__20211231_z6FAmBzrnL75"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod" inside-table="false" id="fact-identifier-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report.&nbsp;&nbsp;<span style="font-family: Times New Roman, Times, Serif">☐</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule&nbsp;12b-2 of the Act).&nbsp;&nbsp;<span id="xdx_902_edei--EntityShellCompany_c20210519__20211231_zlMFxt9rWBa2"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" format="ixt:booleantrue" name="dei:EntityShellCompany" inside-table="false" id="fact-identifier-40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span>&nbsp;<span style="font-family: Times New Roman, Times, Serif">☒</span> &nbsp;No&nbsp;<span style="font-family: Times New Roman, Times, Serif">☐&nbsp;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: justify">The registrant was not a public company at June
30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter, and therefore it cannot calculate
the aggregate market value of its voting and non-voting common equity held by non-affiliates at such date. The registrant’s units
began trading on The Nasdaq Global Market on November 23, 2021 and the registrant’s common stock began separate trading on the Nasdaq
Capital Market on January 14, 2022. The aggregate market value of the registrant’s common stock outstanding, other than shares held
by persons who may be deemed affiliates of the registrant, at January 14, 2022, computed by reference to the closing price for the common
stock on such date, as reported on the Nasdaq Global Market, was $<span id="xdx_906_edei--EntityPublicFloat_iI_c20210630_z9lDXhNAn8Vb"><span><ix:nonfraction name="dei:EntityPublicFloat" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63,830,000</ix:nonfraction></span></span>.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 30, 2022, there were <span id="xdx_904_edei--EntityCommonStockSharesOutstanding_iI_c20220330_zaDOnRbmuE1b"><span><ix:nonfraction name="dei:EntityCommonStockSharesOutstanding" contextref="AsOf2022-03-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,125,000</ix:nonfraction></span></span> shares of
common stock, par value $0.00001 issued and outstanding.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Documents Incorporated by Reference: None.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 1pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b><span style="text-decoration: underline">TABLE OF CONTENTS</span></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">PART 1</td>
    <td style="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 5pt">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 1. Business</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 1A. Risk Factors</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">11</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 1B. Unresolved Staff Comments</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 2. Properties</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 3. Legal Proceedings</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 4. Mine Safety Disclosures</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">PART II</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 5.&nbsp; Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 6. Reserved</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">55</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">55</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 8. Financial Statements and Supplemental Data</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 9A. Controls and Procedures Evaluation of Disclosure Controls and Procedures</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 9B.&nbsp; Other Information.</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 9C.&nbsp; Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">PART III</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item&nbsp;10.&nbsp;&nbsp; Directors, Executive Officers and Corporate Governance.</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item&nbsp;11.&nbsp; Executive Compensation.</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item&nbsp;13. Certain Relationships, and Related Transactions and Director Independence</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item&nbsp;14.&nbsp; Principal Accounting Fees and Services.</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">PART IV</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 15. Exhibits, Financial Statement Schedules.</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 12pt">Item 16. Form 10-K Summary</td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt">76</td></tr>
</tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORWARD LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form 10-K
contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, or the “Securities Act,”
and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. The statements contained in this report that are not purely
historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our or
our management’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer
to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking
statements. The words “anticipates,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,”
“predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking
statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Form
10-K may include, for example, statements about our:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to select an appropriate target business or businesses;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">ability to complete our initial business combination;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense reimbursements;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potential ability to obtain additional financing to complete a business combination;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pool of prospective target businesses;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">ability of our officers and directors to generate a number of potential investment opportunities;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potential change in control if we acquire one or more target businesses for shares;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">public securities’ potential liquidity and trading;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the lack of a market for our securities;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expectations regarding the time during which we will be an “emerging growth company” under the JOBS Act;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">use of proceeds not held in the trust account or available to us from interest income on the trust account balance; or</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">financial performance following our IPO.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The forward-looking statements
contained in this Form 10-K are based on our current expectations and beliefs concerning future developments and their potential effects
on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements
involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or
performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these
risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from
those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except as may be required under applicable securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Part 1</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 1. Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>References in this report to “we,”
“us” or the “Company” refer to Mana Capital Acquisition Corp. References to our “management” or our
“management team” refer to our officers and directors, and references to the “Sponsor” refer to Mana Capital LLC,
a Delaware limited liability company.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Company Profile</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Mana Capital Acquisition Corp. was formed on May 19,
2021 formed under the laws of the State of Delaware, as a blank check company for the purpose of engaging in a merger, share exchange,
asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination, with one or more target businesses
or entities. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region,
although we intend to focus <span style="font-family: Times New Roman PS Std,serif">our search on target businesses operating in North
America, Europe and Asia in the healthcare, technology, green economy, and consumer products sectors.</span> We believe that we will add
value to these businesses primarily by providing them with access to the U.S. capital markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our Registration Statement on Form S-1 was declared
effective by the SEC on November 22, 2021. Ladenburg Thalmann &amp; Co., Inc., acted as lead bookrunner for our initial public offering.
We may refer to our initial public offering in this Annual Report on Form 10-K as our “IPO”. On November 26, 2021, we consummated
our initial public offering of 6,200,000 units. Each unit consists of one share of common stock, par value $0.00001 per share, one-half
of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one share of common stock for $11.50 per share,
subject to adjustment, and one right to receive one-seventh (1/7) of one share of common stock upon the consummation of our initial business
combination. The units were sold at a price of $10.00 per unit, generating gross proceeds to us of $62,000,000. <span style="background-color: white">In
connection with our initial public offering, the underwriters were granted a&nbsp;45-day&nbsp;option to purchase up to 930,000 additional
units to cover over-allotments, if any. On November 30, 2021, the underwriters purchased an additional 300,000 units pursuant to the partial
exercise of the over-allotment option. The additional units were sold at an offering price of $10.00 per unit, generating additional gross
proceeds of $3,000,000.</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Simultaneously with the consummation of the initial
public offering, we completed the private sale of an aggregate of 2,500,000 private warrants to our Sponsor at a purchase price of $1.00
per private warrant, generating gross proceeds to the Company of $2,500,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">A
total of $65,000,000 of the proceeds from the sale of the units and private placement warrants, including the sale of the units from the
partial exercise of the over-allotment option, were placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A., with Continental
Stock Transfer&nbsp;&amp; Trust Company acting as trustee.&nbsp; </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On June 22, 2021, the Sponsor purchased 1,437,500 shares
of our common stock, or founder shares, for $25,000. Subsequently, in September 2021, we amended and restated the subscription agreement
(the “First Amended and Restated Subscription Agreement”) and issued the Sponsor an additional 62,500 shares so that it would
hold an aggregate of 20% of our outstanding common stock after our initial public offering. In November 2021, we entered into a second
amendment and restatement of the subscription agreement with the Sponsor (the “Second Amended and Restated Subscription Agreement”)
pursuant to which we issued it an additional 50,000 shares of Common Stock (so that the Sponsor would hold 20% of our issued and outstanding
shares of common stock after the initial public offering. Further, we agreed that if the underwriters exercise the over-allotment option,
we will issue the Sponsor such number of additional shares of common stock (up to 232,500 shares)&nbsp;so as to enable it to maintain
its ownership of 20% of our issued and outstanding shares of common stock. In connection with the partial exercise by the underwriters
of the over-allotment option, on November 30, 2021, we issued an additional 75,000 shares to the Sponsor pursuant to the Second Amended
and Restated Subscription Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a result of the IPO and the private placement, and
assuming all of the units separate into their component parts, we had: (i) 6,500,000 units, (ii) 8,125,000 shares of common stock, (iii)
6,500,000 rights to acquire an aggregate of 928,571 shares of common stock; and (iv) 5,750,000 whole warrants to acquire 5,750,000 shares
of common stock issued and outstanding as of November 30, 2021. We have not issued any securities since such date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prior to the IPO, there had been no public market for
our units, shares of common stock, rights or warrants. Our units, are listed for trading on the Nasdaq Global Market, or Nasdaq, under
the symbol “MAAQU”. The shares of common stock, rights and warrants comprising the units began separate trading on January
14, 2022 and are traded on Nasdaq under the symbols “MAAQ,” “MAAQR” and “MAAQW,” respectively. As
our IPO registration statement and Form 8A were not declared effective by the SEC until November 22, 2021, we were not a filing company
under the Securities and exchange Act of 1934, as amended until such date.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="background-color: white">A total of $65,000,000
of the proceeds from the sale of the units and private placement warrants, including the sale of the units from the partial exercise of
the over-allotment option, were placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer&nbsp;&amp;
Trust Company acting as trustee.&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of December 31, 2021, there was $65,000,484 in investments
and cash held in the trust account, which includes interest income available to us for franchise tax obligations of approximately $484
and $526,625 of cash held outside the trust account. As of December 31, 2021, we have not withdrawn any interest earned from the trust
account to pay taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The funds held in trust has been invested only in United
States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 180
days or less, or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest
only in direct U.S. government treasury obligations, so that we are not deemed to be an investment company under the Investment Company
Act. Except with respect to interest earned on the funds held in the trust account that may be released to us to pay our income or other
tax obligations, the proceeds will not be released from the trust account until the earlier of the completion of a business combination
or our redemption of 100% of the outstanding public shares if we have not completed a business combination in the required time period.
The proceeds held in the trust account may be used as consideration to pay the sellers of a target business with which we complete a business
combination. Any amounts not paid as consideration to the sellers of the target business may be used to finance operations of the target
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Since our IPO, our sole business activity has been
identifying and evaluating suitable acquisition transaction candidates and engaging in non-binding discussions with potential target entities.
To date we have not entered into any binding agreement with any target entity. We presently have no revenue and have had losses since
inception from incurring formation and operating costs since completion of our IPO.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>Management Business Combination Experience</b></p>

<p style="font: 12pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt"><span style="font-size: 10pt">Our management team
is led by Jonathan Intrater, Allan Liu and Loren Mortman; each has distinctive and complementary experience and extensive networks in
the healthcare</span><span style="font-size: 9pt">,</span><span style="font-size: 11pt">&nbsp;</span><span style="font-size: 10pt">technology,
green economy and consumer products sectors as well as various other industries in North America, Europe, and Asia which we believe can
provide a suitable selection of potential targets. We intend to focus on targeting middle market entities with a valuation in the $150
million to $500 million range.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"><span style="font-family: Times New Roman PS Std,serif">We
believe that our management team is well positioned to identify attractive business combination opportunities with compelling characteristics
and further potential. Members of our management team have extensive experience in executing business combinations, as they are long-term
advisors to buyers and sellers in mergers and acquisitions, private equity investors, or buy and sell-side investment bankers. Jonathan
Intrater, our Chief Executive Officer, is a Managing Director in the investment banking department at Ladenburg, Thalmann and has extensive
experience in merger advisory and public offerings. He also served as a member of the Board and Chairman of the audit committee of GreenVision
Acquisition Corp., a Nasdaq Capital Market-listed special purpose acquisition company that completed its initial business combination
in August 2021. Allan Liu, one of the members of our Board of Directors, is a veteran investment manager in Asia. He has almost 40 years
of broad experience in the financial industry, specializing in capital markets, private equity and venture capital investment.&nbsp;</span>Mr.
Liu has been&nbsp;involved in&nbsp;advising, managing and investing&nbsp;over US $20 billion in capital in hundreds of projects for international
corporations and investors, and participated in building successful funds and asset management platforms.&nbsp;<span style="font-family: Times New Roman PS Std,serif">Loren
Mortman, another member of our Board of Directors, has been President of The Equity Group Inc., an investor relations consulting firm
founded in 1974 that specializes in investor communications, investment community outreach, and IR advisory for small-to-mid-cap public
and pre-public companies, since 2013, Ms. Mortman has over 20 years of experience in developing public company clients’ critical
communications, and advising on transactions and relations with the investment community. Prior to joining The Equity Group, Ms. Mortman
was a Financial Analyst at Brenner Securities, an Investment Bank.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"><span style="font-family: Times New Roman PS Std,serif"></span></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"><span style="font-family: Times New Roman PS Std,serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"><span style="font-family: Times New Roman PS Std,serif">Our
management team will actively source target candidates they believe will be attractive candidates for acquisition, and utilize their deal-making
track record, professional relationships, and capital markets expertise to enhance the growth potential and value of a target business
and provide opportunities for attractive returns to our stockholders. Past performance of our management team is not a guarantee (i) that
we will be able to identify a suitable candidate for our initial business combination or (ii) of success with respect to any business
combination we may consummate. You should not rely on the historical record of our management’s performance as indicative of our
future performance.</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Business Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0 0 12pt; text-indent: 24pt">Our business strategy is to identify and complete
a business combination with a company that meets one or more of the acquisition criteria described below.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0 0 12pt; text-indent: 24pt">Our objective is to generate an attractive return
for stockholders through a merger with an operating company with a strong record and growth potential. We expect to favor opportunities
with certain business characteristics including some or all of the following: compelling long-term growth prospects, attractive competitive
dynamics, consolidation opportunities, leading technological position and strong management. We will also consider additional factors
such as high barriers to entry, significant streams of recurring revenue, margin profiles, and attractive free cash flow characteristics.
Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although we intend
to focus our search on target businesses operating in North America, Europe and Asia in the healthcare, technology, green economy, and
consumer products sectors.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-indent: 24pt">Our selection process will leverage our management
team’s broad and deep relationship network, industry experience, and deal sourcing capabilities to access a range of opportunities.
Our management team has a distinctive combination of capabilities including:</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;analyzing
performance, financial and otherwise, of public and private entities; and</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an
extensive history of accessing the capital markets across various business cycles, including financing businesses and assisting companies
with transition to public ownership.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Our founders intend to communicate with their networks
of relationships to articulate the parameters for our search for a target company and a potential business combination, and begin the
process of pursuing and reviewing potential opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Acquisition Criteria</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-indent: 24pt">Consistent with our business strategy, we have identified
the following general criteria and guidelines that we believe are important in evaluating prospective target businesses. We will use these
criteria and guidelines in evaluating acquisition opportunities, but we may ultimately decide to enter into our initial business combination
with a target business that does not meet these criteria and guidelines. We intend to seek to acquire companies that we believe:</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;have
exhibited strong growth in revenue or profit in recent fiscal periods or have healthy cash flow from operations;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will
offer an attractive return for our stockholders, potential benefit from growth in the target’s business and with an improved capital
structure will provide favorable upside measured against any identified downside risks;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;meet
some key characteristics such as being or having the capability of being a disruptive participant within an industry;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are
capable of achieving significant organic and/or acquisitive growth;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are
positioned to build stockholder value;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;have
the potential to achieve a leading position in the industry in which it competes; or</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;possess
a proven management team prepared for being a public company.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">These criteria are not intended to be exhaustive.
Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on these general
guidelines as well as other considerations, factors and criteria that our management may deem relevant. If we decide to enter into our
business combination with a target business that does not meet all or some of the above criteria and guidelines, we will disclose that
the target business does not meet the above criteria in our stockholder communications related to our initial business combination, which
would be in the form of proxy solicitation materials or tender offer documents that we would file with the SEC and deliver to stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Acquisition Process</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">In evaluating a prospective target business, we
expect to conduct a thorough due diligence review that will encompass, among other things, meetings with incumbent management and key
employees, document reviews and review of facilities, as well as a review of financial and other information that will be made available
to us.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">We are not prohibited from pursuing an initial
business combination with a company that is affiliated with our sponsor, officers or directors. In the event we seek to complete our initial
business combination with a company that is affiliated with our sponsor, officers or directors, we, or a committee of independent directors,
will obtain an opinion from an independent investment banking firm which is a member of FINRA or an independent accounting firm that our
initial business combination is fair to our company from a financial point of view. Our stockholders may not be provided with a copy of
such opinion and they may not be able to rely upon such opinion.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Members of our management team and our independent
directors own or will own, directly or indirectly sponsor shares and/or private warrants following this offering which securities will
be worthless if we fail to complete a business combination and, accordingly, may have a conflict of interest in determining whether a
particular target business is an appropriate business with which to effectuate our initial business combination. Further, each of our
officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or
resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial
business combination.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Each of our officers and directors presently has,
and any of them in the future may have additional fiduciary or contractual obligations to another entity pursuant to which such officer
or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our officers or
directors becomes aware of a business combination opportunity that is suitable for an entity to which he or she has then-current fiduciary
or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination
opportunity to such other entity, subject to their fiduciary duties under Delaware law.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">We do not believe, however, that the fiduciary
duties or contractual obligations of our officers or directors will materially affect our ability to complete our initial business combination.
Our Certificate of Incorporation will provide that we renounce our interest in any corporate opportunity offered to any director or officer
unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company subject
to his or her fiduciary duties under the laws of the State of Delaware and such opportunity is one we are legally and contractually permitted
to undertake and would otherwise be reasonable for us to pursue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Effecting A Business Combination</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">We will either (1) seek stockholder approval of
our initial business combination at a meeting called for such purpose at which stockholders may seek to redeem their shares, regardless
of whether they vote for or against the proposed business combination, into their pro rata share of the aggregate amount then on deposit
in the trust account (net of taxes payable), or (2) provide our stockholders with the opportunity to sell their shares to us by means
of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount
then on deposit in the trust account (net of taxes payable), in each case subject to the limitations described herein. The decision as
to whether we will seek stockholder approval of our proposed business combination or allow stockholders to sell their shares to us in
a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors such as the timing of the transaction
and whether the terms of the transaction would otherwise require us to seek stockholder approval. In the case of a tender offer, we will
file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business
combination as is required under the SEC’s proxy rules. In either case, we will consummate our initial business combination only
if upon such consummation either our shares are listed on a national securities exchange as contemplated by Rule 3a51-1(a) under the Securities
Exchange Act of 1934 (the “Exchange Act”) or we have net tangible assets (as determined in accordance with Rule 3a51-1(g)
of the Exchange Act, or any successor rule) of at least $5,000,001 (in either case, so that we are not subject to Rule 3a51-1, which we
refer to as the SEC’s “penny stock” rules) and, if we seek stockholder approval, a majority of the outstanding shares
of common stock voted are voted in favor of the business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">We have nine months (or up to 21 months if we
extend the period of time to consummate a business combination, as described in more detail below) from the consummation of our IPO to
consummate our initial business combination. Public stockholders will not be offered the opportunity to vote on or redeem their shares
in connection with such extensions. If we are unable to consummate our initial business combination within such time period, we will distribute
the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account (net of taxes
payable), pro rata to our public stockholders, by way of redemption of their shares, and thereafter cease operations except for the purpose
of winding up our affairs, as further described herein. We expect the pro rata redemption price to be $10.00 per share (regardless of
whether or not the underwriters exercise their over-allotment option), without taking into account any interest earned on such funds.
However, we cannot assure you that we will in fact be able to distribute such amounts as a result of claims of creditors which may take
priority over the claims of our public stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">As stated above, we will have nine months from
the consummation of our IPO to consummate our initial business combination. However, if we anticipate that we may not be able to consummate
our initial business combination within nine months, we may, but are not obligated to, extend the period of time to consummate a business
combination up to twelve times, each by an additional one month (for a total of up to 21 months to complete a business combination), subject
to our board of directors authorizing such extension and the sponsor or its affiliates or designees depositing additional funds into the
trust account as set out below. Pursuant to the terms of our amended and restated certificate of incorporation and the trust agreement
entered into between us and Continental Stock Transfer &amp; Trust Company, in order to extend the time available for us to consummate
our initial business combination, our board of directors would adopt a resolution approving such extension and our founders or their respective
affiliates or designees (which may include the potential target business), upon five days advance notice prior to each applicable deadline,
must deposit into the trust account $216,667 (approximately $0.0333 per public share) for each one-month extension, up to an aggregate
of $2,600,004, or $0.40 per public share (for an aggregate of 12 months), on or prior to the date of the applicable deadline, for each
extension. The insiders or sponsor (or their respective affiliates or designees) providing such additional funds will receive non-interest
bearing, unsecured promissory notes equal to the amount of any such deposit. The final and definitive terms of any such loans have not
yet been negotiated, but any such loan would be interest free and will not be repaid in the event that we are unable to close a business
combination unless there are funds available outside the trust account to do so. Such notes would either be paid upon consummation of
our initial business combination, or, at the purchaser's discretion, converted upon consummation of our business combination into additional
warrants on the basis of $1.00 per private warrant for each dollar amount deposited. These warrants would have an exercise price of $11.50
per share. Public stockholders will not be offered the opportunity to vote on or redeem their shares in connection with such extension.
If we are unable to consummate our initial business combination within such time period, we will distribute the aggregate amount then
on deposit in the trust account including interest earned on the funds held in the trust account (net of taxes payable), pro rata to our
public stockholders, by way of redemption of their shares, and thereafter cease operations except for the purpose of winding up our affairs,
as further described herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">In the event that we receive notice from our sponsor
or their respective affiliates or designees at least five days prior to an applicable deadline of their intent to affect an extension,
we intend to issue a press release announcing such intention at least three days prior to such applicable deadline. In addition, we intend
to issue a press release the day after such applicable deadline announcing whether or not the funds had been timely deposited. Our sponsor
and its affiliates or designees and their affiliates or designees are not obligated to fund the trust account to extend the time for us
to complete our initial business combination. To the extent that some, but not all, of our insiders, decide to extend the period of time
to consummate our initial business combination, such insiders (or their affiliates or designees) may deposit the entire amount required.
If we are unable to consummate our initial business combination within such time period, we will, as promptly as possible but not more
than ten business days thereafter, redeem 100% of our outstanding public shares for a pro rata portion of the funds held in the trust
account and then seek to dissolve and liquidate. In such event, all warrants and rights will expire and will be worthless.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">The rules of The Nasdaq Stock Market require that
our business combination must occur with one or more target businesses that together have an aggregate fair market value of at least 80%
of the assets held in the trust account (excluding taxes payable on the interest earned on the trust account) at the time of our signing
a definitive agreement in connection with our business combination. The fair market value of the target or targets will be determined
by our Board of Directors based upon one or more standards generally accepted by the financial community (such as actual and potential
sales, earnings, cash flow and/or book value). Although our Board of Directors will rely on generally accepted standards, our Board of
Directors will have discretion to select the standards employed. In addition, the application of the standards generally involves a substantial
degree of judgment. Accordingly, investors will be relying on the business judgment of the Board of Directors in evaluating the fair market
value of the target or targets. The proxy solicitation materials or tender offer documents used by us in connection with any proposed
transaction will provide public stockholders with our analysis of the fair market value of the target business, as well as the basis for
our determinations. If our Board is not able independently to determine the fair market value of the target business or businesses, we
will obtain an opinion from an independent investment banking firm, or another independent entity that commonly renders valuation opinions,
with respect to the satisfaction of such criteria. Our stockholders may not be provided with a copy of such opinion nor will they be able
to rely on such opinion. However, if Nasdaq delists our securities from trading on its exchange after this offering, we would not be required
to satisfy the fair market value requirement described above and could complete a business combination with a target business having a
fair market value substantially below 80% of the balance in the trust account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">We anticipate structuring our initial business
combination so that the post-transaction company in which our public stockholders own or acquire shares will own or acquire 100% of the
outstanding equity interests or assets of the target business or businesses. We may, however, structure our initial business combination
such that the post-transaction company owns or acquires less than 100% of such interests or assets of the target business in order to
meet certain objectives of the target management team or stockholders or for other reasons, but we will only complete such business combination
if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires
a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment
Company Act. Even if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target, our
stockholders prior to our initial business combination may collectively own a minority interest in the post-transaction company, depending
on valuations ascribed to the target and us in our initial business combination transaction. For example, we could pursue a transaction
in which we issue a substantial number of new shares in exchange for all of the outstanding capital stock of a target, or issue a substantial
number of new shares to third parties in connection with financing our initial business combination. In such cases, we would acquire a
100% controlling interest in the target. However, as a result of the issuance of a substantial number of new shares, our stockholders
immediately prior to our initial business combination could own less than a majority of our outstanding shares subsequent to our initial
business combination. If less than 100% of the outstanding equity interests or assets of a target business or businesses are owned or
acquired by the post-transaction company, the portion of such business or businesses that is owned or acquired by us is what will be valued
for purposes of the 80% of net assets test. If our initial business combination involves more than one target business, the 80% of net
assets test will be based on the aggregate value of all of the target businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Status as a Public Company and Financial Considerations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe our structure will make us an attractive
business combination partner to target businesses. As an existing public company, we offer a target business an alternative to the traditional
initial public offering through a merger or other business combination. In this situation, the owners of the target business would exchange
their shares of stock in the target business for our shares of common stock or for a combination of our shares of common stock and cash,
allowing us to tailor the consideration to the specific needs of the sellers. We believe target businesses might find this method a more
certain and cost-effective method to becoming a public company than the typical initial public offering. In a typical initial public offering,
there are additional expenses incurred in marketing, roadshow and public reporting efforts that will likely not be present to the same
extent in connection with a business combination with us. Furthermore, once the business combination is consummated, the target business
will have effectively become public, whereas an initial public offering is always subject to the underwriters’ ability to complete
the offering, as well as general market conditions that could prevent the offering from occurring. We believe the target business would
then have greater access to capital and an additional means of providing management incentives consistent with stockholders’ interests
than it would have as a privately-held company. It can offer further benefits by augmenting a company’s profile among potential
new customers and vendors and aid in attracting talented employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">While we believe that our status as a public company
will make us an attractive business partner, some potential target businesses may view the inherent limitations in our status as a blank
check company as a deterrent and may prefer to effect a business combination with a more established entity or with a private company.
These inherent limitations include limitations on our available financial resources, which may be inferior to those of other entities
pursuing the acquisition of similar target businesses; the requirement that we seek stockholder approval of a business combination, which
may delay the consummation of a transaction; and the existence of our outstanding rights, which may represent a source of future dilution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">With funds in the trust account of $65,000,000 available
to use for a business combination, we offer a target business a variety of options such as providing the owners of a target business with
shares in a public company and a public means to sell such shares, providing capital for the potential growth and expansion of its operations
or strengthening its balance sheet by reducing its debt ratio. Because we are able to consummate our initial business combination using
our cash, debt or equity securities, or a combination of the foregoing, we have the flexibility to use the most efficient combination
that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires. In connection with any
potential acquisition, we may be required to obtain acquisition financing. However, since we have no specific business combination under
consideration, we have not taken any steps to secure third party financing and there can be no assurance that it will be available to
us. We may seek to raise additional funds through a private offering of debt or equity securities in connection with the completion of
our business combination, and we may effectuate our business combination using the proceeds of such offering rather than using the amounts
held in the trust account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We chose our net tangible asset threshold of $5,000,001
to ensure that we would avoid being subject to Rule 419 promulgated under the Securities Act of 1933, as amended. However, if we seek
to consummate an initial business combination with a target business that imposes any type of working capital closing condition or requires
us to have a minimum amount of funds available from the trust account upon consummation of such initial business combination, we may need
to have more than $5,000,001 in net tangible assets upon consummation and this may force us to seek third party financing which may not
be available on terms acceptable to us or at all. As a result, we may not be able to consummate such initial business combination and
we may not be able to locate another suitable target within the applicable time period, if at all. Public stockholders may therefore have
to wait up to 21 months from the closing of our IPO in order to be able to receive a pro rata share of the trust account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Summary Information Related to Our Securities,
Redemption Rights and Liquidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a Delaware corporation and our affairs are governed
by our amended and restated certificate of incorporation, and the Delaware General Corporation Law. Pursuant to our amended and restated
certificate of incorporation, we are authorized to issue 300,000,000 shares of common stock, $0.00001 par value each. The information
provided below is a summary only and we refer you to our amended and restated certificate of incorporation and our warrant agreement and
rights agreement with Continental Stock Transfer &amp; Trust Company as warrant and rights agent for additional important and material
information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Upon completion of our IPO and as of March 29, 2022,
we had and have 8,125,000 shares of common stock issued and outstanding. Common stockholders of record are entitled to one vote for each
share held on all matters to be voted on by stockholders and vote together as a single class, except as required by law. Unless specified
by applicable law, our amended and restated certificate of incorporation or applicable stock exchange rules, the affirmative vote of a
majority of our shares of common stock that are voted is required to approve any such matter voted on by our stockholders. Directors are
elected for a term of one year. Our stockholders are entitled to receive ratable dividends when, as and if declared by the Board of Directors
out of funds legally available therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will provide our public stockholders with the opportunity
to redeem all or a portion of their public shares upon the completion of our business combination at a per-share price, payable in cash,
equal to the aggregate amount then on deposit in the trust account as of two business days prior to the consummation of our business combination,
including interest (which interest shall be net of taxes payable) divided by the number of then issued and outstanding public shares,
subject to the limitations described herein. The amount in the trust account is initially anticipated to be approximately $10.00 per public
share (subject to increase of up to an additional $0.40 per public share in the event that our sponsor elects to extend the period of
time to consummate a business combination).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our sponsor, officers and directors have entered into
a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares,
private placement shares and any public shares they may hold in connection with the completion of our business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If a stockholder vote is not required by law and we
do not decide to hold a stockholder vote for business or other legal reasons, we will, pursuant to our amended and restated certificate
of incorporation, conduct the redemptions pursuant to the tender offer rules of the SEC, and file tender offer documents with the SEC
prior to completing our business combination. If, however, stockholder approval of the transaction is required by law, or we decide to
obtain stockholder approval for business or other legal reasons, we will, like many blank check companies, offer to redeem shares in conjunction
with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek stockholder approval, we
will complete our business combination only if a majority of the issued and outstanding shares of common stock voted are voted in favor
of the business combination. However, the participation of our sponsor, officers, directors or their affiliates in privately-negotiated
transactions, if any, could result in the approval of our business combination even if a majority of our public stockholders vote, or
indicate their intention to vote, against such business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we seek stockholder approval of our business combination
and we do not conduct redemptions in connection with our business combination pursuant to the tender offer rules, our amended and restated
certificate of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with
whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted
from redeeming its shares with respect to more than an aggregate of 15% of the shares sold in our IPO, which we refer to as the “Excess
Shares.” However, we would not be restricting our stockholders’ ability to vote all of their shares (including Excess Shares)
for or against our business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we do not complete a business combination within
9 months (or up to 21 months, as discussed above) from the closing of our IPO, we will (i) cease all operations except for the purpose
of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding
public shares and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders
and our board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above) to our obligations under Delaware law
to provide for claims of creditors and the requirements of other applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In connection with our IPO and consummation of the
private placement with our sponsor we issued an aggregate of 6,500,000 rights to acquire an aggregate of 928,571 shares of common stock
as a component of the public units. If we enter into a definitive agreement for a business combination in which we will be the surviving
entity, each holder of a right will receive one-seventh (1/7) of one share upon consummation of our business combination, even if the
holder of such right redeemed all shares of common stock held by him, her or it in connection with the business combination or an amendment
to our certificate of incorporation with respect to our pre-business combination activities. No additional consideration will be required
to be paid by a holder of rights in order to receive his, her or its additional shares upon consummation of an business combination as
the consideration related thereto has been included in the unit purchase price paid for by investors in our IPO. The shares issuable upon
exchange of the rights will be freely tradable (except to the extent held by affiliates of ours). Holders of rights are not entitled to
any redemption of voting rights. If we are unable to complete an business combination within the required time period and we liquidate
the funds held in the trust account, holders of rights will not receive any of such funds with respect to their rights, nor will they
receive any distribution from our assets held outside of the trust account with respect to such rights, and the rights will expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In connection with our IPO we issued an aggregate of
3,250,000 whole warrants to acquire an aggregate of 3,250,000 shares of common stock. In addition, in the private placement with our sponsor
that we completed simultaneously with the IPO, we issued 2,500,000 warrants to acquire 2,500,000 shares of common stock. The warrants
purchased in our IPO have been issued in registered form under a warrant agreement between Continental Stock Transfer &amp; Trust Company,
as warrant agent, and us. Each warrant entitles the registered holder to purchase one share of common stock at a price of $11.50 per share,
subject to adjustment as discussed below, at any time commencing on the later of 12 months from the date we consummated our IPO or 30
days from the completion of our business combination. Because the warrants may only be exercised for whole numbers of shares, only an
even number of warrants may be exercised at any given time. Pursuant to the warrant agreement, a warrantholder may exercise its warrants
only for a whole number of shares. This means that only an even number of warrants may be exercised at any given time by a warrantholder.
The warrants will expire five years after the completion of our business combination, at 5:00 p.m., New York City time, or earlier upon
redemption or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Once the warrants become exercisable, we may call the
warrants for redemption:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
whole and not in part;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;upon
a minimum of 30 days’ prior written notice of redemption,</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
if, and only if, the last sales price of our shares of common stock equals or exceeds $18.00 per share for any 20 trading days within
a 30-trading day period ending three business days before we send the notice of redemption, and</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if,
and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants
at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date
of redemption.</p>
<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman PS Std,serif">The
redemption price for the warrants&nbsp;</span>shall be either (i) if the holder of a warrant has followed the procedures specified in
our notice of redemption and surrendered the warrant, the number of shares of common stock as determined in accordance with the “cashless
exercise” provisions of the warrant agreement or (ii) if the holder of a warrant has not followed such procedures specified in our
notice of redemption, the price of $0.01 per warrant. <span style="font-family: Times New Roman PS Std,serif">If the foregoing conditions
are satisfied and we issue a notice of redemption, each warrant holder can exercise his, her or its warrant prior to the scheduled redemption
date either by paying the cash exercise price or on a “cashless exercise” basis. However, the price of our shares of common
stock may fall below the $18.00 trigger price, as well as the $11.50 warrant exercise price after the redemption notice is issued.</span></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 0.5in">The private warrants are identical to the warrants
included in the units sold in our IPO except for certain transfer restrictions as described herein. The purchasers of the private warrants
have agreed not to transfer, assign or sell any of the private warrants or underlying securities (except to the same permitted transferees
as the Sponsor and provided the transferees agree to the same terms and restrictions as the permitted transferees of the Sponsor must
agree to) until the completion of our initial business combination. In the event of a liquidation prior to our initial business combination,
the private warrants will expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">In identifying, evaluating and selecting a target business
for our initial business combination, we may encounter intense competition from other entities having a business objective similar to
ours, including other blank check companies, private equity groups and leveraged buyout funds, and operating businesses seeking strategic
business combinations. Many of these entities are well established and have extensive experience identifying and effecting business combinations
directly or through affiliates. Moreover, many of these competitors possess greater financial, technical, human and other resources than
we do. Our ability to acquire larger target businesses will be limited by our available financial resources. This inherent limitation
gives others an advantage in pursuing the initial business combination of a target business. Furthermore, our obligation to pay cash in
connection with our public stockholders who exercise their redemption rights may reduce the resources available to us for our initial
business combination and our outstanding warrants, and the future dilution they potentially represent, may not be viewed favorably by
certain target businesses. Either of these factors may place us at a competitive disadvantage in successfully negotiating an initial business
combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">We currently have one officer. This individual is not
obligated to devote any specific number of hours to our matters, but he intends to devote as much of his time as he deem necessary to
our affairs until we have completed our initial business combination. The amount of time that he will devote in any time period will vary
based on whether a target business has been selected for our initial business combination and the stage of the initial business combination
process we are in. We do not intend to have any full-time employees prior to the completion of our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.75pt">We are an “emerging growth company,”
as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by the Jumpstart Our Business
Startups Act of 2012, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not
being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley&nbsp;Act of 2002, or the Sarbanes-Oxley&nbsp;Act,
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the
requirements of holding a non-binding&nbsp;advisory vote on executive compensation and stockholder approval of any golden parachute payments
not previously approved. If some investors find our securities less attractive as a result, there may be a less active trading market
for our securities and the prices of our securities may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.75pt">In addition, Section 107 of the JOBS Act also provides
that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the
Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay
the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage
of the benefits of this extended transition period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.75pt">We will remain an emerging growth company until the
earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our IPO, (b) in which we have
total annual gross revenue of at least $1.07&nbsp;billion, or (c) in which we are deemed to be a large accelerated filer, which means
the market value of our shares of common stock that is held by non-affiliates&nbsp;exceeds $700&nbsp;million as of the prior June 30<sup>th</sup>,
and (2) the date on which we have issued more than $1.0&nbsp;billion in non-convertible&nbsp;debt securities during the prior three-year&nbsp;period.
References herein to “emerging growth company” shall have the meaning associated with it in the JOBS Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.75pt">Additionally, we are a “smaller reporting company”
as defined in Item 10(f)(1)&nbsp;of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations,
including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until
the last day of the fiscal year in which (1)&nbsp;the market value of our common stock held by non-affiliates exceeds $250 million as
of the end of that year’s second fiscal quarter, or (2)&nbsp;our annual revenues exceeded $100 million during such completed fiscal
year and the market value of our common stock held by non- affiliates exceeds $700 million as of the end of that year’s second fiscal
quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.75pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.75pt">We are a Delaware corporation incorporated on May
19, 2021. Our executive offices are located at <span style="font-family: Times New Roman PS Std,serif">8 The Green, Suite #12490, Dover,
Delaware 19901</span>, and our telephone number is (302) 281-2147.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are required to file Annual Reports on Form 10-K
and Quarterly Reports on Form 10-Q with the SEC on a regular basis, and are required to disclose certain material events in a Current
Report on Form 8-K. The SEC maintains an Internet website that contains reports, proxy and information statements and other information
regarding issuers that file electronically with the SEC. The SEC’s Internet website is located at www.sec.gov. In addition, the
Company will provide copies of these documents without charge upon request from us in writing at <span style="font-family: Times New Roman PS Std,serif">8
The Green, Suite #12490, Dover, Delaware 19901.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 1A. Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">An investment in our securities involves a high degree
of risk. You should consider carefully all of the risks described below, together with the other information contained in this Annual
Report, before making a decision to invest in our securities. If any of the following events occur, our business, financial condition
and operating results may be materially adversely affected. In that event, the trading price of our securities could decline, and you
could lose all or part of your investment.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: center"><b>Summary of Risk Factors</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 0.5in">Our business is subject to numerous risks and
uncertainties, including those highlighted in the section titled “Risk Factors” immediately following this prospectus summary.
These risks include, but are not limited to:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Our public stockholders may not be afforded an opportunity to vote on our proposed initial business combination, and even if we hold a vote, holders of our sponsor shares will participate in such vote, which means we may complete our initial business combination even though a majority of our public stockholders do not support such a combination.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Your only opportunity to effect your investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Our search for a business combination, and any partner business with which we ultimately complete a business combination, may be materially adversely affected by the recent coronavirus (COVID-19) pandemic, any worsening of the pandemic or other disease outbreaks and the status of debt and equity markets.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We may not be able to complete our initial business combination within nine&nbsp;months after the closing of this offering (or such later period, if extended), in which case we would cease all operations except for the purpose of winding up and we would redeem our public shares and liquidate.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">As the number of special purpose acquisition companies evaluating targets increases, attractive targets may become scarcer and there may be more competition for attractive targets. This could increase the cost of our initial business combination and could even result in our inability to find a target or to consummate an initial business combination.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">If third parties bring claims against us, the funds held in the trust account could be reduced and the per-share&nbsp;redemption amount received by stockholders may be less than $10.00 per share.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We may not hold an annual general meeting until after the consummation of our initial business combination, which could delay the opportunity for our stockholders to appoint directors.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Although we have identified general criteria and guidelines that we believe are important in evaluating prospective target businesses, we may enter into our initial business combination with a target that does not meet such criteria and guidelines, and as a result, the target business with which we enter into our initial business combination may not have attributes entirely consistent with our general criteria and guidelines.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We are not required to obtain an opinion from an independent investment banking firm or from a valuation or appraisal firm, and consequently, you may have no assurance from an independent source that the price we are paying for the business is fair to our stockholders from a financial point of view.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We may issue notes or other debt securities, or otherwise incur substantial debt, to complete a business combination, which may adversely affect our leverage and financial condition and thus negatively impact the value of our stockholders’ investment in us.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We may attempt to complete our initial business combination with a private company about which little information is available, which may result in a business combination with a company that is not as profitable as we suspected, if at all.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We do not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to complete our initial business combination with which a substantial majority of our stockholders do not agree.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We may be unable to obtain additional financing to complete our initial business combination or to fund the operations and growth of a target business, which could compel us to restructure or abandon a particular business combination.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Our initial stockholders control a substantial interest in us and thus may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We may engage in a business combination with one or more target businesses that have relationships with entities that may be affiliated with our sponsor, officers, directors or existing holders which may raise potential conflicts of interest.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Since our sponsor, officers and directors will lose their entire investment in us if our initial business combination is not completed (other than with respect to public shares they may acquire during or after this offering), a conflict of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Our officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our initial business combination.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We may seek business combination opportunities in industries or sectors that may be outside of our management’s areas of expertise.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Our ability to successfully effect our initial business combination and to be successful thereafter will be dependent upon the efforts of our key personnel, some of whom may join us following our initial business combination. The loss of key personnel could negatively impact the operations and profitability of our post-combination&nbsp;business.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Our initial stockholders paid an aggregate of $25,000, or approximately $0.0161 per sponsor share and, accordingly, you will experience immediate and substantial dilution from the purchase of shares of our common stock.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">You will not be permitted to exercise your warrants unless we register and qualify the underlying shares of common stock or certain exemptions are available.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px; padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td style="padding-top: 8pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman PS Std,serif; margin: 0 0 0 1in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">We are a blank check company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.</span></td></tr>
  </tbody></table>
<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 1in">&nbsp;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 1in"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 1in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span></td>
    <td><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Past performance by our management team and their affiliates, including investments and transactions in which they have participated and businesses with which they have been associated, may not be indicative of future performance of an investment in the Company.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">General Risks Factors in Investing in a SPAC
Entity and Completing a Business Combination</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We are an early stage company with no operating
history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are an early stage company established with no operating
results, and we will not commence operations until obtaining funding through our IPO. Because we lack an operating history, you have no
basis upon which to evaluate our ability to achieve our business objective of completing our business combination with one or more target
businesses. We have no plans, arrangements or understandings with any prospective target business concerning a business combination and
may be unable to complete our business combination. <span style="font-family: Times New Roman PS Std,serif">We will not generate any revenues
until, at the earliest, after the consummation of a business combination.</span> If we fail to complete our business combination, we will
never generate any operating revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our public shareholders may not be afforded an
opportunity to vote on our proposed business combination, which means we may complete our business combination even though a majority
of our public shareholders do not support such a combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may not hold a stockholder vote to approve our business
combination unless the business combination would require stockholder approval under applicable Delaware law or the rules of the Nasdaq
or if we decide to hold a stockholder vote for business or other reasons. Examples of transactions that would not ordinarily require stockholder
approval include asset acquisitions and share purchases, while transactions such as direct mergers with our company or transactions where
we issue more than 20% of our outstanding shares would require stockholder. For instance, the Nasdaq rules currently allow us to engage
in a tender offer in lieu of a stockholder meeting but would still require us to obtain stockholder approval if we were seeking to issue
more than 20% of our outstanding shares to a target business as consideration in any business combination. Therefore, if we were structuring
a business combination that required us to issue more than 20% of our outstanding shares, we would seek stockholder approval of such business
combination. Except as required by law or Nasdaq rules, the decision as to whether we will seek stockholder approval of a proposed business
combination or will allow stockholders to sell their shares to us in a tender offer will be made by us, solely in our discretion, and
will be based on a variety of factors, such as the timing of the transaction and whether the terms of the transaction would otherwise
require us to seek stockholder approval. Accordingly, we may consummate our business combination even if holders of a majority of the
issued and outstanding shares of common stock do not approve of the business combination we consummate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If we seek stockholder approval of our business
combination, our sponsor, officers and directors have agreed to vote in favor of such business combination, regardless of how our public
shareholders vote.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Unlike other blank check companies in which the initial
stockholders agree to vote their sponsor shares in accordance with the majority of the votes cast by the public stockholders in connection
with an initial business combination, our sponsor, officers and directors have agreed (and any permitted transferees will agree), pursuant
to the terms of a letter agreement entered into with us, to vote any sponsor shares held by them, as well as any public shares purchased
during or after our IPO, in favor of our initial business combination. We expect that our sponsor and its permitted transferees will own
approximately 20% of our issued and outstanding shares at the time of any such stockholder vote (assuming it does not purchase units in
our IPO, and not taking into account ownership of the private placement warrants). As a result, in addition to our initial stockholder’s
sponsor shares, we would need only 2,437,501, or approximately 37.5%, of the 6,500,000 public shares sold in our IPO to be voted in favor
of a transaction in order to have our initial business combination approved. Further, assuming that only a quorum of 4,062,501 shares
of our common stock is present in person or by proxy at stockholder meeting to approve our initial business combination, if only the minimum
number of shares representing a quorum are voted, such approval would require the affirmative vote of 2,031,251 shares of our common stock,
which means that, in addition to our initial stockholders’ shares, we would need only 406,251, or approximately 6.25%, of the 6,500,000
public shares sold in our IPO to be voted in favor of an initial business combination in order to have our initial business combination
approved. Accordingly, if we seek stockholder approval of our initial business combination, it is more likely that the necessary stockholder
approval will be received than would be the cast if such persons agreed to vote their sponsor shares in accordance with the majority of
the votes cast by our public stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our sponsor has the right to extend the term we
have to consummate our business combination, without providing our stockholders with redemption rights.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">We will have until nine months from the closing of this
offering to consummate our initial business combination. However, if we anticipate that we may not be able to consummate our initial business
combination within nine months, our board of directors may extend the period of time to consummate a business combination up to twelve
(12) times, each by an additional one month period (for a total of up to 21 months to complete a business combination), subject to the
authorization by our board of directors and the deposit of additional funds into the trust account by our sponsor or its affiliates or
designees as described elsewhere in this prospectus. Our stockholders will not be entitled to vote or redeem their shares in connection
with any such extension. In order for the time available for us to consummate our initial business combination to be extended, our sponsor
or its affiliates or designees must deposit into the trust account $216,667 (approximately $0.0333 per public share) for each one-month
extension, on or prior to the date of the applicable deadline, up to an aggregate of $2,600,004, or $0.40 per public share if we extend
for the full twelve months. (for an aggregate of 12 months).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Any such payments may be made in the form of a non-interest-bearing
loan from our sponsor or its affiliates or designees and would be repaid, if at all, from funds released to us upon completion of our
initial business combination. Any obligation to repay such loans may reduce the amount available to us to pay as purchase price in our
initial business combination, and/or may reduce the amount of funds available to the combined company following the initial business combination.
This feature is different than the traditional special purpose acquisition company structure, in which any extension of the company’s
period to complete a business combination requires a vote of the company’s stockholders and stockholders have the right to redeem
their public shares in connection with such vote, and which do not provide the sponsor with the right to loan funds to the company to
fund extension payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Your only opportunity to affect the investment
decision regarding a potential business combination will be limited to the exercise of your right to redeem your shares from us for cash,
unless we seek shareholder approval of the business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">At the time of your investment in us, you will not
be provided with an opportunity to evaluate the specific merits or risks of one or more target businesses. Since our Board of Directors
may complete a business combination without seeking stockholder approval, public stockholders may not have the right or opportunity to
vote on the business combination, unless we seek such stockholder approval. Accordingly, if we do not seek stockholder approval, your
only opportunity to affect the investment decision regarding a potential business combination may be limited to exercising your redemption
rights within the period of time (which will be at least 20 business days) set forth in our tender offer documents mailed to our public
stockholders in which we describe our business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The ability of our public shareholders to redeem
their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult
for us to enter into a business combination with a target.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may seek to enter into a business combination transaction
agreement with a prospective target that requires as a closing condition that we have a minimum net worth or a certain amount of cash.
If too many public stockholders exercise their redemption rights, we would not be able to meet such closing condition and, as a result,
would not be able to proceed with the business combination. Furthermore, in no event will we redeem our public shares in an amount that
would cause our net tangible assets, after payment of the deferred underwriting commissions, to be less than $5,000,001 upon consummation
of our business combination (so that we are not subject to the SEC’s “penny stock” rules) or any greater net tangible
asset or cash requirement which may be contained in the agreement relating to our business combination. Consequently, if accepting all
properly submitted redemption requests would cause our net tangible assets to be less than $5,000,001 upon consummation of our business
combination or such greater amount necessary to satisfy a closing condition as described above, we would not proceed with such redemption
and the related business combination and may instead search for an alternate business combination. Prospective targets will be aware of
these risks and, thus, may be reluctant to enter into a business combination transaction with us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The ability of our public shareholders to exercise
redemption rights with respect to a large number of our shares may not allow us to complete the most desirable business combination or
optimize our capital structure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">At the time we enter into an agreement for our business
combination, we will not know how many stockholders may exercise their redemption rights, and therefore we will need to structure the
transaction based on our expectations as to the number of shares that will be submitted for redemption. If our business combination agreement
requires us to use a portion of the cash in the trust account to pay the purchase price, or requires us to have a minimum amount of cash
at closing, we will need to reserve a portion of the cash in the trust account to meet such requirements, or arrange for third party financing.
In addition, if a larger number of shares are submitted for redemption than we initially expected, we may need to restructure the transaction
to reserve a greater portion of the cash in the trust account or arrange for third party financing. Raising additional third-party financing
may involve dilutive equity issuances or the incurrence of indebtedness at higher than desirable levels. The above considerations may
limit our ability to complete the most desirable business combination available to us or optimize our capital structure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The ability of our public shareholders to exercise
redemption rights with respect to a large number of our shares could increase the probability that our business combination would be unsuccessful
and that you would have to wait for liquidation in order to redeem your shares.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If our business combination agreement requires us to
use a portion of the cash in the trust account to pay the purchase price, or requires us to have a minimum amount of cash at closing,
the probability that our business combination would be unsuccessful is increased. If our business combination is unsuccessful, you would
not receive your pro rata portion of the trust account until we liquidate the trust account. If you are in need of immediate liquidity,
you could attempt to sell your shares in the open market; however, at such time our shares may trade at a discount to the pro rata amount
per share in the trust account. In either situation, you may suffer a material loss on your investment or lose the benefit of funds expected
in connection with our redemption until we liquidate or you are able to sell your shares in the open market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The requirement that we complete our business combination
within the prescribed time frame may give potential target businesses leverage over us in negotiating a business combination and may decrease
our ability to conduct due diligence on potential business combination targets as we approach our dissolution deadline, which could undermine
our ability to complete our business combination on terms that would produce value for our shareholders.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any potential target business with which we enter into
negotiations concerning a business combination will be aware that we must complete our business combination within 9 months from the closing
of our IPO (or up to 21 months from the closing of our IPO if we extend the period of time to consummate a business combination, as described
in more detail in this report). Consequently, such target business may obtain leverage over us in negotiating a business combination,
knowing that if we do not complete our business combination with that particular target business, we may be unable to complete our business
combination with any target business. This risk will increase as we get closer to the timeframe described above. In addition, we may have
limited time to conduct due diligence and may enter into our business combination on terms that we would have rejected upon a more comprehensive
investigation.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>In connection with any vote to approve a business combination,
we will offer each public stockholder the option to vote in favor of a proposed business combination and still seek redemption of his,
her or its shares.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">In connection with any vote to approve a business
combination, we will offer each public stockholder (but not our founders, officers or directors) the right to have his, her or its shares
of common stock redeemed for cash (subject to the limitations described elsewhere in this prospectus) regardless of whether such stockholder
votes for or against such proposed business combination. This ability to seek redemption while voting in favor of our proposed business
combination may make it more likely that we will consummate a business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may not be able to complete our business combination
within the prescribed time frame, in which case we would cease all operations except for the purpose of winding up and we would redeem
our public shares and liquidate, in which case our public shareholders may only receive $10.00 per share, or less than such amount in
certain circumstances, and our rights and warrants will expire worthless.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our sponsor, officers and directors have agreed that
we must complete our business combination within 9 months from the closing of our IPO (or up to 21 months from the closing of our IPO
if we extend the period of time to consummate a business combination). We may not be able to find a suitable target business and complete
our business combination within such time period. If we have not completed our business combination within such time period, we will:
(i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business
days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the
trust account, including interest (which interest shall be net of taxes payable, and less interest to pay dissolution expenses) divided
by the number of then issued and outstanding public shares, which redemption will completely extinguish public stockholders’ rights
as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly
as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our Board of Directors, liquidate
and dissolve, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other
applicable law. In such case, our public stockholders may only receive $10.00 per share, and our rights and warrants will expire worthless.
In certain circumstances, our public stockholders may receive less than $10.00 per share on the redemption of their shares. If third parties
bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by stockholders
may be less than $10.00 per share” and other risk factors herein.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our search for a business combination, and any
target business with which we ultimately consummate a business combination, may be materially adversely affected by the COVID-19 outbreak
and the status of debt and equity markets.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In December 2019, a novel strain of coronavirus was
reported to have surfaced, which has and is continuing to spread throughout the world. On January 30, 2020, the World Health Organization
declared the outbreak of COVID-19 a “Public Health Emergency of International Concern.” On January 31, 2020, U.S. Health and
Human Services Secretary Alex M. Azar II declared a public health emergency for the United States to aid the U.S. healthcare community
in responding to COVID-19, and on March 11, 2020 the World Health Organization characterized the outbreak as a “pandemic.”
The COVID-19 outbreak has resulted in a widespread health crisis that has adversely affected economies and financial markets worldwide,
business operations and the conduct of commerce generally, and the business of any potential target business with which we consummate
a business combination could be, or may already have been, materially and adversely affected. Furthermore, we may be unable to complete
a business combination if concerns relating to COVID-19 continue to restrict travel or limit the ability to have meetings with potential
investors, or the target company’s personnel, vendors and services providers are unavailable to negotiate and consummate a transaction
in a timely manner. The extent to which COVID-19 impacts our search for a business combination will depend on future developments, which
are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions
to contain COVID-19 or treat its impact, among others. If the disruptions posed by COVID-19 or other matters of global concern continue
for an extensive period of time, our ability to consummate a business combination, or the operations of a target business with which we
ultimately consummate a business combination, may be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, our ability to consummate
a transaction may be dependent on the ability to raise equity and debt financing which may be impacted by COVID-19 and other events, including
as a result of increased market volatility and decreased market liquidity and third-party financing being unavailable on terms acceptable
to us or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our sponsor may decide not to extend the term we
have to consummate our business combination, in which case we would cease all operations except for the purpose of winding up and we would
redeem our public shares and liquidate, and the warrants and rights will be worthless.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">We will have until nine months from the closing of this
offering to consummate our initial business combination. However, if we anticipate that we may not be able to consummate our initial business
combination within nine months, we may extend the period of time to consummate a business combination up to twelve (12) times, each by
an additional one month period (for a total of up to 21 months to complete a business combination), subject to our board of directors
authorizing such extension and the sponsor depositing additional funds into the trust account as described elsewhere in this report. However,
our sponsor and its affiliates or designees are not obligated to fund the trust account to extend the time for us to complete our initial
business combination. If we are unable to consummate our initial business combination within the applicable time period, we will, as promptly
as reasonably possible but not more than ten business days thereafter, redeem the public shares for a pro rata portion of the funds held
in the trust account and as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders
and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of
creditors and the requirements of other applicable law. In such event, the warrants and rights will be worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If we seek stockholder approval of our initial
business combination, our sponsor, directors, officers, advisors and their affiliates may elect to purchase shares from public stockholders,
which may influence a vote on a proposed business combination and reduce the public “float” of our common stock.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">If we seek stockholder approval of our initial business
combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules,
our sponsor, directors, officers, advisors or their affiliates may purchase shares in privately negotiated transactions or in the open
market either prior to or following the completion of our initial business combination, although they are under no obligation to do so.
Such a purchase may include a contractual acknowledgement that such stockholder, although still the record holder of our shares is no
longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that our sponsor, directors,
officers, advisors or their affiliates purchase shares in privately negotiated transactions from public stockholders who have already
elected to exercise their redemption rights, such selling stockholders would be required to revoke their prior elections to redeem their
shares. The price per share paid in any such transaction may be different than the amount per share a public stockholder would receive
if it elected to redeem its shares in connection with our initial business combination. The purpose of such purchases could be to vote
such shares in favor of the business combination and thereby increase the likelihood of obtaining stockholder approval of the business
combination or to satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain
amount of cash at the closing of our initial business combination, where it appears that such requirement would otherwise not be met.
This may result in the completion of our initial business combination that may not otherwise have been possible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">In addition, if such purchases are made, the public
“float” of our common stock and the number of beneficial holders of our securities may be reduced, possibly making it difficult
to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If a shareholder fails to receive notice of our
offer to redeem our public shares in connection with our business combination, or fails to comply with the procedures for tendering its
shares, such shares may not be redeemed</b>	</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"><span style="font-family: Times New Roman PS Std,serif">We
will comply with the proxy rules or tender offer rules, as applicable, when conducting redemptions in connection with our initial business
combination. Despite our compliance with these rules, if a stockholder fails to receive our proxy solicitation or tender offer materials,
as applicable, such stockholder may not become aware of the opportunity to redeem its shares. In addition, the proxy solicitation or tender
offer materials, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination
will describe the various procedures that must be complied with in order to&nbsp;</span>validly redeem or tender public shares. For example,
we may require our public stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares
in “street name,” to either tender their certificates to our transfer agent prior to the date set forth in the tender offer
or proxy materials documents mailed to such holders, or up to two business days prior to the scheduled vote on the proposal to approve
the initial business combination in the event we distribute proxy materials, or to deliver their shares to the transfer agent electronically.&nbsp;In
the event that a stockholder fails to comply with these procedures, its shares may not be redeemed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>If we are unable to complete our initial business combination, our public
stockholders may receive only approximately $10.00 per share, or less in certain circumstances, on our redemption, and our warrants and
rights will expire worthless.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may be unable to complete our initial business combination
for a number of reasons. For example, we expect to encounter intense competition from other entities having a business objective similar
to ours, including private investors (which may be individuals or investment partnerships), other blank check companies and other entities,
domestic and international, competing for the types of businesses we intend to acquire. Many of these individuals and entities are well-established
and have extensive experience in identifying and effecting, directly or indirectly, acquisitions of companies operating in or providing
services to various industries and possess greater technical, human and other resources or more local industry knowledge than we do. Further,
our financial resources may be relatively limited when contrasted with those of many of these competitors. While we believe there are
numerous target businesses we could potentially acquire with the net proceeds of our IPO and the sale of the private placement warrants,
our ability to compete with respect to the acquisition of certain target businesses that are sizable will be limited by our available
financial resources. Furthermore, if we are obligated to pay cash for the shares of common stock redeemed, it would reduce the resources
available to us for our initial business combination. Any of these obligations may place us at a competitive disadvantage in successfully
negotiating a business combination. If we are unable to complete our initial business combination, our public stockholders may receive
only approximately $10.00 per share (or less in certain circumstances) on the liquidation of our trust account and our warrants and rights
will expire worthless. In certain circumstances, our public stockholders may receive less than $10.00 per share on the redemption of their
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><span style="font-family: Times New Roman PS Std,serif"><b>Because
of our&nbsp;</b></span><b>structure, limited resources and the significant competition for business combination opportunities, other companies
may have a competitive advantage and we may not be able to consummate an attractive business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">We expect to encounter intense competition from
entities other than blank check companies having a business objective similar to ours, including private investors (which may be individuals
or investment partnerships),<span style="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</span><span style="font-family: Times New Roman PS Std,serif">venture
capital funds, leveraged buyout funds and operating businesses competing for acquisitions. Many of these entities are well established
and have extensive experience in identifying and effecting business combinations directly or through affiliates. Many of these competitors
possess greater technical, human and other resources than we do and our financial resources will be relatively limited when compared to
those of many of these competitors. While we believe that there are numerous potential target businesses that we could acquire with the
net proceeds of this offering, our ability to compete in acquiring certain sizable target businesses will be limited by our available
financial resources. This inherent competitive limitation gives others an advantage in pursuing the acquisition of certain target businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">Our obligation to pay cash in connection with
our public stockholders who exercise their redemption rights may reduce the resources available to us for our initial business combination
may not be viewed favorably by target businesses.<span style="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</span><span style="font-family: Times New Roman PS Std,serif">Furthermore,
seeking stockholder approval or engaging in a tender offer in connection with any proposed business combination may delay the consummation
of such a transaction. Additionally, our outstanding rights and warrants, and the future dilution they potentially represent, may not
be viewed favorably by certain target businesses. Any of the foregoing may place us at a competitive disadvantage in successfully negotiating
and consummating a business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>You will not have any rights or interests in funds
from the trust account, except under certain limited circumstances. To liquidate your investment, therefore, you may be forced to sell
your public shares, rights or warrants, potentially at a loss.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our public stockholders will be entitled to receive
funds from the trust account only upon the earlier to occur of: (i) our completion of an initial business combination, and then only in
connection with those shares of common stock that such stockholder properly elected to redeem, subject to the limitations described herein,
(ii) the redemption of any public shares properly tendered in connection with a stockholder vote to amend our Amended and Restated Certificate
of Incorporation to modify the substance or timing of our obligation to redeem 100% of our public shares if we do not complete our initial
business combination within nine months (or 21 months) from the closing of this offering and (iii) the redemption of our public shares
if we are unable to complete an initial business combination within nine months (or 21 months) from the closing of our IPO, subject to
applicable law and as further described herein. In addition, if we have not completed an initial business combination within the required
time period for any reason, compliance with Delaware law may require that we submit a plan of dissolution to our then existing stockholders
for approval prior to the distribution of the proceeds held in our trust account. In that case, public stockholders may be forced to wait
beyond the end of such period before they receive funds from our trust account. In no other circumstances will a public stockholder have
any right or interest of any kind in the trust account. Holders of warrants and rights will not have any right to the proceeds held in
the trust account with respect to the warrants and rights. Accordingly, to liquidate your investment, you may be forced to sell your public
shares, warrants, or rights, potentially at a loss.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>The requirement that the target business or businesses that we
acquire must collectively have a fair market value equal to at least 80% of the balance of the funds in the trust account (less any taxes
payable on interest earned and less any interest earned thereon that is released to us for taxes) at the time of the execution of a definitive
agreement for our initial business combination may limit the type and number of companies that we may complete such a business combination
with.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 0.5in">Pursuant to the Nasdaq listing rules, the target
business or businesses that we acquire must collectively have a fair market value equal to at least 80% of the balance of the funds in
the trust account (less any taxes payable on interest earned and less any interest earned thereon that is released to us for taxes) at
the time of the execution of a definitive agreement for our initial business combination. This restriction may limit the type and number
of companies that we may complete an initial business combination with. If we are unable to locate a target business or businesses that
satisfy this fair market value test, we may be forced to liquidate and you will only be entitled to receive your pro rata portion of the
funds in the trust account. If Nasdaq delists our securities from trading on its exchange after this offering, we would not be required
to satisfy the fair market value requirement described above and could complete a business combination with a target business having a
fair market value substantially below 80% of the balance in the trust account.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>In connection with any stockholder meeting called to approve a
proposed initial business combination, we may require stockholders who wish to redeem their shares in connection with a proposed business
combination to comply with specific requirements for redemption that may make it more difficult for them to exercise their redemption
rights prior to the deadline for exercising their redemption rights.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">In connection with any stockholder meeting called
to approve a proposed initial business combination, each public stockholder will have the right, regardless of whether he is voting for
or against such proposed business combination, to demand that we redeem his or her shares into a pro rata share of the trust account as
of two business days prior to the consummation of the initial business combination. We may require public stockholders who wish to redeem
their shares in connection with a proposed business combination to either (i) tender their certificates (if any) to our transfer agent
or (ii) deliver their shares to the transfer agent electronically using the Depository Trust Company’s DWAC (Deposit/Withdrawal
At Custodian) System, at the holders’ option, in each case prior to a date set forth in the tender offer documents or proxy materials
sent in connection with the proposal to approve the business combination. In order to obtain a physical share certificate, a stockholder’s
broker and/or clearing broker, DTC and our transfer agent will need to act to facilitate this request. It is our understanding that stockholders
should generally allot at least two weeks to obtain physical certificates from the transfer agent. However, because we do not have any
control over this process or over the brokers or DTC, it may take significantly longer than two weeks to obtain a physical share certificate.
While we have been advised that it takes a short time to deliver shares through the DWAC System, we cannot assure you of this fact. Accordingly,
if it takes longer than we anticipate for stockholders to deliver their shares, stockholders who wish to redeem may be unable to meet
the deadline for exercising their redemption rights and thus may be unable to redeem their shares.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>If, in connection with any stockholder meeting called to approve
a proposed business combination, we require public stockholders who wish to redeem their shares to comply with specific requirements for
redemption, such redeeming stockholders may be unable to sell their securities when they wish to in the event that the proposed business
combination is not approved.</b></p>

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We may require our public stockholders seeking to
exercise their redemption rights, whether they are record holders or hold their shares in “street name,” to either tender
their certificates to our transfer agent prior to the date set forth in the tender offer documents or proxy materials mailed to such holders,
or up to two business days prior to the vote on the proposal to approve the business combination in the event we distribute proxy materials
or to deliver their shares to the transfer agent electronically using The Depository Trust Company’s DWAC (Deposit/Withdrawal At
Custodian) System, rather than simply voting against the initial business combination at the holder’s option. The tender offer or
proxy materials, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination
will indicate whether we are requiring public stockholders to satisfy such delivery requirements, which will include the requirement that
a beneficial holder must identify itself in order to validly redeem its shares. Accordingly, a public stockholder would have from the
time we send out our tender offer materials until the close of the tender offer period, or up to two business days prior to the scheduled
vote on the business combination if we distribute proxy materials, as applicable, to tender its shares if it wishes to seek to exercise
its redemption rights. Pursuant to the tender offer rules, the tender offer period will be not less than 20 business days and, in the
case of a stockholder vote, a final proxy statement would be mailed to public stockholders at least 10 days prior to the stockholder vote.
However, we expect that a draft proxy statement would be made available to such stockholders well in advance of such time, providing additional
notice of redemption if we conduct redemptions in conjunction with a proxy solicitation. Given the relatively short exercise period, it
is advisable for stockholders to use electronic delivery of their public shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">There is a nominal cost associated with the above-referenced
tendering process and the act of certificating the shares or delivering them through The Depository Trust Company’s DWAC (Deposit/Withdrawal
At Custodian) System. The transfer agent will typically charge the tendering broker a nominal fee and it would be up to the broker whether
or not to pass this cost on to the redeeming holder. However, this fee would be incurred regardless of whether or not we require holders
seeking to exercise redemption rights to tender their shares. The need to deliver shares is a requirement of exercising redemption rights
regardless of the timing of when such delivery must be effectuated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The foregoing is different from the procedures used
by many blank check companies. In order to perfect redemption rights in connection with their business combinations, many blank check
companies would distribute proxy materials for the stockholders’ vote on an initial business combination, and a holder could simply
vote against a proposed business combination and check a box on the proxy card indicating such holder was seeking to exercise his or her
redemption rights. After the business combination was approved, the company would contact such stockholder to arrange for him or her to
deliver his or her certificate to verify ownership. As a result, the stockholder then had an “option window” after the completion
of the business combination during which he or she could monitor the price of the company’s stock in the market. If the price rose
above the redemption price, he or she could sell his or her shares in the open market before actually delivering his or her shares to
the company for cancellation. As a result, the redemption rights, to which stockholders were aware they needed to commit before the stockholder
meeting, would become “option” rights surviving past the completion of the business combination until the redeeming holder
delivered its certificate. The requirement for physical or electronic delivery prior to the meeting ensures that a redeeming holder’s
election to redeem is irrevocable once the business combination is approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Any request to redeem such shares, once made, may
be withdrawn at any time up to the date set forth in the tender offer materials or two business days prior to the scheduled date of the
stockholder meeting set forth in our proxy materials, as applicable (unless we elect to allow additional withdrawal rights). Furthermore,
if a holder of a public share delivered its certificate in connection with an election of redemption rights and subsequently decides prior
to the applicable date not to elect to exercise such rights, such holder may simply request that the transfer agent return the certificate
(physically or electronically). It is anticipated that the funds to be distributed to holders of our public shares electing to redeem
their shares will be distributed promptly after the completion of our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">If our initial proposed business combination is not
completed, we may continue to try to complete a business combination until nine months from the consummation of this offering or during
any extension period. If our initial business combination is not approved or completed for any reason, then our public stockholders who
elected to exercise their redemption rights would not be entitled to redeem their shares for the applicable pro rata share of the trust
account. In such case, we will promptly return any certificates delivered by public holders who elected to redeem their shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>You will not be entitled to protections normally
afforded to investors of many other blank check companies.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Since the net proceeds of our IPO and the sale of the
private placement warrants are intended to be used to complete an business combination with a target business that has not been identified,
we may be deemed to be a “blank check” company under the United States securities laws. However, because we have listed our
securities on the Nasdaq Global Market and have net tangible assets in excess of $5,000,001 upon the completion of our IPO and the sale
of the private placement warrants and filed a Current Report on Form 8-K, including an audited balance sheet demonstrating this fact,
we are exempt from rules promulgated by the SEC to protect investors in blank check companies, such as Rule 419. Accordingly, investors
will not be afforded the benefits or protections of those rules. Among other things, this means our units will be immediately tradable
and we may have a longer period of time to complete our business combination than do companies subject to Rule 419. Moreover, if our IPO
were subject to Rule 419, that rule would prohibit the release of any interest earned on funds held in the trust account to us unless
and until the funds in the trust account were released to us in connection with our completion of an business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If we seek shareholder approval of our business
combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a “group” of shareholders
are deemed to hold in excess of 15% of our shares of common stock, you will lose the ability to redeem all such shares in excess of 15%
of our shares of common stock.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we seek stockholder approval of our business combination
and we do not conduct redemptions in connection with our business combination pursuant to the tender offer rules, our amended and restated
certificate of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with
whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted
from seeking redemption rights with respect to more than an aggregate of 15% of the shares sold in our IPO, which we refer to as the “Excess
Shares.” However, we would not be restricting our stockholders’ ability to vote all of their shares (including Excess Shares)
for or against our business combination. Your inability to redeem the Excess Shares will reduce your influence over our ability to complete
our business combination and you could suffer a material loss on your investment in us if you sell Excess Shares in open market transactions.
Additionally, you will not receive redemption distributions with respect to the Excess Shares if we complete our business combination.
And as a result, you will continue to hold that number of shares exceeding 15% and, in order to dispose of such shares, would be required
to sell your shares in open market transactions, potentially at a loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If the net proceeds of our IPO not being held in
the trust account are insufficient to allow us to operate for at least the next 9 months (or up to 21 months from the closing of our IPO
if we extend the period of time to consummate a business combination), we may be unable to complete our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The funds available to us outside of the trust account
may not be sufficient to allow us to operate for at least the next 9 months (or up to 21 months from the closing of our IPO if we extend
the period of time to consummate a business combination), assuming that our business combination is not completed during that time. We
expect to incur significant costs in pursuit of our acquisition plans. We may need to borrow funds from our founders, officers or directors
or their affiliates to operate or may be forced to liquidate. Our founders, officers, directors and their affiliates may, but are not
obligated to, loan us funds, from time to time or at any time, in whatever amount that they deem reasonable in their sole discretion for
our working capital needs. Each working capital loan would be evidenced by a promissory note. The working capital notes would either be
paid upon consummation of our initial business combination, without interest, or, at holder’s discretion, an amount not to exceed
$2,400,000, may be converted into working capital warrants at a price of $1.00 per warrant with an exercise price of $11.50 per share.
We may not be able to raise additional financing from unaffiliated parties necessary to fund our expenses. Any such event in the future
may negatively impact the analysis regarding our ability to continue as a going concern at such time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe that, upon the closing of our IPO, the funds
available to us outside of the trust account, will be sufficient to allow us to operate for at least the next 9 months (or up to 21 months
from the closing of our IPO if we extend the period of time to consummate a business combination); however, we cannot assure you that
our estimate is accurate. Of the funds available to us, we could use a portion of the funds available to us to pay fees to consultants
to assist us with our search for a target business. We could also use a portion of the funds as a down payment or to fund a “no-shop”
provision (a provision in letters of intent designed to keep target businesses from “shopping” around for transactions with
other companies on terms more favorable to such target businesses) with respect to a particular proposed business combination, although
we do not have any current intention to do so. If we entered into a letter of intent where we paid for the right to receive exclusivity
from a target business and were subsequently required to forfeit such funds (whether as a result of our breach or otherwise), we might
not have sufficient funds to continue searching for, or conduct due diligence with respect to, a target business. If we are unable to
complete our business combination, our public stockholders may receive only approximately $10.00 per share (or less in certain circumstances)
on the liquidation of our trust account and our rights and warrants will expire worthless. In certain circumstances, our public stockholders
may receive less than $10.00 per share on the redemption of their shares. If third parties bring claims against us, the proceeds held
in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than $10.00 per share”
and other risk factors herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If the net proceeds of our IPO and the sale of
the private placement warrants not being held in the trust account are insufficient, it could limit the amount available to fund our search
for a target business or businesses and complete our business combination and we will depend on loans from our sponsor or management team
to fund our search, to pay our taxes and to complete our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Of the net proceeds of our IPO and the sale of the
private placement warrants and after payment of estimated offering expenses, only approximately $900,000 was available to us initially
outside the trust account to fund our working capital requirements. In the event that our offering expenses exceed our estimate of approximately
$360,000, we may fund such excess with funds not held in the trust account. In such case, the amount of funds available for working
capital purposes would decrease by a corresponding amount. If we are required to seek additional capital, we would need to borrow funds
from our sponsor, management team or other third parties to operate or may be forced to liquidate. Neither our sponsor, members of our
management team nor any of their affiliates is under any obligation to advance funds to us in such circumstances. Any such advances would
be repaid only from funds held outside the trust account or from funds released to us upon completion of our business combination. If
we are unable to complete our business combination because we do not have sufficient funds available to us, we will be forced to cease
operations and liquidate the trust account. Consequently, our public stockholders may only receive approximately $10.00 per share (or
less in certain circumstances) on our redemption of our public shares, and our rights and warrants will expire worthless. In certain circumstances,
our public stockholders may receive less than $10.00 per share on the redemption of their shares. If third parties bring claims against
us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than
$10.00 per share” and other risk factors herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If third parties bring claims against us, the proceeds
held in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than $10.00 per share.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our placing of funds in the trust account may not protect
those funds from third-party claims against us. Although we will seek to have all vendors, service providers, prospective target businesses
or other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to
any monies held in the trust account for the benefit of our public stockholders, such parties may not execute such agreements, or even
if they execute such agreements they may not be prevented from bringing claims against the trust account, including, but not limited to,
fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of
the waiver, in each case in order to gain advantage with respect to a claim against our assets, including the funds held in the trust
account. If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management
will perform an analysis of the alternatives available to it and will only enter into an agreement with a third party that has not executed
a waiver if management believes that such third party’s engagement would be significantly more beneficial to us than any alternative.
Further, a court may not uphold the validity of such agreements. Making such a request of potential target businesses may make our acquisition
proposal less attractive to them and, to the extent prospective target businesses refuse to execute such a waiver, it may limit the field
of potential target businesses that we might pursue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Examples of possible instances where we may engage a
third party that refuses to execute a waiver include the engagement of a third party consultant whose particular expertise or skills are
believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where
management is unable to find a service provider willing to execute a waiver. In addition, there is no guarantee that such entities will
agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with
us and will not seek recourse against the trust account for any reason. Upon redemption of our public shares, if we are unable to complete
our business combination within the prescribed timeframe, or upon the exercise of a redemption right in connection with our business combination,
we will be required to provide for payment of claims of creditors that were not waived that may be brought against us. Accordingly, the
per-share redemption amount received by public stockholders could be less than the $10.00 per share initially held in the trust account,
due to claims of such creditors.&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">If we are unable to complete a business combination
and distribute the proceeds held in trust to our public stockholders, our sponsor has agreed (subject to certain exceptions) that it will
be liable to ensure that the proceeds in the trust account are not reduced below $10.00 per share by the claims of target businesses or
claims of vendors or other entities that are owed money by us for services rendered or contracted for or products sold to us. We believe
that the primary assets of the sponsor are comprised of our securities and therefore we cannot assure you it will have sufficient liquid
assets to satisfy such obligations if it is required to do so. Therefore, the per-share distribution from the trust account may be less
than $10.00, plus interest, due to such claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"><span style="font-family: Times New Roman PS Std,serif">Additionally,
if we are forced to file a bankruptcy case or an involuntary bankruptcy case is filed against us which is not dismissed, the proceeds
held in the trust account could be subject to applicable bankruptcy law, and may be included in our bankruptcy estate and subject to the
claims of third parties with priority over the claims of our stockholders. To the extent any bankruptcy claims deplete the trust account,
we may not be able to return to our public stockholders at least $10.00.</span>&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b>We may not have sufficient funds to satisfy
indemnification claims of our directors and executive officers.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">We have agreed to indemnify our officers and directors
to the fullest extent permitted by law. However, our officers and directors have agreed to waive any right, title, interest or claim of
any kind in or to any monies in the trust account and to not seek recourse against the trust account for any reason whatsoever. Accordingly,
any indemnification provided will be able to be satisfied by us only if (i) we have sufficient funds outside of the trust account or (ii)
we consummate an initial business combination. Our obligation to indemnify our officers and directors may discourage stockholders from
bringing a lawsuit against our officers or directors for breach of their fiduciary duty. These provisions also may have the effect of
reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might
otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay
the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our directors may decide not to enforce the indemnification
obligations of our sponsor, resulting in a reduction in the amount of funds in the trust account available for distribution to our public
shareholders.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the event that the proceeds in the trust account
are reduced below $10.00 per public share and our sponsor asserts that it is unable to satisfy its obligations or that it has no indemnification
obligations related to a particular claim, our independent directors would determine whether to take legal action against our sponsor
to enforce its indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf
against our sponsor to enforce its indemnification obligations to us, it is possible that our independent directors in exercising their
business judgment may choose not to do so in any particular instance. For example, the cost of such legal action may be deemed by the
independent directors to be too high relative to the amount recoverable or the independent directors may determine that a favorable outcome
is not likely.&nbsp;If our independent directors choose not to enforce these indemnification obligations, the amount of funds in the trust
account available for distribution to our public stockholders may be reduced below $10.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If, after we distribute the proceeds in the trust
account to our public shareholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not
dismissed, a bankruptcy court may seek to recover such proceeds, and the members of our Board of Directors may be viewed as having breached
their fiduciary duties to our creditors, thereby exposing the members of our Board of Directors and us to claims of punitive damages.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If, after we distribute the proceeds in the trust account
to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed,
any distributions received by stockholders could be viewed under applicable debtor/creditor and/or bankruptcy laws as either a “preferential
transfer” or a “fraudulent conveyance.” As a result, a bankruptcy court could seek to recover all amounts received by
our stockholders. In addition, our Board of Directors may be viewed as having breached its fiduciary duty to our creditors and/or having
acted in bad faith, thereby exposing itself and us to claims of punitive damages, by paying public stockholders from the trust account
prior to addressing the claims of creditors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If, before distributing the proceeds in the trust
account to our public shareholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not
dismissed, the claims of creditors in such proceeding may have priority over the claims of our shareholders and the per-share amount that
would otherwise be received by our shareholders in connection with our liquidation may be reduced.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If, before distributing the proceeds in the trust account
to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed,
the proceeds held in the trust account could be subject to applicable bankruptcy law, and may be included in our bankruptcy estate and
subject to the claims of third parties with priority over the claims of our stockholders. To the extent any bankruptcy claims deplete
the trust account, the per-share amount that would otherwise be received by our stockholders in connection with our liquidation may be
reduced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If we are deemed to be an investment company under
the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which
may make it difficult for us to complete our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman PS Std,serif">A
company that, among other things, is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business
of investing, reinvesting, owning, trading or holding certain types of securities would be deemed an investment company under the Investment
Company Act, as amended, or the Investment Company Act. Since we will invest the proceeds held in the trust account, it is possible that
we could be deemed an investment company. </span>If we are deemed to be an investment company under the Investment Company Act, our activities
may be restricted, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;restrictions
on the nature of our investments; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;restrictions
on the issuance of securities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">each of which may make it difficult
for us to complete our business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we may have imposed
upon us burdensome requirements, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;registration
as an investment company;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;adoption
of a specific form of corporate structure; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reporting,
record keeping, voting, proxy and disclosure requirements and other rules and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Compliance with these additional regulatory burdens
would require additional expense for which we have not allotted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">We do not believe that our anticipated principal activities
will subject us to the Investment Company Act. The proceeds held in the trust account may be invested by the trustee only in United States
government treasury bills with a maturity of 180 days or less or in money market funds investing solely in United States Treasuries and
meeting certain conditions under Rule 2a-7 under the Investment Company Act. Because the investment of the proceeds will be restricted
to these instruments, we believe we will meet the requirements for the exemption provided in Rule 3a-1 promulgated under the Investment
Company Act. If we were deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would
require additional expenses for which we have not allotted funds and may hinder our ability to complete a business combination. If we
are unable to complete our business combination, our public stockholders may receive only approximately $10.00 per share, or less in certain
circumstances, on the liquidation of our trust account and our rights and warrants will expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>The securities in which we invest the funds held in the trust account
could bear a negative rate of interest, which could reduce the value of the assets held in trust such that the per-share redemption amount
received by public stockholders may be less than $10.00 per share.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">The proceeds held in the trust account will be
invested only in U.S. government treasury obligations with a maturity of 180 days or less or in money market funds meeting certain conditions
under Rule&nbsp;2a-7&nbsp;under the&nbsp;Investment Company Act, which invest only in direct U.S. government treasury obligations. While
short-term&nbsp;U.S. government treasury obligations currently yield a positive rate of interest, they have briefly yielded&nbsp;negative
interest rates&nbsp;in recent years. Central banks in Europe and Japan pursued interest rates below zero in recent years, and the Open
Market Committee of the Federal Reserve has not ruled out the possibility that it may in the future adopt similar policies in the United
States. In the event that we are unable to complete our initial business combination or make certain amendments to our amended and restated
certificate of incorporation, our public stockholders are entitled to receive their pro-rata&nbsp;share of the proceeds held in the trust
account, plus any interest income, net of taxes paid or payable (less, in the case we are unable to complete our initial business combination,
$50,000 of interest).&nbsp; Negative interest rates could reduce the value of the assets held in trust such that the per-share&nbsp;redemption
amount received by public stockholders may be less than $10.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If we are unable to consummate our business combination
within 9 months (or up to 21 months from the closing of our IPO if we extend the period of time to consummate a business combination)
of the closing of our IPO, our public shareholders may be forced to wait beyond such 9 months (or up to 21 months) before redemption from
our trust account.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 22.5pt">If we are unable to consummate our business
combination within 9 months from the closing of our IPO (or up to 21 months from the closing of our IPO if we extend the period of time
to consummate a business combination), we will distribute the aggregate amount then on deposit in the trust account (less the net interest
earned thereon to pay dissolution expenses), pro rata to our public stockholders by way of redemption and cease all operations except
for the purposes of winding up of our affairs, as further described herein. If we are required to windup, liquidate the trust account
and distribute such amount therein, pro rata, to our public stockholders, as part of any liquidation process, such winding up, liquidation
and distribution must comply with the applicable provisions of applicable Delaware law. In that case, investors may be forced to wait
beyond the 9 months (or up to 21 months) before the redemption proceeds of our trust account become available to them and they receive
the return of their pro rata portion of the proceeds from our trust account. Only after the expiration of this full time period will public
security holders be entitled to distributions from the trust account if we are unable to complete a business combination. Accordingly,
investors’ funds may be unavailable to them until after such date and to liquidate your investment, public security holders may
be forced to sell their public shares or warrants, potentially at a loss. We have no obligation to return funds to investors prior to
the date of our redemption or liquidation unless we consummate our business combination prior thereto and only then in cases where investors
have sought to redeem their shares of common stock. Only upon our redemption or any liquidation will public stockholders be entitled to
distributions if we are unable to complete our business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font-family: Times New Roman PS Std,serif"><b></b></span></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font-family: Times New Roman PS Std,serif"><b>Our
stockholders may be held liable for claims by third parties against us to the extent of distributions&nbsp;</b></span><b>received by them.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Under the Delaware General Corporation Law, or the
DGCL, stockholders may be held liable for claims by third parties against a corporation to the extent of distributions received by them
in a dissolution. The pro rata portion of our trust account distributed to our public stockholders upon the redemption of our public shares
in the event we do not complete our initial business combination within the required time period may be considered a liquidating distribution
under Delaware law. If a corporation complies with certain procedures set forth in Section&nbsp;280 of the DGCL intended to ensure that
it makes reasonable provision for all claims against it, including a 60-day notice period during which any third-party claims can be brought
against the corporation, a 90-day period during which the corporation may reject any claims brought, and an additional 150-day waiting
period before any liquidating distributions are made to stockholders, any liability of stockholders with respect to a liquidating distribution
is limited to the lesser of such stockholder’s pro rata share of the claim or the amount distributed to the stockholder, and any
liability of the stockholder would be barred after the third anniversary of the dissolution. However, it is our intention to redeem our
public shares as soon as reasonably possible following the ninth (9<sup>th</sup>) month from the closing of this offering (or the end
of any extension period) in the event we do not complete our initial business combination and, therefore, we do not intend to comply with
the foregoing procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Because we do not intend to comply with Section&nbsp;280,
Section&nbsp;281(b)&nbsp;of the DGCL requires us to adopt a plan, based on facts known to us at such time that will provide for our payment
of all existing and pending claims or claims that may be potentially brought against us within the 10 years following our dissolution.
However, because we are a blank check company, rather than an operating company, and our operations will be limited to searching for prospective
target businesses to acquire, the only likely claims to arise would be from our vendors (such as lawyers, investment bankers, consultants,&nbsp;etc.)
or prospective target businesses. If our plan of distribution complies with Section&nbsp;281(b)&nbsp;of the DGCL, any liability of stockholders
with respect to a liquidating distribution is limited to the lesser of such stockholder’s pro rata share of the claim or the amount
distributed to the stockholder, and any liability of the stockholder would likely be barred after the third anniversary of the dissolution.
We cannot assure you that we will properly assess all claims that may be potentially brought against us. As such, our stockholders could
potentially be liable for any claims to the extent of distributions received by them (but no more) and any liability of our stockholders
may extend beyond the third anniversary of such date. Furthermore, if the pro rata portion of our trust account distributed to our public
stockholders upon the redemption of our public shares in the event we do not complete our initial business combination within the required
time period is not considered a liquidating distribution under Delaware law and such redemption distribution is deemed to be unlawful,
then pursuant to Section&nbsp;174 of the DGCL, the statute of limitations for claims of creditors could then be six years after the unlawful
redemption distribution, instead of three years, as in the case of a liquidating distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may not hold an annual meeting of shareholders
until after the consummation of our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"><span style="font-family: Times New Roman PS Std,serif">The
Nasdaq corporate governance requirements do not require us to hold an annual meeting until the first anniversary of our first fiscal year
end following our listing on Nasdaq.&nbsp;</span>We may not hold an annual meeting of stockholders until after we consummate our initial
business combination and thus may not be in compliance with Section&nbsp;211(b)&nbsp;of the DGCL, which requires an annual meeting of
stockholders be held for the purposes of electing directors in accordance with a company’s bylaws unless such election is made by
written consent in lieu of such a meeting. Therefore, if our stockholders want us to hold an annual meeting prior to our consummation
of our initial business combination, they may attempt to force us to hold one by submitting an application to the Delaware Court of Chancery
in accordance with Section&nbsp;211(c)&nbsp;of the DGCL. Until we hold an annual meeting of stockholders, public stockholders may not
be afforded the opportunity to discuss company affairs with management.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b>Holders of rights and public warrants will
not have redemption rights with respect to such securities<i>.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we are unable to complete an initial business combination
within the required time period and we redeem the funds held in the trust account, the rights and public warrants will expire and holders
of such securities will not receive any of the amounts held in the trust account in exchange for their rights or public warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The grant of registration rights to our sponsor
and holders of our private placement warrants may make it more difficult to complete our business combination, and the future exercise
of such rights may adversely affect the market price of our shares of common stock.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We entered into a registration rights agreement with
our sponsor and our other initial stockholders, pursuant to which such persons and their permitted transferees can demand that we register
their founder shares, the private placement warrants, the shares underlying such warrants, and any warrants we may issue upon conversion
of working capital loans. We will bear the cost of registering these securities. The registration and availability of such a significant
number of securities for trading in the public market may have an adverse effect on the market price of our shares of common stock. In
addition, the existence of the registration rights may make our business combination more costly or difficult to conclude. This is because
the stockholders of the target business may increase the equity stake they seek in the combined entity or ask for more cash consideration
to offset the negative impact on the market price of our shares of common stock that is expected when the shares owned by our sponsor,
holders of our private placement warrants or holders of our working capital loans or their respective permitted transferees are registered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Because we are neither limited to evaluating target businesses in a
particular industry, sector or geographic area nor have we selected any specific target businesses with which to pursue our initial business
combination, you will be unable to ascertain the merits or risks of any particular target business’s operations.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We may seek to complete a business combination with
an operating company in any industry, sector or geographic area. However, we will not, under our amended and restated certificate of incorporation,
be permitted to effectuate our initial business combination solely with another blank check company or similar company with nominal operations.
Because we have not yet selected or approached any specific target business with respect to a business combination, there is no basis
to evaluate the possible merits or risks of any particular target business’s operations, results of operations, cash flows, liquidity,
financial condition or prospects. To the extent we complete our initial business combination, we may be affected by numerous risks inherent
in the business operations with which we combine. For example, if we combine with a financially unstable business or an entity lacking
an established record of sales or earnings, we may be affected by the risks inherent in the business and operations of a financially unstable
or a development stage entity. Although our officers and directors will endeavor to evaluate the risks inherent in a particular target
business, we cannot assure you that we will properly ascertain or assess all of the significant risk factors or that we will have adequate
time to complete due diligence. Furthermore, some of these risks may be outside of our control and leave us with no ability to control
or reduce the chances that those risks will adversely impact a target business. We also cannot assure you that an investment in our units
will ultimately prove to be more favorable to investors than a direct investment, if such opportunity were available, in a business combination
target. Accordingly, any stockholders or warrant holders who choose to remain a stockholder or warrant holder following our initial business
combination could suffer a reduction in the value of their securities. Such stockholders or warrant holders are unlikely to have a remedy
for such reduction in value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may seek acquisition opportunities in industries
or sectors that may be outside of our management’s areas of expertise.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">Although we expect to
focus our search for a target business in the healthcare</span><span style="font-size: 9pt">,</span>&nbsp;<span style="font-size: 10pt">technology,
green economy and consumer products sectors, we will consider a business combination outside of our management’s areas of expertise
if a business combination candidate is presented to us and we determine that such candidate offers an attractive acquisition opportunity
for our company. In the event we elect to pursue an acquisition outside of the areas of our management’s expertise, our management’s
expertise may not be directly applicable to its evaluation or operation, and the information contained in this report regarding the areas
of our management’s expertise would not be relevant to an understanding of the business that we elect to acquire. As a result, our
management may not be able to adequately ascertain or assess all of the significant risk factors. Accordingly, any stockholders who choose
to remain stockholders following our business combination could suffer a reduction in the value of their shares. Such stockholders are
unlikely to have a remedy for such reduction in value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Although we have identified general criteria and
guidelines that we believe are important in evaluating prospective target businesses, we may enter into our business combination with
a target that does not meet such criteria and guidelines, and as a result, the target business with which we enter into our business combination
may not have attributes entirely consistent with our general criteria and guidelines.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Although we have identified general criteria and guidelines
for evaluating prospective target businesses, it is possible that a target business with which we enter into our business combination
will not have all of these positive attributes. If we complete our business combination with a target that does not meet some or all of
these guidelines, such combination may not be as successful as a combination with a business that does meet all of our general criteria
and guidelines. In addition, if we announce a prospective business combination with a target that does not meet our general criteria and
guidelines, a greater number of stockholders may exercise their redemption rights, which may make it difficult for us to meet any closing
condition with a target business that requires us to have a minimum net worth or a certain amount of cash. In addition, if stockholder
approval of the transaction is required by law, or we decide to obtain stockholder approval for business or other legal reasons, it may
be more difficult for us to attain stockholder approval of our business combination if the target business does not meet our general criteria
and guidelines. If we are unable to complete our business combination, our public stockholders may receive only approximately $10.00 per
share on the liquidation of our trust account and our rights and warrants will expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: justify"><b>If we do not conduct an adequate due diligence investigation
of a target business, we may be required to subsequently take write-downs or write-offs, restructuring, and impairment or other charges
that could have a significant negative effect on our financial condition, results of operations and our stock price, which could cause
you to lose some or all of your investment.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"><span style="font-family: Times New Roman PS Std,serif">We
must conduct a due diligence investigation of the target businesses we intend to acquire. Intensive due diligence is time consuming and
expensive due to the operations, accounting, finance and legal professionals who must be involved in the due diligence process. Even if
we conduct extensive due diligence on a target business, this diligence may not reveal all material issues that may affect a particular
target business, that it would be possible to uncover all material issues through a customary amount of due diligence, or that factors
outside the control of the target business and outside of our control may later arise. If our diligence fails to identify issues specific
to a target business, industry or the environment in which the target business operates, we may be forced to later write-down or write-off
assets, restructure our operations, or incur impairment or other charges that could result in our reporting losses. </span>Even if our
due diligence successfully identifies certain risks, unexpected risks may arise and previously known risks may materialize in a manner
not consistent with our preliminary risk analysis. <span style="font-family: Times New Roman PS Std,serif">Even though these charges may
be non-cash items and not have an immediate impact on our liquidity, the fact that we report charges of this nature could contribute to
negative market perceptions about us or our shares of common stock. In addition, charges of this nature may cause us to violate net worth
or other covenants to which we may be subject as a result of assuming pre-existing debt held by a target business or by virtue of our
obtaining post-combination debt financing. </span>Accordingly, any stockholders who choose to remain stockholders following the business
combination could suffer a reduction in the value of their shares. Such stockholders are unlikely to have a remedy for such reduction
in value.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may seek acquisition opportunities with a financially
unstable business or an entity lacking an established record of revenue or earnings.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To the extent we complete our business combination
with a financially unstable business or an entity lacking an established record of sales or earnings, we may be affected by numerous risks
inherent in the operations of the business with which we combine. These risks include volatile revenues or earnings and difficulties in
obtaining and retaining key personnel. Although our officers and directors will endeavor to evaluate the risks inherent in a particular
target business, we may not be able to properly ascertain or assess all of the significant risk factors and we may not have adequate time
to complete due diligence. Furthermore, some of these risks may be outside of our control and leave us with no ability to control or reduce
the chances that those risks will adversely impact a target business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Because we must furnish our stockholders with target
business financial statements, we may lose the ability to complete an otherwise advantageous business combination with some prospective
target businesses.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The federal proxy rules require that a proxy statement
with respect to a vote on a business combination meeting certain financial significance tests include historical and/or pro forma financial
statement disclosure in periodic reports. We will include the same financial statement disclosure in connection with our tender offer
documents, whether or not they are required under the tender offer rules. These financial statements may be required to be prepared in
accordance with, or be reconciled to, accounting principles generally accepted in the United States of America, or U.S. GAAP, or international
financing reporting standards as issued by the International Accounting Standards Board, or IFRS, depending on the circumstances and the
historical financial statements may be required to be audited in accordance with the standards of the Public Company Accounting Oversight
Board (United States), or PCAOB. These financial statement requirements may limit the pool of potential target businesses we may acquire
because some targets may be unable to provide such statements in time for us to disclose such statements in accordance with federal proxy
rules and complete our business combination within the prescribed time frame.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Because we must furnish our stockholders with target
business financial statements, we may lose the ability to complete an otherwise advantageous business combination with some prospective
target businesses.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The federal proxy rules require that a proxy statement
with respect to a vote on a business combination meeting certain financial significance tests include historical and/or pro forma financial
statement disclosure in periodic reports. We will include the same financial statement disclosure in connection with our tender offer
documents, whether or not they are required under the tender offer rules. These financial statements may be required to be prepared in
accordance with, or be reconciled to, accounting principles generally accepted in the United States of America, or U.S. GAAP, or international
financing reporting standards as issued by the International Accounting Standards Board, or IFRS, depending on the circumstances and the
historical financial statements may be required to be audited in accordance with the standards of the Public Company Accounting Oversight
Board (United States), or PCAOB. These financial statement requirements may limit the pool of potential target businesses we may acquire
because some targets may be unable to provide such statements in time for us to disclose such statements in accordance with federal proxy
rules and complete our business combination within the prescribed time frame.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We are not required to obtain an opinion from an
independent investment banking or from an independent accounting firm, and consequently, you may have no assurance from an independent
source that the price we are paying for the business is fair to our company from a financial point of view.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless we complete our business combination with an
affiliated entity, or our Board of Directors cannot independently determine the fair market value of the target business or businesses,
we are not required to obtain an opinion from an independent investment banking firm, another independent firm that commonly renders valuation
opinions for the type of company we are seeking to acquire or from an independent accounting firm that the price we are paying for a target
is fair to our company from a financial point of view. If no opinion is obtained, our stockholders will be relying on the business judgment
of our Board of Directors, which will have significant discretion in choosing the standard used to establish the fair market value of
the target or targets, and different methods of valuation may vary greatly in outcome from one another. Such standards used will be disclosed
in our tender offer documents or proxy solicitation materials, as applicable, related to our business combination. However, if our Board
of Directors is unable to determine the fair value of an entity with which we seek to complete an business combination based on such standards,
we will be required to obtain an opinion as described above.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b>We may issue shares of our capital stock
or debt securities to complete a business combination, which would reduce the equity interest of our stockholders and could cause a change
in control of our ownership.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">Our Certificate of Incorporation authorizes the
issuance of up to 300,000,000 shares of common stock, $0.00001 par value, and 100,000,000 shares of preferred stock, $0.00001 par value.
Following our IPO, we have 285,196,429 authorized but unissued shares of common stock available for issuance (after appropriate reservation
for the issuance of the shares underlying the public and private warrants and the rights, but excluding any working capital warrants).
Although we have no commitment as of the date of this report, we may issue a substantial number of additional shares of common stock or
preferred stock, or a combination of shares of common stock and preferred stock, to obtain additional working capital or to complete a
business combination. The issuance of additional shares of common stock or preferred stock will not reduce the per-share redemption amount
in the trust account, but:</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
significantly dilute the equity interest of investors in our IPO;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
subordinate the rights of holders of shares of common stock if we issue shares of preferred stock with rights senior to those afforded
to our shares of common stock;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
cause a change in control if a substantial number of shares of common stock are issued, which may affect, among other things, our ability
to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;
and</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
adversely affect prevailing market prices for our shares of common stock.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Similarly, if we issue debt securities, it could
result in:</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;default
and foreclosure on our assets if our operating revenues after a business combination are insufficient to repay our debt obligations;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acceleration
of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants
that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; and</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing
while the debt security is outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>our
inability to pay dividends on our common stock;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>using
a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends
on our common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>limitations
on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>increased
vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;
and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>limitations
on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of
our strategy and other purposes and other disadvantages compared to our competitors who have less debt.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">If we incur indebtedness, our lenders will not
have a claim on the cash in the trust account and such indebtedness will not decrease the per-share redemption amount in the trust account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may reincorporate in another jurisdiction in
connection with our business combination and such reincorporation may result in taxes imposed on shareholders.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may, in connection with our business combination
and subject to requisite stockholder approval under Delaware law, reincorporate in the jurisdiction in which the target company or business
is located. The transaction may require a stockholder to recognize taxable income in the jurisdiction in which the stockholder is a tax
resident or in which its members are resident if it is a tax transparent entity. We do not intend to make any cash distributions to stockholders
to pay such taxes. Stockholders may be subject to withholding taxes or other taxes with respect to their ownership of us after the reincorporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Resources could be spent in researching acquisitions
that are not completed, which could materially adversely affect subsequent attempts to locate and acquire or merge with another business.
If we are unable to complete our business combination, our public shareholders may receive only approximately $10.00 per share, or less
than such amount in certain circumstances, on the liquidation of our trust account and our rights and warrants will expire worthless.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We anticipate that the investigation of each specific
target business and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments will require
substantial management time and attention and substantial costs for accountants, attorneys and others. If we decide not to complete a
specific business combination, the costs incurred up to that point for the proposed transaction likely would not be recoverable. Furthermore,
if we reach an agreement relating to a specific target business, we may fail to complete our business combination for any number of reasons
including those beyond our control. Any such event will result in a loss to us of the related costs incurred which could materially adversely
affect subsequent attempts to locate and acquire or merge with another business. If we are unable to complete our business combination,
our public stockholders may receive only approximately $10.00 per share on the liquidation of our trust account and our rights and warrants
will expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Ladenburg Thalmann may have a conflict of interest in rendering services
to us in connection with our initial business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have entered into a Business Combination Marketing
Agreement with Ladenburg Thalmann. Pursuant to this agreement, Ladenburg Thalmann will provide certain specified services to us in connection
with our initial business combination, though such services will not include the provision of any M&amp;A-related advisory services. This
agreement will provide that we will pay Ladenburg Thalmann the Marketing Fee for such services upon the consummation of our initial business
combination in an amount equal to, in the aggregate, 2.5% of the gross proceeds of our IPO. In the ordinary course of business, Ladenburg
Thalmann and its affiliates may at any time hold long or short positions, and may trade or otherwise effect transactions, for its own
account and the accounts of customers, in the debt or equity securities of us, our affiliates or other entities that may be involved in
the transactions contemplated by the Business Combination Marketing Agreement, and may provide advisory and other services to one or more
actual or potential business combination targets, investors or other parties to any business combination or other transaction entered
into by us, for which services Ladenburg Thalmann or one or more of its affiliates may be paid fees, including fees conditioned upon the
closing of a particular business combination or other transaction or transactions. This financial interest may result in Ladenburg Thalmann
having a conflict of interest when providing the services to us in connection with an initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may issue notes or other debt securities, or
otherwise incur substantial debt, to complete a business combination, which may adversely affect our leverage and financial condition
and thus negatively impact the value of our stockholders’ investment in us.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Although we presently have no commitments to issue
any notes or other debt securities, or to otherwise incur outstanding debt following our IPO, we may choose to incur substantial debt
to complete our business combination. We have agreed that we will not incur any indebtedness unless we have obtained from the lender a
waiver of any right, title, interest or claim of any kind in or to the monies held in the trust account. As such, no issuance of debt
will affect the per-share amount available for redemption from the trust account. Nevertheless, the incurrence of debt could have a variety
of negative effects, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;default
and foreclosure on our assets if our operating revenues after an business combination are insufficient to repay our debt obligations;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acceleration
of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants
that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing
while the debt security is outstanding;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
inability to pay dividends on our shares of common stock;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;using
a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends
on our shares of common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;limitations
on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;increased
vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;
and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;limitations
on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of
our strategy and other purposes and other disadvantages compared to our competitors who have less debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may only be able to complete one business combination
with the proceeds of our IPO and the sale of the private placement warrants, which will cause us to be solely dependent on a single business
which may have a limited number of products or services. This lack of diversification may negatively impact our operations and profitability.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Of the net proceeds from our IPO and the sale of the
private placement warrants, $65,000,000 is available to complete our business combination and pay related fees and expenses (which includes
up to approximately $1,625,000 for the payment of fees under the Business Combination Marketing Agreement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may effectuate our business combination with a single
target business or multiple target businesses simultaneously or within a short period of time. However, we may not be able to effectuate
our business combination with more than one target business because of various factors, including the existence of complex accounting
issues and the requirement that we prepare and file pro forma financial statements with the SEC that present operating results and the
financial condition of several target businesses as if they had been operated on a combined basis. By completing our business combination
with only a single entity our lack of diversification may subject us to numerous economic, competitive and regulatory risks. Further,
we would not be able to diversify our operations or benefit from the possible spreading of risks or offsetting of losses, unlike other
entities which may have the resources to complete several business combinations in different industries or different areas of a single
industry. Accordingly, the prospects for our success may be:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;solely
dependent upon the performance of a single business, property or asset; or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Symbol">·</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dependent
upon the development or market acceptance of a single or limited number of products, processes or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This lack of diversification may subject us to numerous
economic, competitive and regulatory risks, any or all of which may have a substantial adverse impact upon the particular industry in
which we may operate subsequent to our business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may attempt to simultaneously complete business
combinations with multiple prospective targets, which may hinder our ability to complete our business combination and give rise to increased
costs and risks that could negatively impact our operations and profitability.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we determine to simultaneously acquire several businesses
that are owned by different sellers, we will need for each of such sellers to agree that our purchase of its business is contingent on
the simultaneous closings of the other business combinations, which may make it more difficult for us, and delay our ability, to complete
our business combination. With multiple business combinations, we could also face additional risks, including additional burdens and costs
with respect to possible multiple negotiations and due diligence investigations (if there are multiple sellers) and the additional risks
associated with the subsequent assimilation of the operations and services or products of the acquired companies in a single operating
business. If we are unable to adequately address these risks, it could negatively impact our profitability and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may attempt to complete our business combination
with a private company about which little information is available, which may result in a business combination with a company that is
not as profitable as we suspected, if at all.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In pursuing our acquisition strategy, we may seek to
effectuate our business combination with a privately held company. Very little public information generally exists about private companies,
and we could be required to make our decision on whether to pursue a potential business combination on the basis of limited information,
which may result in a business combination with a company that is not as profitable as we suspected, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">Risks Relating to our Management and Directors</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><span style="font-family: Times New Roman PS Std,serif"><b>Our ability
to successfully effect a business combination and to be successful thereafter will be totally dependent upon the efforts of our key personnel,
some of whom may join us following a business combination. While we intend to closely scrutinize any individuals we engage after a business
combination, we cannot assure you that our assessment of these individuals will prove to be correct.</b></span><b> Further, the loss of
key personnel could negatively impact the operations and profitability of our post-combination business</b>.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Our ability to successfully effect a business combination
is dependent upon the efforts of our key personnel. We believe that our success depends on the continued service of our key personnel,
at least until we have consummated our initial business combination. We cannot assure you that any of our key personnel will remain with
us for the immediate or foreseeable future, either due to health conditions or otherwise. In addition, none of our officers is required
to commit any specified amount of time to our affairs and, accordingly, our officers will have conflicts of interest in allocating management
time among various business activities, including identifying potential business combinations and monitoring the related due diligence.
We do not have employment agreements with, or key-man insurance on the life of, any of our officers. The unexpected loss of the services
of our key personnel could have a detrimental effect on us.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">The role of our key personnel after a business
combination, however, cannot presently be ascertained. Although some of our key personnel may serve in senior management or as members
of the Board of Directors or advisory positions following a business combination, it is likely that most, if not all, of the management
of the target business will remain in place. While we intend to closely scrutinize any individuals we engage after a business combination,
we cannot assure you that our assessment of these individuals will prove to be correct. These individuals may be unfamiliar with the requirements
of operating a public company which could cause us to have to expend time and resources helping them become familiar with such requirements.
This could be expensive and time-consuming and could lead to various regulatory issues which may adversely affect our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We are dependent upon our officers and directors
and their departure could adversely affect our ability to operate.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our operations are dependent upon a relatively small
group of individuals and, in particular, Mr. Liu and our other officers and directors. We believe that our success depends on the continued
service of our officers and directors, at least until we have completed our business combination. In addition, our officers and directors
are not required to commit any specified amount of time to our affairs and, accordingly, will have conflicts of interest in allocating
management time among various business activities, including identifying potential business combinations and monitoring the related due
diligence. We do not have an employment agreement with, or key-man insurance on the life of, any of our directors or officers. The unexpected
loss of the services of one or more of our directors or officers could have a detrimental effect on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our key personnel may negotiate employment or consulting
agreements with a target business in connection with a particular business combination. These agreements may provide for them to receive
compensation following our business combination and as a result, may cause them to have conflicts of interest in determining whether a
particular business combination is the most advantageous.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our key personnel may be able to remain with the company
after the completion of our business combination only if they are able to negotiate employment or consulting agreements in connection
with the business combination. Such negotiations would take place simultaneously with the negotiation of the business combination and
could provide for such individuals to receive compensation in the form of cash payments and/or our securities for services they would
render to us after the completion of the business combination. The personal and financial interests of such individuals may influence
their motivation in identifying and selecting a target business, subject to his or her fiduciary duties under Delaware law. However, we
believe the ability of such individuals to remain with us after the completion of our business combination will not be the determining
factor in our decision as to whether or not we will proceed with any potential business combination. There is no certainty, however, that
any of our key personnel will remain with us after the completion of our business combination. We cannot assure you that any of our key
personnel will remain in senior management or advisory positions with us. The determination as to whether any of our key personnel will
remain with us will be made at the time of our business combination.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>Our officers and directors may not have significant experience
or knowledge regarding the jurisdiction or industry of the target business we may seek to acquire.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">We may consummate a business combination with a
target business in any geographic location or industry we choose. We cannot assure you that our officers and directors will have enough
experience or have sufficient knowledge relating to the jurisdiction of the target or its industry to make an informed decision regarding
a business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may have a limited ability to assess the management
of a prospective target business and, as a result, may effect our business combination with a target business whose management may not
have the skills, qualifications or abilities to manage a public company.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">When evaluating the desirability of effecting our
business combination with a prospective target business, our ability to assess the target business’s management may be limited due
to a lack of time, resources or information. Our assessment of the capabilities of the target’s management, therefore, may prove
to be incorrect and such management may lack the skills, qualifications or abilities we suspected. Should the target’s management
not possess the skills, qualifications or abilities necessary to manage a public company, the operations and profitability of the post-combination
business may be negatively impacted. Accordingly, any stockholders who choose to remain stockholders following the business combination
could suffer a reduction in the value of their shares. Such stockholders are unlikely to have a remedy for such reduction in value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The officers and directors of an acquisition candidate
may resign upon completion of our business combination. The departure of a business combination target’s key personnel could negatively
impact the operations and profitability of our post-combination business. The role of an acquisition candidates’ key personnel upon
the completion of our business combination cannot be ascertained at this time. Although we contemplate that certain members of an acquisition
candidate’s management team will remain associated with the acquisition candidate following our business combination, it is possible
that members of the management of an acquisition candidate will not wish to remain in place. As a result, we may need to reconstitute
the management team of the post-transaction company in connection with our initial business combination, which may adversely impact our
ability to complete an acquisition in a timely manner or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our officers and directors will allocate their
time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This
conflict of interest could have a negative impact on our ability to complete our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our officers and directors are not required to, and
will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations
and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion
of our business combination. Each of our officers is engaged in several other business endeavors for which he or she may be entitled to
substantial compensation and our officers are not obligated to contribute any specific number of hours per week to our affairs. Our independent
directors also serve as officers and board members for other entities. If our officers’ and directors’ other business affairs
require them to devote substantial amounts of time to such affairs in excess of their current commitment levels, it could limit their
ability to devote time to our affairs which may have a negative impact on our ability to complete our business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Certain of our officers and directors are now,
and all of them may in the future become, affiliated with entities engaged in business activities similar to those intended to be conducted
by us and, accordingly, may have conflicts of interest in determining to which entity a particular business opportunity should be presented.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Following the completion of our IPO and until we consummate
our business combination, we intend to engage in the business of identifying and combining with one or more businesses. Our sponsor and
officers and directors are, or may in the future become, affiliated with other blank check companies like ours or other entities (such
as operating companies or investment vehicles) that are engaged in making and managing investments in a similar business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our officers and directors also may become aware of
business opportunities which may be appropriate for presentation to us and the other entities to which they owe certain fiduciary or contractual
duties. Accordingly, they may have conflicts of interest in determining to which entity a particular business opportunity should be presented.
These conflicts may not be resolved in our favor and a potential target business may be presented to other entities prior to its presentation
to us, subject to his or her fiduciary duties under applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have not adopted a policy that expressly prohibits
our directors, officers, security holders or affiliates from having a direct or indirect pecuniary or financial interest in any investment
to be acquired or disposed of by us or in any transaction to which we are a party or have an interest. In fact, we may enter into a business
combination with a target business that is affiliated with our sponsor, our directors or officers, although we do not intend to do so.
Nor do we have a policy that expressly prohibits any such persons from engaging for their own account in business activities of the types
conducted by us. Accordingly, such persons or entities may have a conflict between their interests and ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><b>Our sponsor, officers and directors may have a conflict of interest
in determining whether a particular target business is appropriate for a business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">Our sponsor and officers and directors have waived
their right to redeem their sponsor shares or any other shares purchased in this offering or thereafter, or to receive distributions from
the trust account with respect to their sponsor shares upon our liquidation if we are unable to consummate a business combination. Accordingly,
the shares and any private warrants acquired prior to this offering will be worthless if we do not consummate a business combination.
The personal and financial interests of our directors and officers may influence their motivation in timely identifying and selecting
a target business and completing a business combination. Consequently, our directors’ and officers’ discretion in identifying
and selecting a suitable target business may result in a conflict of interest when determining whether the terms, conditions and timing
of a particular business combination are appropriate and, in our stockholders’, best interest. &nbsp;This risk may become more acute
as the deadline for completing our initial business combination nears.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b></b></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>Our officers and directors or their affiliates have pre-existing
fiduciary and contractual obligations and accordingly, may have conflicts of interest in determining to which entity a particular business
opportunity should be presented.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 0.5in"><span style="font-family: Times New Roman PS Std,serif">Our
officers and directors or their affiliates have pre-existing fiduciary and contractual obligations to other companies. Accordingly, they
may participate in transactions and have obligations that may be in conflict or competition with our consummation of our initial business
combination. Additionally, a potential target business may be presented by our management team to another entity prior to its presentation
to us and we may not be afforded the opportunity to engage in a transaction with such target business.&nbsp;</span>Our amended and restated
certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer unless
such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity
is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue. Accordingly, if any
of our officers or directors becomes aware of a business combination opportunity which is suitable for one or more entities to which he
or she has fiduciary, contractual or other obligations or duties, he or she will honor these obligations and duties to present such business
combination opportunity to such entities first, and only present it to us if such entities reject the opportunity and he or she determines
to present the opportunity to us.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">For example, our Chief Executive Officer is affiliated
with Ladenburg, Thalmann, which was also the underwriter in our IPO. He owes a pre-existing&nbsp;fiduciary duty to Ladenburg, Thalmann
and will present opportunities to them prior to presenting them to us, if, for example, a potential target company is open to either raising
funds in an offering or engaging in a transaction with a SPAC. This may limit the number of potential targets they present to us for purposes
of completing a business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">These conflicts may not be resolved in our favor
and a potential target business may be presented to another entity prior to its presentation to us. For a more detailed description of
the pre-existing fiduciary and contractual obligations of our management team<span style="font-family: Times New Roman PS Std,serif">,
and the potential conflicts of interest that such obligations may present, see the section titled “<i>Management — Conflicts
of Interest</i>.”</span></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>Our officers and directors and their affiliates will control a
substantial interest in us and thus may influence certain actions requiring a stockholder vote.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Upon consummation of our IPO, our sponsor, officers
and directors and their affiliates will own approximately 20% of our issued and outstanding shares of common stock (excluding accounting
for any private warrants). Further, our sponsor, officers, directors or their affiliates could determine in the future to purchase our
securities in the open market or in private transactions, to the extent permitted by law, to increase their holdings in order to influence
the vote or magnitude of the number of stockholders seeking to tender their shares to us. If we are unable to complete our initial business
combination, our public stockholders may receive only approximately $10.00 per share, or less in certain circumstances, on the liquidation
of our trust account, and our warrants and rights will expire worthless. In connection with any vote for a proposed business combination,
our sponsor officers and directors have agreed to vote their sponsor shares, as well as any public shares acquired in or after this offering
in favor of any proposed business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><b>Past performance by members of our management
team and their respective affiliates may not be indicative of future performance of an investment in us.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Information regarding performance by, or businesses
associated with, members of our management team and their respective affiliates, is presented for informational purposes only. Any past
experience and performance, including related to acquisitions, of members of our management team and their respective affiliates, is not
a guarantee either: (1)&nbsp;that we will be able to successfully identify a suitable candidate for our initial business combination;
or (2)&nbsp;of any results with respect to any initial business combination we may consummate. You should not rely on the historical record
of our management team’s or their affiliates’ performance, as indicative of the future performance of an investment in us
or the returns we will, or are likely to, generate going forward.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our officers, directors, security holders and their respective affiliates
may have competitive pecuniary interests that conflict with our interests.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We have not adopted a policy that expressly prohibits
our directors, officers, security holders or affiliates from having a direct or indirect pecuniary or financial interest in any investment
to be acquired or disposed of by us or in any transaction to which we are a party or have an interest. In fact, we may enter into a business
combination with a target business that is affiliated with one or more of our sponsors, directors or officers. We do not have a policy
that expressly prohibits any such persons from engaging for their own account in business activities of the types conducted by us. Accordingly,
such persons or entities may have a conflict between their interests and ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may engage in a business combination with one
or more target businesses that have relationships with entities that may be affiliated with our sponsor, officers, directors or existing
holders which may raise potential conflicts of</b> interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">In light of the involvement of our initial stockholders,
officers and directors, and their affiliates with other businesses, we may decide to acquire one or more businesses affiliated with or
competitive with our initial stockholders, officers and directors, and their respective affiliates. Our directors also serve as officers
and/or board members for other entities. Such entities may compete with us for business combination opportunities. Our initial stockholders,
officers and directors are not currently aware of any specific opportunities for us to complete our initial business combination with
any entities with which they are affiliated, and there have been no substantive discussions concerning a business combination with any
such entity or entities. Although we will not be specifically focusing on, or targeting, any transaction with any affiliated entities,
we would pursue such a transaction if we determined that such affiliated entity met our criteria for a business combination and such transaction
was approved by a majority of our independent and disinterested directors. Despite our agreement to obtain an opinion from an independent
investment banking firm that is a member of FINRA or from an independent accounting firm, regarding the fairness to our company from a
financial point of view of a business combination with one or more domestic or international businesses affiliated with our sponsors,
officers or directors, potential conflicts of interest still may exist and, as a result, the terms of the business combination may not
be as advantageous to our public stockholders as they would be absent any conflicts of interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Moreover, we may, at our option, pursue an affiliated
joint acquisition opportunity with an initial stockholder or one of their affiliates or with other entities to which an officer or director
has a fiduciary, contractual or other obligation or duty. Any such parties may co-invest with us in the target business at the time of
our initial business combination, or we could raise additional proceeds to complete the acquisition by making a future issuance of securities
to any such parties, which may give rise to certain conflicts of interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Since our sponsor, officers and directors will
lose their entire investment in us if our business combination is not completed, a conflict of interest may arise in determining whether
a particular business combination target is appropriate for our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In June 2021, our sponsor purchased 1,437,500 shares
of our common stock, for $25,000. Subsequently, we amended and restated our subscription agreement with the sponsor on two occasions and
ultimately issued it an additional 187,500 shares of common stock, for an aggregate of 1,625,000 shares prior to the investment in the
company of $25,000 by our sponsor, the company had no assets, tangible or intangible. Giving effect to these issuances, our sponsor and
other initial stockholders own 20% of our issued and outstanding shares after our IPO. The founder shares will be worthless if we do not
complete an business combination. In addition, our sponsor has purchased an aggregate of 2,500,000 private placement warrants, for a purchase
price of $2,500,000, or $1.00 per warrant, that will also be worthless if we do not complete a business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The founder shares are identical to the shares of common
stock included in the units being sold in our IPO except that (i) the founder shares are subject to certain transfer restrictions and
(ii) our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed (A) to waive
their redemption rights with respect to their founder shares, private placement shares and public shares in connection with the completion
of our business combination, (B) to waive their redemption rights with respect to any founder shares, private placement shares and public
shares held by them in connection with a stockholder vote to approve an amendment to our amended and restated certificate of incorporation
(x) to modify the substance or timing of our obligation to provide for the redemption of our public shares in connection with an business
combination or to redeem 100% of our public shares if we have not consummated our business combination within the timeframe set forth
therein or (y) with respect to any other provision relating to stockholders’ rights or pre-business combination activity and (C)
to waive their rights to liquidating distributions from the trust account with respect to their founder shares and private placement shares
if we fail to complete our business combination within 9 months from the closing of our IPO (or up to 21 months from the closing of our
IPO if we extend the period of time to consummate a business combination) (although they will be entitled to liquidating distributions
from the trust account with respect to any public shares they hold if we fail to complete our business combination within the prescribed
time frame).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The personal and financial interests of our officers
and directors may influence their motivation in identifying and selecting a target business combination, completing an business combination
and influencing the operation of the business following the business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Since our sponsor, officers and directors may not
be eligible to be reimbursed for their out-of-pocket expenses if our business combination is not completed, a conflict of interest may
arise in determining whether a particular business combination target is appropriate for our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">At the closing of our business combination, our sponsor,
officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection
with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations.
There is no cap or ceiling on the reimbursement of out-of-pocket expenses incurred in connection with activities on our behalf. These
financial interests of our sponsor, officers and directors may influence their motivation in identifying and selecting a target business
combination and completing an business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">Risks Relating to the Post-Business Combination
Company</span></b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0"><b>Our management may not have control of a target business after
our initial business combination. We cannot provide assurance that new management will possess the skills, qualifications or abilities
necessary to profitably operate such business.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 0.5in">We may structure our initial business combination
so that the post-transaction company in which our public stockholders own shares will own less than 100% of the equity interests or assets
of a target business, but we will only complete such business combination if the post-transaction company owns or acquires 50% or more
of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for us not to
be required to register as an investment company under the Investment Company Act. We will not consider any transaction that does not
meet such criteria. Even if the post-transaction company owns 50% or more of the voting securities of the target, our stockholders prior
to our initial business combination may collectively own a minority interest in the post business combination company, depending on valuations
ascribed to the target and us in the business combination. For example, we could pursue a transaction in which we issue a substantial
number of new shares of common stock in exchange for all of the outstanding capital stock of a target. In this case, we would acquire
a 100% interest in the target. However, as a result of the issuance of a substantial number of new shares of common stock, our stockholders
immediately prior to such transaction could own less than a majority of our outstanding shares of common stock subsequent to such transaction.
In addition, other minority stockholders may subsequently combine their holdings resulting in a single person or group obtaining a larger
share of the company’s shares than we initially acquired. Accordingly, this may make it more likely that our management will not
be able to maintain control of the target business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>We do not have a specified maximum redemption threshold. The absence
of such a redemption threshold may make it possible for us to complete our initial business combination with which a substantial majority
of our stockholders do not agree.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Our amended and restated certificate of incorporation
will not provide a specified maximum redemption threshold, except that in no event will we redeem, upon our initial business combination,
our public shares in an amount that would cause our net tangible assets to be less than $5,000,001, nor will we consummate our initial
business combination if we would otherwise become subject to the SEC’s “penny stock” rules. As a result, we may be able
to complete our initial business combination even though a substantial majority of our public stockholders do not agree with the transaction
and have redeemed their shares or, if we seek stockholder approval of our initial business combination and do not conduct redemptions
in connection with our initial business combination pursuant to the tender offer rules, have entered into privately negotiated agreements
to sell their shares to our founders, officers, directors, advisors or any of their respective affiliates. In the event the aggregate
cash consideration we would be required to pay for all shares of common stock that are validly submitted for redemption plus any amount
required to satisfy cash conditions pursuant to the terms of the proposed business combination exceed the aggregate amount of cash available
to us, we will not complete the business combination or redeem any shares, all shares of common stock submitted for redemption will be
returned to the holders thereof, and we instead may search for an alternate business combination (including, potentially, with the same
target).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>In order to effectuate an initial business combination, blank check
companies have, in the recent past, amended various provisions of their charters and modified governing instruments, including their warrant
agreements. We cannot assure you that we will not seek to amend our amended and restated certificate of incorporation or governing instruments,
including our warrant agreement, in a manner that will make it easier for us to complete our initial business combination that some of
our stockholders or warrant holders may not support.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">In order to effectuate an initial business combination,
blank check companies have, in the recent past, amended various provisions of their charters and modified governing instruments, including
their warrant agreements. For example, blank check companies have amended the definition of business combination, increased redemption
thresholds, extended the time to consummate an initial business combination and, with respect to their warrants, amended their warrant
agreements to require the warrants to be exchanged for cash and/or other securities. We cannot assure you that we will not seek to amend
our charter or governing instruments or extend the time to consummate an initial business combination in order to effectuate our initial
business combination. To the extent any such amendment would be deemed to fundamentally change the nature of any of the securities offered
through the registration statement of which this prospectus forms a part, we would register, or seek an exemption from registration for,
the affected securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The provisions of our amended and restated certificate
of incorporation that relate to our pre-business combination activity (and corresponding provisions of the agreement governing the release
of funds from our trust account), including an amendment to permit us to withdraw funds from the trust account such that the per share
amount investors will receive upon any redemption or liquidation is substantially reduced or eliminated, may be amended with the approval
of holders of a majority of our shares of common stock who attend and vote in a general meeting, which is a lower amendment threshold
than that of some other blank check companies. It may be easier for us, therefore, to amend our amended and restated certificate of incorporation
to facilitate the completion of an business combination that some of our stockholders may not support.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Some other blank check companies have a provision in
their charter which prohibits the amendment of certain of its provisions, including those which relate to a company’s pre-business
combination activity, without approval by a supermajority of the company’s stockholders. Our amended and restated certificate of
incorporation provides that any of its provisions, including those related to pre-business combination activity may be amended if approved
by holders of at least a majority of our outstanding shares of common stock. Our sponsor and other initial stockholders, which beneficially
own 20% of our shares of common stock upon the closing of our IPO (not taking into account ownership of the private placement warrants),
will participate in any vote to amend our amended and restated certificate of incorporation. As a result, we may be able to amend the
provisions of our amended and restated certificate of incorporation which govern our pre-business combination behavior more easily than
some other blank check companies, and this may increase our ability to complete a business combination with which you do not agree. Our
stockholders may pursue remedies against us for any breach of our amended and restated certificate of incorporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Certain agreements related to our IPO may be amended
without stockholder approval.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Certain agreements, including the letter agreement
among us and our initial stockholders, officers and directors and the registration rights agreement among us and our initial stockholders
may be amended without stockholder approval. These agreements contain various provisions, including transfer restrictions on our sponsor
shares and private placement warrants and the securities included therein, that our public stockholders might deem to be material. While
we do not expect our board of directors to approve any amendment to any of these agreements prior to our initial business combination,
it may be possible that our board of directors, in exercising its business judgment and subject to its fiduciary duties, chooses to approve
one or more amendments to any such agreement in connection with the consummation of our initial business combination. Any such amendments
would not require approval from our stockholders, may result in the completion of our initial business combination that may not otherwise
have been possible, and may have an adverse effect on the value of an investment in our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may be unable to obtain additional financing
to complete our business combination or to fund the operations and growth of a target business, which could compel us to restructure or
abandon a particular business combination</b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Although we believe that the net proceeds of our IPO
and the sale of the private placement warrants will be sufficient to allow us to complete our business combination, because we have not
yet identified any prospective target business we cannot ascertain the capital requirements for any particular transaction. If the net
proceeds of our IPO and the sale of the private placement warrants prove to be insufficient, either because of the size of our business
combination, the depletion of the available net proceeds in search of a target business, the obligation to redeem for cash a significant
number of shares from stockholders who elect redemption in connection with our business combination or the terms of negotiated transactions
to purchase shares in connection with our business combination, we may be required to seek additional financing or to abandon the proposed
business combination. We cannot assure you that such financing will be available on acceptable terms, if at all. To the extent that additional
financing proves to be unavailable when needed to complete our business combination, we would be compelled to either restructure the transaction
or abandon that particular business combination and seek an alternative target business candidate. In addition, even if we do not need
additional financing to complete our business combination, we may require such financing to fund the operations or growth of the target
business. The failure to secure additional financing could have a material adverse effect on the continued development or growth of the
target business. None of our officers, directors or stockholders is required to provide any financing to us in connection with or after
our business combination. If we are unable to complete our business combination, our public stockholders may only receive approximately
$10.00 per share on the liquidation of our trust account, and our rights and warrants will expire worthless. In certain circumstances,
our public stockholders may receive less than $10.00 per share on the redemption of their shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b><span style="text-decoration: underline">Risk Related to Our Securities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><b>We may amend the terms of the warrants in a manner that may be
adverse to holders with the approval by the holders of at least a majority of the then outstanding warrants.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">Our warrants are issued in registered form under
a warrant agreement between Continental Stock Transfer &amp; Trust Company, as warrant agent, and us. The warrant agreement provides that
the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision. The
warrant agreement requires the approval by the holders of at least a majority of the then outstanding warrants in order to make any change
that adversely affects the interests of the registered holders. &nbsp;Accordingly, we may amend the terms of the public warrants in a
manner adverse to a holder if holders of at least a majority of the then outstanding public warrants approve of such amendment. Although
our ability to amend the terms of the public warrants with the consent of at least a majority of the then outstanding public warrants
is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, convert
the warrants into cash or stock (at a ratio different than initially provided), shorten the exercise period or decrease the number of
shares of our common stock purchasable upon exercise of a warrant.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b>We may amend the terms of the rights in a
way that may be adverse to holders with the approval by the holders of a majority of the then outstanding rights.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our rights are issued in registered form under a rights
agreement between Continental Stock Transfer &amp; Trust Company, as rights agent, and us. The rights agreement provides that the terms
of the rights may be amended without the consent of any holder to cure any ambiguity or correct any defective provision. The rights agreement
requires the approval by the holders of a majority of the then outstanding rights in order to make any change that adversely affects the
interests of the registered holders</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: justify"><b>Our founders paid an aggregate of $25,000 or approximately
an average of $0.0161 per share, for the sponsor shares and, accordingly, you will experience immediate and substantial dilution from
the purchase of our shares of common stock.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The difference between the public offering price per
share (allocating all of the unit purchase price to the shares of common stock and none to the rights or warrants included in the units)
and the pro forma net tangible book value per share after our IPO constitutes the dilution to you and the other the investors in our IPO.
Our founders acquired the sponsor shares at a nominal price, significantly contributing to this dilution. Upon the consummation of our
IPO, and assuming no value is ascribed to the warrants included in the units, you and the other public stockholders will incur an immediate
and substantial dilution of approximately 95.7% (or $8.37 per share) (assuming no exercise of the underwriters’ over-allotment option)
(or 96.2%, or $8.42 per share if the over-allotment is exercised in full), the difference between the pro forma net tangible book value
per share of $0.38 (or $0.33 if the over-allotment is exercised in full) and the effective initial offering price of $8.75 per unit (adjusted
to include the value of the rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Investors may view our units as less attractive
than those of other blank check companies.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unlike other blank check companies that sell units
comprised of shares and warrants each to purchase one full share in their public offerings, in our IPO we sold units comprised of shares
of common stock, rights entitling the holder to receive one-seventh (1/7) of one share of common stock, and one-half of a warrant. The
rights and warrants will not have any voting rights and will expire and be worthless if we do not consummate an business combination.
Furthermore, no fractional shares will be issued upon exercises of the warrants and it is not our intent to issue fractional shares upon
conversion of any rights. As a result, unless you acquire at least two warrants, you will not be able to receive a share upon exercise
of your warrants and if you acquire less than ten rights, you may, in our discretion, not receive one whole share. Any rounding down and
extinguishment may be done with or without any in lieu cash payment or other compensation being made to the holder of the relevant rights.
Accordingly, investors in our IPO will not be issued the same securities as part of their investment as they may have in other blank check
company offerings, which may have the effect of limiting the potential upside value of your investment in our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Because each unit contains one-half of one redeemable
warrant and only a whole warrant may be exercised, the units may be worth less than units of other blank check companies.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each unit contains one-half of one redeemable warrant
to acquire a share of common stock. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.
Accordingly, unless you purchase at least two units, you will not be able to receive or trade a whole warrant. This is different from
other offerings similar to ours whose units include one share and one warrant to purchase one whole share. We have established the components
of the units in this way in order to reduce the dilutive effect of the warrants upon completion of a business combination since the warrants
will be exercisable in the aggregate for one half of the number of shares compared to units that each contain a warrant to purchase one
whole share, thus making us, we believe, a more attractive merger partner for target businesses. Nevertheless, this unit structure may
cause our units to be worth less than if they included a warrant to purchase one whole share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>There is no guarantee that our warrants will be
in the money at the time they become exercisable, and they may expire worthless.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 24.5pt; background-color: white">The exercise price
for our warrants, including our public warrants, is $11.50 per share of common stock. There is no guarantee that any of our warrants will
be in the money following the time they become exercisable and prior to their expiration, and as such, the warrants may expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; background-color: white"><b>A significant portion of our total outstanding
shares are restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of our
common stock and/or warrants to drop significantly.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have registered as part of
our IPO the resale of the 1,625,000 founders shares, 2,500,000 private warrants, and 2,500,000 shares of common stock issuable upon the
exercise of the private warrants, which securities are owned by our sponsor and insiders. Although these shares of common stock and private
warrants are subject to the transfer restrictions described in the insider letter, those securities may be immediately resold upon the
expiration of those lockup periods. The market price of the shares of our common stock and warrants could decline as a result of the sale
of a substantial number of our shares of common stock or warrants in the public market or the perception in the market that the holders
of a large number of shares or warrants intend to sell their shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our warrant agreement and rights agreement with
our transfer agent will designate the courts of the State of New York or the United States District Court for the Southern District of
New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants,
which could limit the ability of warrant holders or rights holders to obtain a favorable judicial forum for disputes with our company.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our warrant agreement and rights agreement with our
transfer agent, which govern the terms of the warrants and rights, respectively, provides that, subject to applicable law, (i) any action,
proceeding or claim against us or the warrant agent arising out of or relating in any way to the warrant agreement shall be brought and
enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and (ii) that
we and the warrant agent and rights agent irrevocably submit to such jurisdiction, which jurisdiction shall be the exclusive forum for
any such action, proceeding or claim. We and the warrant agent and rights agent will waive any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Notwithstanding the foregoing, this exclusive forum
provision shall not apply to suits brought to enforce a duty or liability created by the Exchange Act, any other claim for which the federal
courts have exclusive jurisdiction or any complaint asserting a cause of action arising under the Securities Act against us or any of
our directors, officers, other employees or agents. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits
brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. In addition, stockholders
cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Other than with respect to claims under the Securities
Act or Exchange Act, this choice-of-forum provision may limit a warrant holder’s or right’s holder’s ability to bring
a claim in a judicial forum that it finds favorable for disputes with our company, which may discourage such lawsuits. Alternatively,
if a court were to find this provision of our warrant agreement inapplicable or unenforceable with respect to one or more of the specified
types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could
materially and adversely affect our business, financial condition and results of operations and result in a diversion of the time and
resources of our management and board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>A provision of our warrant agreement for the public
warrants may make it more difficult for us to consummate an initial business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">Unlike most blank check companies,&nbsp;if (i)
we issue additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of
our initial business combination at a newly issued price of less than $9.20 per share; (ii)&nbsp;the aggregate gross proceeds from such
issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business
combination on the date of the consummation of our initial business combination (net of redemptions), and (iii) the volume weighted average
trading price of our common stock during the 20 trading day period starting on the trading day prior to the day on which we consummate
our initial business combination (“Market Price”) is below $9.20 per share, the exercise price of the public warrants will
be adjusted (to the nearest cent) to be equal to 115% of the Market Price, and the $18.00 per share redemption trigger price described
above will be adjusted (to the nearest cent) to be equal to 180% of the Market Value. This term of the warrants may make it more difficult
for us to consummate an initial business combination with a target business because the target entity owners may find such adjustment
objectionable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We may redeem your unexpired warrants prior to
their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We have the ability to redeem outstanding public warrants
at any time after they become exercisable and prior to their expiration, if, among other things, the last reported sales price of our
common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and
the like) for any 20 trading days within a 30 trading-day period ending on the third trading day prior to the date we send the notice
of redemption to the warrant holders.&nbsp;<span style="font-family: Times New Roman PS Std,serif">The redemption price&nbsp;</span>shall
be either (i) if the holder of a warrant has followed the procedures specified in our notice of redemption and surrendered the warrant,
the number of shares of common stock as determined in accordance with the “cashless exercise” provisions of the warrant agreement
or (ii) if the holder of a warrant has not followed such procedures specified in our notice of redemption, the price of $0.01 per warrant.
If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the
underlying securities for sale under all applicable state securities laws. As a result, we may redeem the public warrants as set forth
above even if the holders are otherwise unable to exercise the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Redemption of the outstanding warrants could force
you to: (1)&nbsp;exercise your warrants and pay the exercise price therefor (or exercise such warrants on a “cashless” basis)
at a time when it may be disadvantageous for you to do so; (2)&nbsp;sell your warrants at the then-current market price when you might
otherwise wish to hold your warrants; (3)&nbsp;<span style="font-family: Times New Roman PS Std,serif">request that we redeem your warrants
by surrendering such warrants and receiving the redemption price as if the warrants were exercised on a “cashless” basis;
or (4)&nbsp;</span>accept the nominal redemption price of $0.01, which, at the time the outstanding warrants are called for redemption,
we expect would be substantially less than the market value of your warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The private warrants will be subject to redemption
on the same terms as applicable to the public warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our management’s ability to require holders
of our warrants to exercise such warrants on a cashless basis will cause holders to receive fewer shares of common stock upon their exercise
of the warrants than they would have received had they been able to exercise their warrants for cash.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we call our public warrants for redemption after
the redemption criteria described elsewhere in this report have been satisfied, our management will have the option to require any holder
that wishes to exercise his warrant (including any warrants held by our sponsor, officers or directors, other purchasers of our founders’
units, or their permitted transferees) to do so on a “cashless basis.” If our management chooses to require holders to exercise
their warrants on a cashless basis, the number of shares of common stock received by a holder upon exercise will be fewer than it would
have been had such holder exercised his warrant for cash. This will have the effect of reducing the potential “upside” of
the holder’s investment in our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our rights, warrants and founder shares may have
an adverse effect on the market price of our shares of common stock and make it more difficult to effectuate our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have issued rights convertible into 928,571 of our
shares of common stock and warrants to purchase 3,250,000 of our shares of common stock as part of the units offered in our IPO and, simultaneously
with the closing of our IPO, an aggregate of 2,500,000 private placement warrants in a private placement. In each case, each whole warrants
is exercisable to purchase one share of common stock at a price of $11.50 per whole share, subject to adjustment as provided herein. In
addition, our sponsor and other initial directors hold an aggregate of 1,625,000 founder shares in a private placement. In addition, if
our sponsor makes any working capital loans, up to $2,400,000 of such loans may be converted into warrants, at the price of $1.00 per
warrant at the option of the lender. To the extent we issue shares of common stock to effectuate a business transaction, the potential
for the issuance of a substantial number of additional shares upon exercise of these warrants or conversion rights could make us a less
attractive acquisition vehicle to a target business. Any such issuance will increase the number of issued and outstanding shares and reduce
the value of the shares of common stock issued to complete the business transaction. Therefore, our rights, warrants and founder shares
may make it more difficult to effectuate a business combination or increase the cost of acquiring the target business. Additionally, the
issuance, or even the possibility of issuance, of the shares underlying the warrants could have an adverse effect on the market price
for our securities or on our ability to obtain future financing. If and to the extent these warrants are exercised, you may experience
dilution to your holdings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Nasdaq may delist our securities from trading on
its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions
or reduce protections under Nasdaq rules available to them.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Our securities, including our common stock, rights and
warrants, are listed on the Nasdaq Global Market. We cannot guarantee that our securities will be approved for listing on Nasdaq for any
particular period of time. Although after giving effect to our IPO we met, on a pro forma basis, the minimum listing standards set forth
in the Nasdaq listing standards, we cannot assure you that our securities will be, or will continue to be, listed on Nasdaq in the future
or prior to our business combination. In order to continue listing our securities on Nasdaq prior to our business combination, we must
maintain certain financial, distribution and stock price levels. Additionally, following closing of our business combination, we will
be required to demonstrate compliance with Nasdaq’s listing requirements on a post-closing basis, which are more rigorous than Nasdaq’s
continued listing requirements, in order to continue to maintain the listing of our securities on Nasdaq. We cannot assure you that we
will be able to meet those listing requirements at that time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-indent: 24pt">If Nasdaq delists our securities from trading on its
exchange, we could face significant material adverse consequences, including:</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt">•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
limited availability of market quotations for our securities;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt">•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reduced
liquidity with respect to our securities;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt">•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
determination that our shares of common stock are “penny stock” which will require brokers trading in our shares of common
stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for
our shares of common stock;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt">•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
limited amount of media and analyst coverage of our company; and</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt">•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
decreased ability to issue additional securities or obtain additional financing in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The National Securities Markets
Improvement Act of 1996, which is a federal statute, prevents or pre-empts the states from regulating the sale of certain securities,
which are referred to as “covered securities.” Because we expect that our units and eventually our shares of common stock,
warrants, and rights will be listed on the Nasdaq Global Market, our units, shares of common stock, warrants, and rights will be covered
securities. Although the states are preempted from regulating the sale of covered securities, the federal statute does allow the states
to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate
or bar the sale of covered securities in a particular case. While we are not aware of a state having used these powers to prohibit or
restrict the sale of securities issued by blank check companies, other than the State of Idaho, certain state securities regulators view
blank check companies unfavorably and might use these powers, or threaten to use these powers, to hinder the sale of securities of blank
check companies in their states. Further,&nbsp;if we were no longer listed on Nasdaq, our securities would not be covered securities and
we would be subject to regulation in each state in which we offer our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">General Risks</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Compliance obligations under the Sarbanes-Oxley
Act may make it more difficult for us to effectuate our business combination, require substantial financial and management resources,
and increase the time and costs of completing an acquisition.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Section 404 of the Sarbanes-Oxley Act requires that
we evaluate and report on our system of internal controls beginning with our Annual Report on Form 10-K for the year ending December 31,
2022. Only in the event we are deemed to be a large accelerated filer or an accelerated filer will we be required to comply with the independent
registered public accounting firm attestation requirement on our internal control over financial reporting. Further, for as long as we
remain an emerging growth company, we will not be required to comply with the independent registered public accounting firm attestation
requirement on our internal control over financial reporting. <span style="font-family: Times New Roman PS Std,serif">If we fail to maintain
the adequacy of our internal controls, we could be subject to regulatory scrutiny, civil or criminal penalties and/or stockholder litigation.
Any inability to provide reliable financial reports could harm our business. Section 404 of the Sarbanes-Oxley Act also requires that
our independent registered public accounting firm report on management’s evaluation of our system of internal controls. A target
company may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of their internal controls. The development
of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary
to complete any such acquisition. Furthermore, any failure to implement required new or improved controls, or difficulties encountered
in the implementation of adequate controls over our financial processes and reporting in the future, could harm our operating results
or cause us to fail to meet our reporting obligations. Inferior internal controls could also cause investors to lose confidence in our
reported financial information, which could have a negative effect on the trading price of our shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>We are an emerging growth company within the meaning
of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies,
this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public
companies.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are an “emerging growth company” within
the meaning of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being
required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result,
our stockholders may not have access to certain information they may deem important. We could be an emerging growth company for up to
five years, although circumstances could cause us to lose that status earlier, including if the market value of our shares of common stock
held by non-affiliates exceeds $700 million as of any June 30 before that time, in which case we would no longer be an emerging growth
company as of the following December 31. We cannot predict whether investors will find our securities less attractive because we will
rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading
prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the
trading prices of our securities may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when
a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company,
can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our
financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has
opted out of using the extended transition period difficult or impossible because of the potential differences in accountant standards
used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.25in">Additionally, we are a “smaller reporting
company” as defined in Item 10(f)(1)&nbsp;of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure
obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting
company until the last day of the fiscal year in which (1)&nbsp;the market value of our common stock held by non-affiliates exceeds $250
million as of the end of that year’s second fiscal quarter, or (2)&nbsp;our annual revenues exceeded $100 million during such completed
fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the end of that year’s second
fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements
with other public companies difficult or impossible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Changes in laws or regulations, or a failure to
comply with any laws and regulations, may adversely affect our business, investments and results of operations.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are subject to laws and regulations enacted by national, regional and
local governments. In particular, we will be required to comply with certain SEC and other legal requirements. Compliance with, and monitoring
of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and
application may also change from time to time and those changes could have a material adverse effect on our business, investments and
results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a
material adverse effect on our business and results of operations.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b>We may be subject to cybersecurity risks
following consummation of a business combination.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Any entity we may seek to acquire may rely on information
technology systems, including third-party hosted servers and cloud-based servers, to keep business, financial, and corporate records,
communicate internally and externally, and operate other critical functions. If any of those internal systems or the systems of its third-party
providers are compromised due to cyber incidents, then sensitive documents could be exposed or deleted, and the company’s ability
to conduct business could be impaired. Cyber incidents can result from deliberate attacks or unintentional events. These incidents can
include, but are not limited to, unauthorized access to systems, computer viruses or other malicious code, denial of service attacks,
malware, ransomware, phishing, SQL injection attacks, human error, or other events that result in security breaches or give rise to the
manipulation or loss of sensitive information or assets. Cyber incidents can be caused by various persons or groups, including disgruntled
employees and vendors, activists, organized crime groups, and state-sponsored and individual hackers. Cyber incidents can also be caused
or aggravated by natural events, such as earthquakes, floods, fires, power loss, and telecommunications failures. In addition to operational
and business consequences, if a target business’ cybersecurity is breached, it could be held liable to its customers or other parties
in regulatory or other actions, and it may be exposed to reputation damages and loss of trust and business. This could result in costly
investigations and litigation, civil or criminal penalties, fines, and negative publicity. Any of the foregoing could have a material
adverse effect on the operations and profitability of a target business we seek to acquire.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b>There may be tax consequences to our business
combinations that may adversely affect us.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">While we expect to undertake any merger or acquisition
with a target business so as to minimize taxes both to the acquired target business and us, such business combination might not meet the
statutory requirements of a tax-free reorganization, or the parties might not obtain the intended tax-free treatment upon a transfer of
shares or assets. A non-qualifying reorganization could result in the imposition of substantial taxes.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b>Tax reform legislation enacted in the U.S.
in 2017 could adversely affect our business and financial condition following a business combination.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 20pt">On December 22, 2017, the Tax Cuts and Jobs Act
of 2017 (the “Tax Act”) was signed into law, making significant changes to the Internal Revenue Code of 1986, as amended.
Changes under the Tax Act include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning
after December 31, 2017, a mandatory deemed repatriation of previously untaxed cumulative foreign earnings (generally applicable to 10%
U.S. stockholders of a “controlled foreign corporation” or “CFC” and taxed at reduced rates), a limitation of
the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), a limitation of the deduction
for net operating losses to 80% of current year taxable income and the elimination of net operating loss carrybacks the transition to
a “participation exemption system” for the taxation of earnings of foreign corporations, where a U.S. C corporation can generally
deduct 100% of dividends received from the foreign source of income of a 10% owned foreign corporation, immediate deductions for certain
new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits.
The overall impact of the Tax Act is uncertain, and it could make completing a business combination with us less appealing than with companies
in other countries. In addition, it is uncertain if and to what extent various states will conform to the Tax Act and what effect any
legal challenges will have on the Tax Act, including litigation in the U.S. and international challenges brought by organizations such
as the World Trade Organization. The impact of the Tax Act on holders of our securities is also uncertain and could be adverse. Investors
should consult with their legal and tax advisors with respect to the Tax Act and the potential tax consequences of investing in or holding
our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b></b></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>We cannot predict how&nbsp;tax
reform&nbsp;legislation will affect us, our initial business combination, or our investors.</b></p>

<p style="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt; background-color: white">Legislative or other actions
relating to taxes could have a negative effect on us, our investors, or our initial business combination. The rules dealing with U.S.
federal income taxation are constantly under review by legislators and by the Internal Revenue Service and the U.S. Treasury Department.
We cannot predict with certainty how any changes in the tax laws might affect us, our investors, or our initial business combination.
New legislation and any U.S. Treasury regulations, administrative interpretations or court decisions interpreting such legislation could
significantly and negatively affect the U.S. federal income tax consequences to us and our investors or could have other adverse consequences,
including changes in tax rates that could impact our effective tax rate. Investors are urged to consult with their tax advisors regarding
tax legislative, regulatory, or administrative developments and proposals and their potential effect on an investment in our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>There are no authorities addressing the proper
allocation of tax basis to the components of a unit, and therefore, investors may not appropriately allocate such basis for U.S. federal
income tax purposes.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">No statutory, administrative or judicial authority directly
addresses the treatment of a unit or instruments similar to a unit for U.S. federal income tax purposes and, therefore, that treatment
is not entirely clear. We intend to treat the acquisition of a unit, for U.S. federal income tax purposes, as the acquisition of one share
of our common stock, one half of one warrant and one right to receive one-seventh (1/7) of a share of our common stock upon the consummation
of an initial business combination, and, by purchasing a unit, you agree to adopt such treatment for U.S. federal income tax purposes.
For U.S. federal income tax purposes, each holder of a unit must allocate the purchase price paid by such holder for such unit between
the one share of our common stock, one half of one warrant and one right to receive one-seventh (1/7) of a share of our common stock upon
the consummation of an initial business combination based on the relative fair market value of each at the time of issuance. The price
allocated should be the stockholder’s tax basis in such share or right, as the case may be. Any disposition of a unit should be
treated for U.S. federal income tax purposes as a disposition of the share of our share of our common stock, one half of one warrant and
one right to receive one-seventh (1/7) of a share of our common stock upon the consummation of an initial business combination comprising
the unit, and the amount realized on the disposition should be allocated between the common stock and the right based on their respective
relative fair market values at the time of disposition. The foregoing treatment of the unit and a holder’s purchase price allocation
are not binding on the Internal Revenue Service, or “IRS”, or the courts. The IRS or the courts may not agree with such characterization
and investors could suffer adverse U.S. federal income tax consequences as a result. Accordingly, we urge each prospective investor to
consult its own tax advisors regarding the tax consequences of an investment in a unit (including alternative characterizations of a unit).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our amended and restated certificate of incorporation designates the
Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated
by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with our company
or our company’s directors, officers or other employees.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Our amended and restated certificate of incorporation
requires, to the fullest extent permitted by law, that derivative actions brought in our name, actions against our directors, officers,
other employees or stockholders for breach of fiduciary duty and certain other actions may be brought only in the Court of Chancery in
the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service
of process on such stockholder’s counsel except any action (A)&nbsp;as to which the Court of Chancery in the State of Delaware determines
that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent
to the personal jurisdiction of the Court of Chancery within ten days following such determination), (B)&nbsp;which is vested in the exclusive
jurisdiction of a court or forum other than the Court of Chancery or (C)&nbsp;for which the Court of Chancery does not have subject matter
jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have
notice of and consented to the forum provisions in our amended and restated certificate of incorporation. This choice of forum provision
may limit or make more costly a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims.
Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation
to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions,
which could harm our business, operating results and financial condition.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Our amended and restated certificate of incorporation
will provide that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law, subject to certain
exceptions. Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability
created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits
brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.
In addition, our amended and restated certificate of incorporation will provide that, unless we consent in writing to the selection of
an alternative forum, the federal district courts of the United&nbsp;States of America shall, to the fullest extent permitted by law,
be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, or the rules
and regulations promulgated thereunder. We note, however, that there is uncertainty as to whether a court would enforce this provision
and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section&nbsp;22
of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability
created by the Securities Act or the rules and regulations thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">Risks Associated with Acquiring and Operating
a Business Outside of the United States</span></b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>We may pursue a target company with operations or opportunities
outside of the United States for our initial business combination. Accordingly, we may face additional burdens in connection with investigating,
agreeing to and completing such initial business combination, and if we effect such initial business combination, we would be subject
to a variety of additional risks that may negatively impact our operations.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">We may pursue a target a company with operations
or opportunities outside of the United States for our initial business combination, and therefore may be subject to risks associated with
cross-border business combinations, including in connection with investigating, agreeing to and completing our initial business combination,
conducting due diligence in a foreign jurisdiction, having such transaction approved by any local governments, regulators or agencies
and changes in the purchase price based on fluctuations in foreign exchange rates.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">If we effect our initial business combination with
such a company, we would be subject to any special considerations or risks associated with companies operating in an international setting,
including any of the following:</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;costs
and difficulties inherent in managing cross-border business operations;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rules
and regulations regarding currency redemption;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;complex
corporate withholding taxes on individuals;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;laws
governing the manner in which future business combinations may be effected;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;exchange
listing and/or delisting requirements;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;tariffs
and trade barriers;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;regulations
related to customs and import/export matters;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;local
or regional economic policies and market conditions;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;unexpected
changes in regulatory requirements;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;longer
payment cycles;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;tax
issues, such as tax law changes and variations in tax laws as compared to the United States;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;currency
fluctuations and exchange controls;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rates
of inflation;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;challenges
in collecting accounts receivable;&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cultural
and language differences;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;employment
regulations;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;underdeveloped
or unpredictable legal or regulatory systems;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;corruption;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;protection
of intellectual property;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;social
unrest, crime, strikes, riots and civil disturbances;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;regime
changes and political upheaval;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;terrorist
attacks and wars; and</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;deterioration
of political relations with the United States.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">We may not be able to adequately address these
additional risks. If we were unable to do so, we may be unable to complete such initial business combination, or, if we complete such
combination, our operations might suffer, either of which may adversely impact our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">After our initial business combination, substantially
all of our assets may be located in a foreign country and substantially all of our revenue will be derived from our operations in such
country. Accordingly, our results of operations and prospects will be subject, to a significant extent, to the economic, political and
legal policies, developments and conditions in the country in which we operate.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">The economic, political and social conditions,
as well as government policies, of the country in which our operations are located could affect our business. Economic growth could be
uneven, both geographically and among various sectors of the economy and such growth may not be sustained in the future. If in the future
such country’s economy experiences a downturn or grows at a slower rate than expected, there may be less demand for spending in
certain industries. A decrease in demand for spending in certain industries could materially and adversely affect our ability to find
an attractive target business with which to consummate our initial business combination and if we effect our initial business combination,
the ability of that target business to become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>After our business combination, it is possible
that a majority of our directors and officers will live outside the United States and all of our assets will be located outside the United
States; therefore investors may not be able to enforce federal securities laws or their other legal rights.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">It is possible that after our business combination,
a majority of our directors and officers will reside outside of the United States and all of our assets will be located outside of the
United States. As a result, it may be difficult, or in some cases not possible, for investors in the United States to enforce their legal
rights, to effect service of process upon all of our directors or officers or to enforce judgments of United States courts predicated
upon civil liabilities and criminal penalties on our directors and officers under United States laws. In particular, investors should
be aware that there is uncertainty as to whether the courts of other applicable jurisdictions would recognize and enforce judgments of
U.S. courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of
the United States or any state in the United States or entertain original actions brought in another jurisdiction’s courts against
us or our directors or officers predicated upon the securities laws of the United States or any state in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If our management following our business combination
is unfamiliar with United States securities laws, they may have to expend time and resources becoming familiar with such laws, which could
lead to various regulatory issues.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Following our business combination, any or all of our
management could resign from their positions as officers of the Company, and the management of the target business at the time of the
business combination will remain in place. Management of the target business may not be familiar with United States securities laws. If
new management is unfamiliar with United States securities laws, they may have to expend time and resources becoming familiar with such
laws. This could be expensive and time-consuming and could lead to various regulatory issues which may adversely affect our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>If we effect a business combination with a company
located outside of the United States, the laws applicable to such company will likely govern all of our material agreements and we may
not be able to enforce our legal rights.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we effect a business combination with a company
located outside of the United States, the laws of the country in which such company operates will govern almost all of the material agreements
relating to its operations. We cannot assure you that the target business will be able to enforce any of its material agreements or that
remedies will be available in this new jurisdiction. The system of laws and the enforcement of existing laws in such jurisdiction may
not be as certain in implementation and interpretation as in the United States. The inability to enforce or obtain a remedy under any
of our future agreements could result in a significant loss of business, business opportunities or capital. Additionally, if we acquire
a company located outside of the United States, it is likely that substantially all of our assets would be located outside of the United
States and some of our officers and directors might reside outside of the United States. As a result, it may not be possible for investors
in the United States to enforce their legal rights, to effect service of process upon our directors or officers or to enforce judgments
of United States courts predicated upon civil liabilities and criminal penalties of our directors and officers under Federal securities
laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Because of the costs and difficulties inherent
in managing cross-border business operations after we acquire it, our results of operations may be negatively impacted following a business
combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Managing a business, operations, personnel or assets
in another country is challenging and costly. Management of the target business that we may hire (whether based abroad or in the U.S.)
may be inexperienced in cross-border business practices and unaware of significant differences in accounting rules, legal regimes and
labor practices. Even with a seasoned and experienced management team, the costs and difficulties inherent in managing cross-border business
operations, personnel and assets can be significant (and much higher than in a purely domestic business) and may negatively impact our
financial and operational performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Many countries, and especially those in emerging
markets, have difficult and unpredictable legal systems and underdeveloped laws and regulations that are unclear and subject to corruption
and inexperience, which may adversely impact our results of operations and financial condition.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our ability to seek and enforce legal protections,
including with respect to intellectual property and other property rights, or to defend ourselves with regard to legal actions taken against
us in a given country, may be difficult or impossible, which could adversely impact our operations, assets or financial condition. Rules
and regulations in many countries, including some of the emerging markets within the regions we will initially focus, are often ambiguous
or open to differing interpretation by responsible individuals and agencies at the municipal, state, regional and federal levels. The
attitudes and actions of such individuals and agencies are often difficult to predict and inconsistent. Delay with respect to the enforcement
of particular rules and regulations, including those relating to customs, tax, environmental and labor, could cause serious disruption
to operations abroad and negatively impact our results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>After our business combination, substantially all
of our assets may be located in a foreign country and substantially all of our revenue may be derived from our operations in such country.
Accordingly, our results of operations and prospects will be subject, to a significant extent, to the economic, political and legal policies,
developments and conditions in the country in which we operate.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The economic, political and social conditions, as well
as government policies, of the country in which our operations are located could affect our business. The economies in developing markets
we will initially focus on differ from the economies of most developed countries in many respects. Such economic growth has been uneven,
both geographically and among various sectors of the economy and such growth may not be sustained in the future. If in the future such
country’s economy experiences a downturn or grows at a slower rate than expected, there may be less demand for spending in certain
industries. A decrease in demand for spending in certain industries could materially and adversely affect our ability to find an attractive
target business with which to consummate our business combination and if we effect our business combination, the ability of that target
business to become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Exchange rate fluctuations and currency policies
may cause a target business’ ability to succeed in the international markets to be diminished.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the event we acquire a non-U.S. target, all revenues
and income would likely be received in a foreign currency, the dollar equivalent of our net assets and distributions, if any, could be
adversely affected by reductions in the value of the local currency. The value of the currencies in our target regions fluctuate and are
affected by, among other things, changes in political and economic conditions. Any change in the relative value of such currency against
our reporting currency may affect the attractiveness of any target business or, following consummation of our business combination, our
financial condition and results of operations. Additionally, if a currency appreciates in value against the dollar prior to the consummation
of our business combination, the cost of a target business as measured in dollars will increase, which may make it less likely that we
are able to consummate such transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Because our business objective includes the possibility
of acquiring one or more operating businesses with primary operations in emerging markets we will focus on, changes in the exchange rate
between the U.S. dollar and the currency of any relevant jurisdiction may affect our ability to achieve such objective. For instance,
the exchange rates between the Turkish lira or the Indian rupee and the U.S. dollar has changed substantially in the last two decades
and may fluctuate substantially in the future. If the U.S. dollar declines in value against the relevant currency, any business combination
will be more expensive and therefore more difficult to complete. Furthermore, we may incur costs in connection with conversions between
U.S. dollars and the relevant currency, which may make it more difficult to consummate a business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Because foreign law could govern almost all of
our material agreements, we may not be able to enforce our rights within such jurisdiction or elsewhere, which could result in a significant
loss of business, business opportunities or capital.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Foreign law could govern almost all of our material
agreements. The target business may not be able to enforce any of its material agreements or that remedies will be available outside of
such foreign jurisdiction’s legal system. The system of laws and the enforcement of existing laws and contracts in such jurisdiction
may not be as certain in implementation and interpretation as in the United States. Judiciaries in such jurisdiction may also be relatively
inexperienced in enforcing corporate and commercial law, leading to a higher than usual degree of uncertainty as to the outcome of any
litigation. As a result, the inability to enforce or obtain a remedy under any of our future agreements could result in a significant
loss of business and business opportunities.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b>We may be exposed to liabilities under the
Foreign Corrupt Practices Act, and any determination that we violated the Foreign Corrupt Practices Act could have a material adverse
effect on our business.</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">We are subject to the Foreign Corrupt Practice
Act, or FCPA, and other laws that prohibit improper payments or offers of payments to foreign governments and their officials and political
parties by U.S. persons and issuers as defined by the statute for the purpose of obtaining or retaining business. We will have operations,
agreements with third parties and may make sales overseas, which may experience corruption. Activities overseas may create the risk of
unauthorized payments or offers of payments by one of the employees, consultants, or sales agents of our Company, because these parties
are not always subject to our control. It will be our policy to implement safeguards to discourage these practices by our employees. Also,
our existing safeguards and any future improvements may prove to be less than effective, and the employees, consultants, or sales agents
of our Company may engage in conduct for which we might be held responsible. Violations of the FCPA may result in severe criminal or civil
sanctions, and we may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.
In addition, the government may seek to hold our Company liable for successor liability FCPA violations committed by companies in which
we invest or that we acquire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Corporate governance standards in foreign countries
may not be as strict or developed as in the United States and such weakness may hide issues and operational practices that are detrimental
to a target business.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">General corporate governance standards in some countries
are weak in that they do not prevent business practices that cause unfavorable related party transactions, over-leveraging, improper accounting,
family company interconnectivity and poor management. Local laws often do not go far to prevent improper business practices. Therefore,
stockholders may not be treated impartially and equally as a result of poor management practices, asset shifting, conglomerate structures
that result in preferential treatment to some parts of the overall company, and cronyism. The lack of transparency and ambiguity in the
regulatory process also may result in inadequate credit evaluation and weakness that may precipitate or encourage financial crisis. In
our evaluation of a business combination we will have to evaluate the corporate governance of a target and the business environment, and
in accordance with United States laws for reporting companies take steps to implement practices that will cause compliance with all applicable
rules and accounting practices. Notwithstanding these intended efforts, there may be endemic practices and local laws that could add risk
to an investment we ultimately make and that result in an adverse effect on our operations and financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Companies in foreign countries may be subject to accounting,
auditing, regulatory and financial standards and requirements that differ, in some cases significantly, from those applicable to public
companies in the United States, which may make it more difficult or complex to consummate a business combination. In particular, the assets
and profits appearing on the financial statements of a foreign company may not reflect its financial position or results of operations
in the way they would be reflected had such financial statements been prepared in accordance with U.S. GAAP and there may be substantially
less publicly available information about companies in certain jurisdictions than there is about comparable United States companies. Moreover,
foreign companies may not be subject to the same degree of regulation as are United States companies with respect to such matters as insider
trading rules, tender offer regulation, stockholder proxy requirements and the timely disclosure of information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Legal principles relating to corporate affairs and
the validity of corporate procedures, directors’ fiduciary duties and liabilities and stockholders’ rights for foreign corporations
may differ from those that may apply in the U.S., which may make the consummation of a business combination with a foreign company more
difficult. We therefore may have more difficulty in achieving our business objective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Because a foreign judiciary may determine the scope
and enforcement of almost all of our target business’ material agreements under the law of such foreign jurisdiction, we may be
unable to enforce our rights inside and outside of such jurisdiction.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The law of a foreign jurisdiction, may govern almost
all of our target business’ material agreements, some of which may be with governmental agencies in such jurisdiction. We cannot
assure you that the target business or businesses will be able to enforce any of their material agreements or that remedies will be available
outside of such jurisdiction. The inability to enforce or obtain a remedy under any of our future agreements may have a material adverse
impact on our future operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>A slowdown in economic growth in the markets that
our business target operates in may adversely affect our business, financial condition, results of operations, the value of its equity
shares and the trading price of our shares following our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Following the business combination, our results of
operations and financial condition may be dependent on, and may be adversely affected by, conditions in financial markets in the global
economy, and, particularly in the markets where the business operates. The specific economy could be adversely affected by various factors
such as political or regulatory action, including adverse changes in liberalization policies, business corruption, social disturbances,
terrorist attacks and other acts of violence or war, natural calamities, interest rates, inflation, commodity and energy prices and various
other factors which may adversely affect our business, financial condition, results of operations, value of our equity shares and the
trading price of our shares following the business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Regional hostilities, terrorist attacks, communal
disturbances, civil unrest and other acts of violence or war may result in a loss of investor confidence and a decline in the value of
our equity shares and trading price of our shares following our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Terrorist attacks, civil unrest and other acts of violence
or war may negatively affect the markets in which we may operates our business following our business combination and also adversely affect
the worldwide financial markets. In addition, the countries we will focus on, have from time to time experienced instances of civil unrest
and hostilities among or between neighboring countries. Any such hostilities and tensions may result in investor concern about stability
in the region, which may adversely affect the value of our equity shares and the trading price of our shares following our business combination.
Events of this nature in the future, as well as social and civil unrest, could influence the economy in which our business target operates,
and could have an adverse effect on our business, including the value of equity shares and the trading price of our shares following our
business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The occurrence of natural disasters may adversely
affect our business, financial condition and results of operations following our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The occurrence of natural disasters, including hurricanes,
floods, earthquakes, tornadoes, fires and pandemic disease may adversely affect our business, financial condition or results of operations
following our business combination. The potential impact of a natural disaster on our results of operations and financial position is
speculative, and would depend on numerous factors. The extent and severity of these natural disasters determines their effect on a given
economy. Although the long term effect of diseases such as the H5N1 “avian flu,” or H1N1, the swine flu, cannot currently
be predicted, previous occurrences of avian flu and swine flu had an adverse effect on the economies of those countries in which they
were most prevalent. An outbreak of a communicable disease in our market could adversely affect our business, financial condition and
results of operations following our business combination. We cannot assure you that natural disasters will not occur in the future or
that its business, financial condition and results of operations will not be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Any downgrade of credit ratings of the country
in which the company we acquire does business may adversely affect our ability to raise debt financing following our business combination.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">No assurance can be given that any rating organization
will not downgrade the credit ratings of the sovereign foreign currency long-term debt of the country in which our business target operates,
which reflect an assessment of the overall financial capacity of the government of such country to pay its obligations and its ability
to meet its financial commitments as they become due. Any downgrade could cause interest rates and borrowing costs to rise, which may
negatively impact both the perception of credit risk associated with our future variable rate debt and our ability to access the debt
markets on favorable terms in the future. This could have an adverse effect on our financial condition following our business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Returns on investment in foreign companies may
be decreased by withholding and other taxes.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our investments will incur tax risk unique to investment
in developing economies. Income that might otherwise not be subject to withholding of local income tax under normal international conventions
may be subject to withholding of income tax in a developing economy. Additionally, proof of payment of withholding taxes may be required
as part of the remittance procedure. Any withholding taxes paid by us on income from our investments in such country may or may not be
creditable on our income tax returns. We intend to seek to minimize any withholding tax or local tax otherwise imposed. However, there
is no assurance that the foreign tax authorities will recognize application of such treaties to achieve a minimization of such tax. We
may also elect to create foreign subsidiaries to effect the business combinations to attempt to limit the potential tax consequences of
a business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 1B. Unresolved Staff Comments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 2. Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We do not own any real estate or other physical properties
materially important to our operations. <span style="font-family: Times New Roman PS Std,serif">We currently maintain our principal executive
offices at 8 The Green, Suite #12490, Dover, Delaware 19901. The cost for this space is $50 per month with an unaffiliated third party
and the third party provides limited general and administrative services commencing on May 28, 2021 and is on a month to month basis.
We consider our current office space, combined with the other office space otherwise available to our executive officers, adequate for
our current operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 3. Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are not currently a party to any material litigation
or other legal proceedings brought against us. We are also not aware of any legal proceeding, investigation or claim, or other legal exposure
that has a more than remote possibility of having a material adverse effect on our business, financial condition, or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 4. Mine Safety Disclosures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 5. Market for Registrant’s Common Equity,
Related Shareholder Matters and Issuer Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Market Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On January 12, 2022, we announced that the holders
of the Company’s Units may elect to separately trade the securities underlying such units which commenced on January 14, 2022. Any
units not separated will continue to trade on The Nasdaq Global Market under the symbol “MAAQU”. Any underlying shares of
common stock, warrants, and rights that are separated are traded on The Nasdaq Global Market under the symbols “MAAQ”, “MAAQW”
and “MAAQR” respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">No fractional warrants are issuable upon separation
of the units and only whole warrants will trade. Each warrant entitles the holder to purchase one share of common stock at a price of
$11.50. Warrants may only be exercised for whole shares and will become exercisable on the later of 30 days after the completion of our
initial business combination or twelve months from the closing of our initial public offering. The warrants will expire five years after
the completion of a Business Combination or earlier upon redemption or liquidation. Except in cases where we are not the surviving company
in a business combination, each holder of a right will automatically receive one-seventh (1/7) of one share of common stock upon consummation
of a business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of March 30, 2022, there was one holder of record
of our units, four holders of record of our common stock, two holders of record of our warrants, and one holder of record of our rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;The number of record holders was determined from
the records of our transfer agent and does not include beneficial owners of any of our securities whose securities are held in the names
of various security brokers, dealers, and registered clearing agencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The transfer agent for our units and common stock and
warrant agent for our warrants and the rights agent for our rights is Continental Stock Transfer &amp; Trust Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have not paid any cash dividends on our common stock
to date and do not intend to pay cash dividends prior to the completion of an initial business combination. The payment of cash dividends
in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial conditions subsequent
to completion of an initial business combination. The payment of any cash dividends subsequent to an initial business combination will
be within the discretion of our board of directors at such time. If we incur any indebtedness, our ability to declare dividends may be
limited by restrictive covenants we may agree to in connection therewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Securities Authorized for Issuance Under Equity
Compensation Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sales of Unregistered Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On June 22, 2021, the Sponsor received 1,437,500 shares
of our common stock, or founder shares, for $25,000. Subsequently, in September 2021, under the First Amended and Restated Subscription
Agreement, we issued the sponsor an additional 62,5000 Shares so that it would hold an aggregate of 20% of our outstanding common stock
after our initial public offering. In November 2021, under the Second Amended and Restated Subscription Agreement, we issued the sponsor
an additional 50,000 shares of Common Stock (so that it would hold 20% of our issued and outstanding shares of common stock after the
initial public offering). Further, we agreed that if the underwriters exercise the over-allotment option, we will issue the sponsor such
number of additional shares of common stock (up to 232,500 shares)&nbsp;so as to enable it to maintain its ownership of 20% of our issued
and outstanding shares of common stock. In connection with the partial exercise by the underwriters of the over-allotment option, on November
30, 2021, we issued an additional 75,000 shares to the Sponsor pursuant to the Second Amended and Restated Subscription Agreement. Such
securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. Our sponsor is
an accredited investor for purposes of Rule 501 of Regulation D.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Simultaneously with the closing of our initial public
offering, we completed the private sale of an aggregate of 2,500,000 warrants to the Sponsor at a purchase price of $1.00 per private
warrant, generating gross proceeds to us of $2,500,000. The private warrants are identical to the public warrants sold in our initial
public offering, except that the Sponsor has agreed not to transfer, assign or sell any of the private warrants, (except to certain permitted
transferees) until 30 days after the completion of our initial business combination. No underwriting discounts or commissions were paid
with respect to the private placement. The private placement was conducted as a non-public transaction and, as a transaction by an issuer
not involving a public offering, is exempt from registration under the Securities Act of 1933 in reliance upon Section 4(a)(2) thereof.
&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Use of Proceeds</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On November 26, 2021, we consummated our initial public
offering of 6,200,000 units. Each unit consists of one share of common stock, par value $0.00001 per share, one-half of one redeemable
warrant, with each whole warrant entitling the holder thereof to purchase one share of common stock for $11.50 per share, subject to adjustment,
and one right to receive one-seventh (1/7) of one share of common stock upon the consummation of our initial business combination. The
units were sold at a price of $10.00 per unit, generating gross proceeds to us of $62,000,000. <span style="background-color: white">In
connection with our initial public offering, the underwriters were granted a&nbsp;45-day&nbsp;option to purchase up to 930,000 additional
units to cover over-allotments, if any. On November 30, 2021, the underwriters purchased an additional 300,000 units pursuant to the partial
exercise of the over-allotment option. The additional units were sold at an offering price of $10.00 per unit, generating additional gross
proceeds of $3,000,000.</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Simultaneously with the consummation of the initial
public offering, we completed the private sale of an aggregate of 2,500,000 private warrants to our Sponsor at a purchase price of $1.00
per private warrant, generating gross proceeds to the Company of $2,500,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="background-color: white">A total of $65,000,000
of the proceeds from the sale of the units and private placement warrants, including the sale of the units from the partial exercise of
the over-allotment option, were placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer&nbsp;&amp;
Trust Company acting as trustee.&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Sponsor previously advanced expenses or loaned
us the sum of $125,872, evidenced by a note dated as of June 11, 2021. In connection with the completion of our initial public offering,
the Sponsor instructed us to offset repayment of the amount outstanding under the note with a corresponding portion of the purchase price
for the private placement of warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We incurred transaction costs for our initial public
offering of $1,697,431, consisting of $1,300,000 of underwriting fees and $397,431 of other offering costs. The net proceeds from our
IPO available to us out of trust for our working capital requirements in searching for a business combination and for working capital
requirements are approximately $900,000. We intend to use the proceeds for legal, accounting and other expenses of structuring and negotiating
business combinations, due diligence of prospective target businesses, legal and accounting fees related to SEC reporting obligations,
our monthly office rent, as well as for reimbursement of any out-of-pocket expenses incurred by our founders, officers and directors in
connection with activities on our behalf as described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 58 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The funds held in trust has been invested only in United
States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 180
days or less, or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest
only in direct U.S. government treasury obligations, so that we are not deemed to be an investment company under the Investment Company
Act. Except with respect to interest earned on the funds held in the trust account that may be released to us to pay our income or other
tax obligations, the proceeds will not be released from the trust account until the earlier of the completion of a business combination
or our redemption of 100% of the outstanding public shares if we have not completed a business combination in the required time period.
The proceeds held in the trust account may be used as consideration to pay the sellers of a target business with which we complete a business
combination. Any amounts not paid as consideration to the sellers of the target business may be used to finance operations of the target
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Officers, directors and founders will receive reimbursement
for any out-of-pocket expenses incurred by them in connection with activities on our behalf, such as identifying potential target businesses,
performing business due diligence on suitable target businesses and business combinations as well as traveling to and from the offices,
plants or similar locations of prospective target businesses to examine their operations. Our audit committee will review and approve
all reimbursements and payments made to our founders, officers, directors or our or their respective affiliates, with any interested director
abstaining from such review and approval. There is no limit on the amount of such expenses reimbursable by us; provided, however, that
to the extent such expenses exceed the available proceeds not deposited in the trust account, such expenses would not be reimbursed by
us unless we consummate an initial business combination. Since the role of present management after a business combination is uncertain,
we have no ability to determine what remuneration, if any, will be paid to those persons after a business combination.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 6. [Reserved]</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 7. Management’s Discussion and Analysis of Financial Condition
and Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Special Note Regarding Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All statements other than statements
of historical fact included in this Form 10-K including, without limitation, statements under “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and
the plans and objectives of management for future operations, are forward-looking statements. When used in this Form 10-K, words such
as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions,
as they relate to us or the Company’s management, identify forward-looking statements. Such forward-looking statements are based
on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management.
Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed
in our filings with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following discussion and analysis
of our financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto
contained elsewhere in this Report. Certain information contained in the discussion and analysis set forth below includes forward-looking
statements that involve risks and uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Overview</b>&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">We were formed on May 19, 2021 for the purpose
of engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business
combination, which we refer to throughout this report as our initial business combination, with one or more businesses or entities with
one or more target businesses. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic
region. We intend to utilize cash derived from the proceeds of our initial public offering and contemporaneous private placement and our
securities, debt or a combination of cash, securities and debt, in effecting a business combination. The issuance of additional shares
of common stock or preferred stock:</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"></p>

<!-- Field: Page; Sequence: 59 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
significantly reduce the equity interest of our stockholders;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
subordinate the rights of holders of shares of common stock if we issue shares of preferred stock with rights senior to those afforded
to our shares of common stock;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will
likely cause a change in control if a substantial number of our shares of common stock are issued, which may affect, among other things,
our ability to use our net operating loss carry forwards, if any, and most likely will also result in the resignation or removal of our
present officers and directors; and</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
adversely affect prevailing market prices for our securities.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 7pt 0 0; text-indent: 24pt">Similarly, if we issue debt securities, it could
result in:</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;default
and foreclosure on our assets if our operating revenues after a business combination are insufficient to pay our debt obligations;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acceleration
of our obligations to repay the indebtedness even if we have made all principal and interest payments when due if the debt security contains
covenants that required the maintenance of certain financial ratios or reserves and we breach any such covenant without a waiver or renegotiation
of that covenant;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
inability to obtain additional financing, if necessary, if the debt security contains covenants restricting our ability to obtain additional
financing while such security is outstanding;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>our
inability to pay dividends on our common stock;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>using
a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends
on our common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>limitations
on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>increased
vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;
and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>limitations
on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of
our strategy and other purposes and other disadvantages compared to our competitors who have less debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 24pt"><span style="font-family: Times New Roman PS Std,serif">We
have neither engaged in any operations nor generated any revenues to date. </span>We expect to continue to incur significant costs in
the pursuit of our acquisition plans. We cannot assure you that our plans to complete a business combination will be successful.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 7pt 0 0; text-indent: 24pt">We are an emerging growth company as defined in
the JOBS Act. As an emerging growth company, we have elected to delay the adoption of new or revised accounting standards that have different
effective dates for public and private companies until those standards apply to private companies. As such, our financial statements may
not be comparable to companies that comply with public company effective dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have neither engaged in any operations nor generated
any revenues to date. Our only activities from inception through December 31, 2021 were organizational activities, those necessary to
prepare for our initial public offering, described below, and subsequently identifying a target business for a business combination. We
do not expect to generate any operating revenues until after the completion of our business combination. We generate non-operating income
in the form of interest income on marketable securities held in the trust account with Continental Stock Transfer &amp; Trust Company
after the initial public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are incurring expenses as a result of being a public
company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with
completing a business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 32.05pt">For the period from May 19, 2021 (date of
inception) through December&nbsp;31, 2021, we had a net loss of $144,837, which consisted of formation costs and operating expenses of
$20,887 and a provision for income taxes of $124,434, which was partially offset by interest income on marketable securities held in the
Trust Account of $484.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On November 26, 2021, we consummated the initial public
offering of 6,200,000 units at a price of $10.00 per unit, generating gross proceeds of $62,000,000. Simultaneously with the closing of
the initial public offering, we consummated the sale of an aggregate of 2,500,000 private warrants for a total purchase price of $2,500,000
in a private placement to our sponsor. On November 30, 2021, we sold an additional 300,000 units to the underwriter pursuant to the <span style="background-color: white">partial
exercise of the over-allotment option at an offering price of $10.00 per unit, generating additional gross proceeds to the Company of
$3,000,000, or $65,000,000 in total. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following the initial public offering
and the sale of the private placement warrants, a total of $65,000,000 was placed in the trust account located in the United States and
we had $900,000 of cash held outside of the trust account, after payment of costs related to the Initial Public Offering, and available
for working capital purposes. We incurred $1,697,431 in transaction costs, including $1,300,000 of underwriting fees and $397,431 of other
costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the year ended December 31,
2021, cash used in operating activities was $300,944. Net loss of $144,837 was affected by interest earned on marketable securities held
in the trust account of $484 and changes in operating assets and liabilities, which provided $300,944 of cash used in operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of December 31, 2021, we had cash and marketable
securities of $65,000,484 held in the trust account. We intend to use substantially all of the funds held in the trust account, including
any amounts representing interest earned on the trust account primarily to identify and evaluate prospective acquisition candidates, perform
business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target
businesses, review corporate documents and material agreements of prospective target businesses, select the target business to acquire
and structure, negotiate and consummate a Business Combination. We may withdraw interest to pay taxes. During the period ended December
31, 2021, we did not withdraw any interest earned on the trust account. To the extent that our capital stock or debt is used, in whole
or in part, as consideration to complete our business combination, the remaining proceeds held in the trust account will be used as working
capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">In order to fund working capital deficiencies or finance
transaction costs in connection with an intended initial business combination, our founders, officers and directors and their affiliates
may, but are not obligated to, loan us funds as may be required. If we complete our initial business combination, we may repay such loaned
amounts out of the proceeds of the trust account released to us. In the event that our initial business combination does not close, we
may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from our trust account
would be used for such repayment. Up to $2,400,000 of such loans may be convertible into working capital warrants at a price of $1.00
per warrant at the option of the lender. The warrants would be identical to the private placement warrants issued to our initial stockholders.
The terms of such loans by our founders, officers and directors and their affiliates if any, have not been determined and no written agreements
exist with respect to such loans. Prior to the completion of our business combination, we do not expect to seek loans from parties other
than our founders, officers and directors and their affiliates if any, as we do not believe third parties will be willing to loan such
funds and provide a waiver against any and all rights to seek access to funds in our trust account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 61 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 24pt">We do not believe we will need to raise additional
funds in order to meet the expenditures required for operating our business. If our estimates of the costs of unde<span style="font-family: Times New Roman PS Std,serif">rtaking
in-depth due diligence and negotiating an initial business combination is less than the actual amount necessary to do so, or we earn less
interest on the funds held in the trust account than anticipated, we may have insufficient funds available to operate our business prior
to our initial business combination. Moreover, we may need to obtain additional financing either to consummate our initial business combination
or because we become obligated to redeem a significant number of our public shares upon consummation of our initial business combination,
in which case we may issue additional securities or incur debt in connection with such business combination. We do not have a maximum
debt leverage ratio or a policy with respect to how much debt we may incur. The amount of debt we will be willing to incur will depend
on the facts and circumstances of the proposed business combination and market conditions at the time of the potential business combination.
At this time, we are not party to any arrangement or understanding with any third party with respect to raising additional funds through
the sale of our securities or the incurrence of debt. Subject to compliance with applicable securities laws, we would only consummate
such financing simultaneously with the consummation of our initial business combination. In the current economic environment, it has become
especially difficult to obtain acquisition financing. </span>If we are unable to complete our Business Combination because we do not have
sufficient funds available to us, we will be forced to cease operations and liquidate the trust account. In addition, following our Business
Combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;<b>&nbsp;</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Off-balance sheet financing arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 34.1pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 24pt">We have no obligations, assets or liabilities, which
would be considered off-balance sheet arrangements as of December 31, 2021. We do not participate in transactions that create relationships
with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established
for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Contractual obligations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 34.1pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 24pt">We do not have any long-term debt,
capital lease obligations, operating lease obligations or long-term liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">Pursuant to a Business Combination Marketing Agreement,
we have engaged Ladenburg Thalmann &amp; Co. and I-Bankers Securities, Inc. as advisors in connection with our business combination to
assist us in holding meetings with our stockholders to discuss the potential business combination and the target business’s attributes,
introduce us to potential investors that are interested in purchasing our securities in connection with the potential business combination,
provide financial advisory services to assist us in our efforts to obtain any stockholder approval for the business combination and assist
us with our press releases and public filings in connection with the business combination. This agreement will provide that we will pay
Ladenburg Thalmann and I-Bankers Securities, Inc. the marketing fee for such services upon the consummation of our initial business combination
in an amount equal to, in the aggregate, 2.5% of the gross proceeds of our initial public offering. As a result, Ladenburg Thalmann and
I-Bankers Securities, Inc. will not be entitled to such fee unless we consummate our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Critical Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 24pt">The preparation of financial statements
and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities
at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from
those estimates. We have identified the following critical accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 62 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Shares subject to redemption</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 24pt">We account for our shares of common
stock subject to possible conversion in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480
“<i>Distinguishing Liabilities from Equity</i>.” Shares subject to mandatory redemption are classified as a liability instrument
and are measured at fair value. Conditionally redeemable shares (including shares that feature redemption rights that are either within
the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified
as temporary equity. At all other times, shares are classified as shareholders’ equity. Our shares feature certain redemption rights
that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, shares subject to
possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of our balance
sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Recent accounting pronouncements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 24pt">Management does not believe that
any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 7A. Quantitative and Qualitative Disclosures
About Market Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 24pt">As of December 31, 2021, we were not subject to any
market or interest rate risk. The net proceeds of our Initial Public Offering completed November 26, 2021, including amounts in the Trust
Account, have been invested in U.S. government treasury bills, notes or bonds with a maturity of 180 days or less or in certain money
market funds that invest solely in U.S. treasuries. Due to the short-term nature of these investments, we believe there will be no associated
material exposure to interest rate risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 8. Financial Statements and Supplemental Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This information appears following Item 15 of this
Report and is included herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 9. Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 9A. Controls and Procedures Evaluation of
Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the supervision and with the participation of
our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of
the effectiveness of our disclosure controls and procedures as of December 31, 2021 and for the period from May 19, 2021 (inception) through
December 31, 2021, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal
executive officer and principal financial and accounting officer have concluded that during the period covered by this report, our disclosure
controls and procedures were not effective. As a result, we performed additional analysis as deemed necessary to ensure that our financial
statements were prepared in accordance with U.S. generally accepted accounting principles. Accordingly, management believes that the financial
statements included in this Form&nbsp;10-K present fairly in all material respects our financial position, results of operations
and cash flows for the period presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disclosure controls and procedures are designed to
ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within
the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management,
including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow
timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><br>
We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and
procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the
disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there
are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure
controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all
our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated
goals under all potential future conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 63 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Management’s Report on Internal Controls
Over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This Annual Report on Form 10-K does not include a
report of management’s assessment regarding internal control over financial reporting or an attestation report of our independent
registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Changes in Internal Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There have been no changes in
our internal control over financial reporting during the period ended December 31, 2021 that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 9B. Other Information.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<b>Item 9C. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item&nbsp;10. Directors, Executive Officers and Corporate Governance.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our current directors and executive
officers are as follows:&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 19%; text-align: justify"><span style="font-size: 10pt">Jonathan Intrater </span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 10%; text-align: center"><span style="font-size: 10pt">64</span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td><span style="font-size: 10pt">Chairman, Chief Executive Officer and Principal Financial Officer</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><span style="font-size: 10pt">Allan Liu</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">65 </span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">Loren Mortman</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">48 </span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<br>
<b>Biographical Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><i>Jonathan Intrater</i> has been our Chairman, Chief Executive Officer
and Principal Financial Officer since our inception. Mr. Intrater is a Managing Director in the investment banking department at Ladenburg,
Thalmann&nbsp;&amp; Co., Inc., which he joined in 1998. His broad transactional experience over the past 29&nbsp;years of investment banking
encompassing over $10 billion in public equity and high-yield note offerings, private placements of debt and equity securities, merger
advisory transactions, and various debt restructuring assignments. From September 2019 to August 2021, he served as a member of the board
and Chairman of the audit committee of GreenVision Acquisition Corp., a Nasdaq Capital Market-listed special purpose acquisition company
which completed its initial business combination in August 2021. Prior to joining Ladenburg Thalmann, he served as a Managing Director
at the Brenner Securities Corporation from 1982 to 1989 and a Senior Vice President, BIA/Frazier, Gross&nbsp;&amp; Kadlec, the nation’s
largest telecommunications valuation firm from 1982 to 1989. Mr. Intrater holds an M.B.A from Vanderbilt University and a bachelor’s
degree from the University of Pennsylvania.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><i>Allan Liu</i>, has been one of our independent directors since
June 2021. Mr. Liu is a partner and Asia Chairman of the Versant Group, as well as Chairman of VG Asset Management Co, a Hong Kong SFC
licensed company focused on asset management since 2018.&nbsp;Prior to joining Versant, from 2006 to 2018, Mr. Liu was with Hong Kong-based
Pacific Alliance Group (PAG) as a co-founding partner of the group’s private equity business. PAG is now a leading alternative asset
manager in Asia with over $40 billion USD under management. Prior to joining PAG, in 1995 Mr. Liu co-founded and led American International
Group’s direct investment fund in China,&nbsp; Since the early 1980s, Mr. Liu has been&nbsp;involved in&nbsp;advising, managing
and investing&nbsp;over $20 billion capital in numerous projects for international corporations and investors, and participated in building
successful funds and asset management platforms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><i></i></p>

<!-- Field: Page; Sequence: 64 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><i>Loren Mortman</i> has been one of our independent directors since
June 2021. Ms. Mortman is President of The Equity Group Inc., an investor relations consulting firm founded in 1974 that specializes in
investor communications, investment community outreach, and IR advisory for small-to-mid-cap public and pre-public companies. After joining
The Equity Group in 1997, she spent 10 years implementing comprehensive investor relations programs for clients in various industries,
including industrials, cleantech, gaming, technology, healthcare and business services. Client programs involved investment thesis development,
written communications, investment community outreach, media relations, market intelligence and C-suite advisory. In 2007, Loren became
a Senior Vice President of The Equity Group, focusing on corporate development, and was appointed President in 2013. Loren acts in an
advisory capacity, counseling clients on transactions, critical communications, relations with the investment community, and other areas
that relate to their postures as public companies. Prior to joining The Equity Group, Loren was a Financial Analyst at Brenner Securities,
an Investment Bank. Ms. Mortman earned her BBA in Finance from the Goizueta Business School at Emory University.<b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Number and Terms of Office of Officers and Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We currently have three directors. Our board of directors
will be elected each year at our annual meeting of stockholders. In accordance with Nasdaq corporate governance requirements, we are not
required to hold an annual meeting until one year after our first fiscal year end following our listing on Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our officers are appointed by
the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors
is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws provide that our officers
may consist of a Chairman of the Board, Chief Executive Officers, Chief Financial Officer, President, Vice Presidents, Secretary, Treasurer,
Assistant Secretaries and such other offices as may be determined by the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our board has determined that
each of Allan Liu and Loren Mortman is an “independent director” under Nasdaq listing standards and applicable SEC rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Nasdaq listing standards require that a majority
of our Board of Directors be independent. An “independent director” is defined generally as a person who has no material relationship
with the listed company (either directly or as a partner, stockholder or officer of an organization that has a relationship with the company).
Our independent directors expect to have regularly scheduled meetings at which only independent directors are present. Any affiliated
transactions will be on terms no less favorable to us than could be obtained from independent parties. Our board of directors will review
and approve all affiliated transactions with any interested director abstaining from such review and approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;<b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Committees of the Board of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Upon the effective date of the registration statement
for our IPO, we established three standing committees: an audit committee, a compensation committee and a nominating and corporate governance
committee. Subject to phase-in rules, the Nasdaq rules&nbsp;and Rule&nbsp;10A-3 of the Exchange Act require that the audit committee of
a listed company be comprised solely of independent directors, and the Nasdaq rules require that the compensation committee and the nominating
and corporate governance committee of a listed company be comprised solely of independent directors. Each committee will operate under
a charter that will be approved by our board of directors and will have the composition and responsibilities described below.<b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 65 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b><i>Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 0.5in">Upon the effective date of the registration statement
for our IPO<span style="font-family: Times New Roman PS Std,serif">, we established an audit committee of the Board of Directors consisting
of Allan Liu and Loren Mortman. Mr. Liu and Ms. Mortman are each an independent director under Nasdaq listing standards. The audit committee’s
duties, which are specified in our Audit Committee Charter, include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reviewing
and discussing with management and the independent auditor the annual audited financial statements, and recommending to the Board whether
the audited financial statements should be included in our Form 10-K;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;discussing
with management and the independent auditor significant financial reporting issues and judgments made in connection with the preparation
of our financial statements;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;discussing
with management major risk assessment and risk management policies;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;monitoring
the independence of the independent auditor;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;verifying
the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible
for reviewing the audit as required by law;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reviewing
and approving all related-party transactions;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;inquiring
and discussing with management our compliance with applicable laws and regulations;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pre-approving
all audit services and permitted non-audit services to be performed by our independent auditor, including the fees and terms of the services
to be performed;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;appointing
or replacing the independent auditor;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determining
the compensation and oversight of the work of the independent auditor (including resolution of disagreements between management and the
independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work;&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0 0 0 47.5pt; text-indent: -23.75pt">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0 0 0 45pt; text-indent: -22.5pt">&nbsp;<span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reviewing
and approving any annual or long-term incentive cash bonus or equity or other incentive plans in which our executive officers may participate;&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;establishing
procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or
reports which raise material issues regarding our financial statements or accounting policies; and</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;approving
reimbursement of expenses incurred by our management team in identifying potential target businesses.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b><i>Financial Experts on Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">The audit committee will at all times be composed
exclusively of directors who are “financially literate” as defined under Nasdaq’s listing standards.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">In addition, we must certify to Nasdaq that the
committee has, and will continue to have, at least one member who has past employment experience in finance or accounting, requisite professional
certification in accounting, or other comparable experience or background that results in the individual’s financial sophistication.
The Board of Directors has determined that Ms. Loren Mortman qualifies as an “audit committee financial expert,” as defined
under rules and regulations of the SEC.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b></b></p>

<!-- Field: Page; Sequence: 66 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>Compensation Committee</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"><span style="font-family: Times New Roman PS Std,serif">Upon
the effective date upon the date of </span>the registration statement for our IPO<span style="font-family: Times New Roman PS Std,serif">,
we established a compensation committee of the Board of Directors, consisting of Allan Liu and Loren Mortman. Mr. Liu and Ms. Mortman
are each an independent director under Nasdaq’s listing standards. The compensation committee’s duties, which are specified
in our Compensation Committee Charter, include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>establishing,
reviewing, and approving our overall executive compensation philosophy and policies;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reviewing
and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, evaluating
our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration
(if any) of our Chief Executive Officer based on such evaluation;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reviewing
and approving the compensation of all of our other executive officers;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reviewing
our executive compensation policies and plans;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;r</span>eceiving
and evaluating performance target goals for the senior officers and employees (other than executive officers) and reviewing periodic
reports from the CEO as to the performance and compensation of such senior officers and employees;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0 0 0 48pt; text-indent: -24pt">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;implementing
and administering our incentive compensation equity-based remuneration plans;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0 0 0 48pt; text-indent: -24pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -22.5pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>reviewing
and approving any annual or long-term incentive cash bonus or equity or other incentive plans in which our executive officers may participate;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0 0 0 45pt; text-indent: -22.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -22.5pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>reviewing
and approving for our CEO and other executive officers any employment agreements, severance arrangements, and change in control agreements
or provisions;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -22.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -22.5pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reviewing
and discussing with management the Compensation Discussion and Analysis set forth in Securities and Exchange Commission Regulation S-K,
Item 402, if required, and, based on such review and discussion, determine whether to recommend to the Board that the Compensation Discussion
and Analysis be included in our annual report or proxy statement for the annual meeting of stockholders;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;assisting
management in complying with our proxy statement and annual report disclosure requirements;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;approving
all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and
employees;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
required, producing a report on executive compensation to be included in our annual proxy statement;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
reviewing and recommending to the Board for approval the frequency with which we will conduct Say-on-Pay Votes, taking into account the
results of the most recent shareholder advisory vote on frequency of Say-on-Pay Votes required by Section 14A of the Exchange Act, and
review and recommend to the Board for approval the proposals regarding the Say-on-Pay Vote and the frequency of the Say-on-Pay Vote to
be included in our proxy statement filed with the SEC;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>conducting
an annual performance evaluation of the committee; and</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reviewing,
evaluating and recommending changes, if appropriate, to the remuneration for directors.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b><i>Nominating Committee</i></b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Upon the effective of the registration statement
for our IPO, we established a nominating committee of the Board of Directors consisting of Allan Liu and Loren Mortman. Mr. Liu and Ms.
Mortman are each an independent director under Nasdaq’s listing standards. The nominating committee is responsible for overseeing
the selection of persons to be nominated to serve on our Board of Directors. The nominating committee considers persons identified by
its members, management, stockholders, investment bankers and others.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><i>Guidelines for Selecting Director Nominees</i></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">The guidelines for selecting nominees, which are
specified in the Nominating Committee Charter, generally provide that persons to be nominated:</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;should
have demonstrated notable or significant achievements in business, education or public service;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"></p>

<!-- Field: Page; Sequence: 67 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;should
possess the requisite intelligence, education and experience to make a significant contribution to the Board of Directors and bring a
range of skills, diverse perspectives and backgrounds to its deliberations; and</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;should
have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the stockholders.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-indent: 24pt">The Nominating Committee will consider a number of qualifications
relating to management and leadership experience, background and integrity and professionalism in evaluating a person’s candidacy
for membership on the Board of Directors. The nominating committee may require certain skills or attributes, such as financial or accounting
experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its
members to obtain a broad and diverse mix of board members. The nominating committee does not distinguish among nominees recommended by
stockholders and other persons.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Code of Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have adopted a written code of business conduct
and ethics, which applies to our principal executive officer, principal financial or accounting officer or person serving similar functions
and all of our other employees and members of our board of directors. The code of ethics codifies the business and ethical principles
that govern all aspects of our business. We did not waive any provisions of the code of business ethics during the year ended December
31, 2021 (we did not adopt a Code of Ethics until our IPO was completed). We have previously filed a copy of our form of Code of Ethics
(and our audit committee charter and compensation committee charter) as exhibits to the registration statement for our IPO. You will be
able to review these documents by accessing our public filings at the SEC’s web site at www.sec.gov. In addition, a copy of the
Code of Ethics will be provided without charge upon request from us. We intend to disclose any amendments to or waivers of certain provisions
of our Code of Ethics in a Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Compensation Committee Interlocks and Insider Participation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None of our officers currently
serves, or in the past year has served, as a member of the compensation committee of any entity that has one or more officers serving
on our board of directors.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0; text-align: justify"><b>Conflicts of Interest</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Potential investors should be aware of the following
potential conflicts of interests:</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 47.5pt; text-indent: -23.75pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of our officers and directors is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest
in allocating their time among various business activities.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 47.5pt; text-indent: -23.75pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the course of their other business activities, our officers and directors may become aware of investment and business opportunities which
may be appropriate for presentation to our company as well as the other entities with which they are affiliated. Our management has pre-existing
fiduciary duties and contractual obligations to such entities (as well as to us) and may have conflicts of interest in determining to
which entity a particular business opportunity should be presented.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0 47.5pt; text-indent: -23.75pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
officers and directors may in the future become affiliated with entities, including other blank check companies, engaged in business
activities similar to those intended to be conducted by our company.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 8pt 47.5pt; text-indent: -23.75pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
certain limited exceptions, the sponsor shares will not be transferable or assignable by our sponsor and other initial stockholders until
the earlier of six months after the date of the consummation of our initial business combination and the date on which the closing price
of our shares of common stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations
and recapitalizations) for any 20 trading days within any 30-trading day period commencing after our initial business combination, or
earlier, if, subsequent to our initial business combination, we consummate a liquidation, merger, stock exchange or other similar transaction
which results in all of our stockholders having the right to exchange their shares for cash, securities or other property. With certain
limited exceptions, the private placement warrants, working capital warrants, extension warrants, and the common stock underlying such
warrants, will not be transferable, assignable or saleable by our sponsor or its permitted transferees until 30&nbsp;days after the completion
of our initial business combination. Since our sponsor and officers and directors may directly or indirectly own common stock and warrants,
our officers and directors may have a conflict of interest in determining whether a particular target business is an appropriate business
with which to effectuate our initial business combination.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 8pt 47.5pt; text-indent: -23.75pt"></p>

<!-- Field: Page; Sequence: 68 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 8pt 47.5pt; text-indent: -23.75pt">&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 8pt 47.5pt; text-indent: -23.75pt"><span style="font-size: 16pt">•</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our officers and directors may loan funds to us after our initial public offering and may be owed reimbursement for expenses
incurred in connection with certain activities on our behalf which may only be repaid from the trust account if we complete an initial
business combination. For the foregoing reasons, the personal and financial interests of our directors and executive officers may influence
their motivation in identifying and selecting a target business, completing a business combination in a timely manner and being able
to transfer their shares and private warrants.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>Our
sponsor, officers and directors have agreed to waive their redemption rights with respect to any sponsor shares and any public shares
held by them in connection with the consummation of our initial business combination. Additionally, our initial stockholders, officers
and directors have agreed to waive their redemption rights with respect to any sponsor shares held by them if we fail to consummate our
initial business combination within nine months after the closing of our initial public offering or during any extension period. However,
if our sponsor or any of our officers, directors or affiliates acquire public shares in or after our initial public offering, they will
be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to consummate our initial
business combination within the prescribed time frame. If we do not complete our initial business combination within such applicable
time period, the proceeds of the sale of the private placement warrants held in the trust account will be used to fund the redemption
of our public shares, and the private placement warrants will expire worthless.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -21pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>Our
key personnel may negotiate employment or consulting agreements with a target business in connection with a particular business combination.
These agreements may provide for them to receive compensation following our initial business combination and as a result, may cause them
to have conflicts of interest in determining whether to proceed with a particular business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0 48pt; text-indent: -24pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 16pt">•</span><span style="font-family: Times New Roman PS Std,serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>Our
key personnel may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation
of any such key personnel was included by a target business as a condition to any agreement with respect to our initial business combination.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">As a result of multiple business affiliations,
our officers and directors may have similar legal obligations relating to presenting business opportunities to multiple entities. In addition,
conflicts of interest may arise when our board evaluates a particular business opportunity. We cannot assure you that any of the above-mentioned
conflicts will be resolved in our favor. Furthermore, each of our officers and directors has pre-existing fiduciary or contractual obligations
to other businesses of which they are officers or directors. To the extent they identify business opportunities which may be suitable
for the entities to which they owe pre-existing fiduciary or contractual obligations, our officers and directors will honor those fiduciary
or contractual obligations subject to his or her fiduciary duties under the laws of the State of Delaware. Accordingly, it is possible
they may not present opportunities to us that otherwise may be attractive to us unless the entities to which they owe pre-existing fiduciary
or contractual obligations and any successors to such entities have declined to accept such opportunities subject to his or her fiduciary
duties under the laws of the State of Delaware.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Our amended and restated certificate of incorporation
provides that we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly
offered to such person solely in his or her capacity as a director or officer of our company subject to his or her fiduciary duties under
the laws of the State of Delaware and such opportunity is one we are legally and contractually permitted to undertake and would otherwise
be reasonable for us to pursue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.75pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.75pt">The conflicts described above may not be resolved
in our favor.&nbsp;<span style="font-family: Times New Roman PS Std,serif">The following table summarizes the other relevant pre-existing
fiduciary or contractual obligations of our officers and directors:&nbsp;</span></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 30%; padding-right: 3pt"><span style="font-family: Times New Roman PS Std,serif; font-size: 9pt"><b>Name of Individual</b></span></td>
    <td style="white-space: nowrap; width: 4%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 35%; text-align: center"><span style="font-family: Times New Roman PS Std,serif; font-size: 9pt"><b>Name of Affiliated Entity</b></span></td>
    <td style="white-space: nowrap; width: 5%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 26%; text-align: center"><span style="font-family: Times New Roman PS Std,serif; font-size: 9pt"><b>Position at Affiliated Entity</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Jonathan Intrater</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Ladenburg, Thalmann &amp; Co. Inc.</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Managing Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="padding-top: 5pt; text-align: justify"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Allan Liu</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">
    <p style="font: 10pt Times New Roman PS Std,serif; margin: 0">Versant Group</p>
    <p style="font: 10pt Times New Roman PS Std,serif; margin: 5pt 0 0">VG Asset Management Co</p></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">
    <p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: justify">Asia Chairman</p>
    <p style="font: 10pt Times New Roman PS Std,serif; margin: 5pt 0 0; text-align: justify">Chairman</p></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-top: 5pt; text-align: justify"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">Loren Mortman</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="padding-top: 5pt; text-align: justify"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">The Equity Group Inc.</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="padding-top: 5pt; text-align: justify"><span style="font-family: Times New Roman PS Std,serif; font-size: 10pt">President</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 32.05pt"></p>

<!-- Field: Page; Sequence: 69 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 32.05pt">If we submit our initial business combination
to our public stockholders for a vote, our sponsor, as well as all of our management team have agreed to vote any shares held by them
in favor of our initial business combination. In addition, they have agreed to waive their respective rights to participate in any liquidation
distribution with respect to their founder shares. If they purchase shares of common stock, however, they would be entitled to participate
in any liquidation distribution in respect of such shares but have agreed not to redeem such shares in connection with the consummation
of an initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 32.05pt">All ongoing and future transactions between
us and any of our sponsor or management team, or their respective affiliates, will be on terms believed by us to be no less favorable
to us than are available from unaffiliated third parties. Such transactions will require prior approval by a majority of our uninterested
“independent” directors or the members of our&nbsp;board of&nbsp;directors who do not have an interest in the transaction,
in either case who had access, at our expense, to our attorneys or independent legal counsel. We will not enter into any such transaction
unless our disinterested “independent” directors determine that the terms of such transaction are no less favorable to us
than those that would be available to us with respect to such a transaction from unaffiliated third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 32.05pt">We are not prohibited from pursuing an initial
business combination with a business that is affiliated with our sponsors, officers or directors.<span style="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</span><span style="font-family: Times New Roman PS Std,serif">To
further minimize conflicts of interest, we have agreed not to consummate an initial business combination with an entity that is affiliated
with any of our founders, officers or directors unless we have obtained an opinion from an independent investment banking firm, or another
independent entity that commonly renders valuation opinions, and the approval of a majority of our disinterested independent directors
that the business combination is fair to our unaffiliated stockholders from a financial point of view. Furthermore, in no event will any
of our founders, members of our management team or their respective affiliates be paid any finder’s fee, consulting fee or other
similar compensation prior to, or for any services they render in order to effectuate, an initial business combination (regardless of
the type of transaction that it is) other than the amounts described in the prospectus set forth in the registration statement for our
initial public offering and reimbursement of any out-of-pocket expenses.</span></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">As noted above, our Chief Executive Officer is
affiliated with Ladenburg Thalmann, which was also the underwriter in our initial public offering. He will owe a pre-existing&nbsp;fiduciary
duty to Ladenburg Thalmann, meaning that he will present opportunities to Ladenburg Thalmann prior to presenting them to us, if, for example,
a potential target company is open to either raising funds in an offering or engaging in a transaction with a SPAC. This may limit the
number of potential targets they present to us for purposes of completing a business combination.&nbsp;</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Ladenburg Thalmann is continuously made aware of
potential business opportunities, one or more of which we may desire to pursue for an initial business combination. While Ladenburg Thalmann
will not have any duty to offer acquisition opportunities to us, Ladenburg Thalmann may become aware of a potential transaction that is
an attractive opportunity for us, which Ladenburg Thalmann may decide to share with us. In addition, our officers and directors may have
a duty to offer acquisition opportunities to other entities to which they owe duties or clients of affiliates of our sponsor. In addition,
investment ideas generated within Ladenburg Thalmann, including by our Chief Executive Officer and other persons who may make decisions
for the company, may be suitable both for us and for affiliates of Ladenburg Thalmann or any of their respective clients, and may be directed
initially to such persons rather than to us. None of Ladenburg Thalmann nor members of our management team who are also employed by Ladenburg
Thalmann have any obligation to present us with any opportunity for a potential business combination of which they become aware unless
it is offered to them solely in their capacity as a director or officer of the Company and after they have satisfied their contractual
and fiduciary obligations to other parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 70 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">Upon the closing of our initial public offering,
we entered into a Business Combination Marketing Agreement with Ladenburg Thalmann, pursuant to which we engaged Ladenburg Thalmann to
provide certain specified services to us in connection with our initial business combination. In particular, Ladenburg Thalmann may assist
us in holding meetings with our stockholders to discuss the potential business combination and the target business’s attributes,
introduce us to potential investors that are interested in purchasing our securities in connection with the potential business combination,
provide financial advisory services to assist us in our efforts to obtain any stockholder approval for the business combination and assist
us with our press releases and public filings in connection with the business combination, but will not provide any M&amp;A-related advisory
services pursuant to the Business Combination Marketing Agreement. This agreement provides that we will pay Ladenburg Thalmann the Marketing
Fee for such services upon the consummation of our initial business combination in an amount equal to, in the aggregate, 2.5% of the gross
proceeds of our initial public offering. In the ordinary course of business, Ladenburg Thalmann and its affiliates may at any time hold
long or short positions, and may trade or otherwise effect transactions, for its own account and the accounts of customers, in debt or
equity securities of us, our affiliates or other entities that may be involved in the transactions contemplated by the Business Combination
Marketing Agreement, and may provide advisory and other services to one or more actual or potential business combination targets, investors
or other parties to any business combination or other transaction entered into by us, for which services Ladenburg Thalmann or one or
more of its affiliates may be paid fees, including fees conditioned upon the closing of a particular business combination or other transaction
or transactions. This financial interest may result in Ladenburg Thalmann having a conflict of interest when providing the services to
us in connection with an initial business combination.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 12pt 0 0"><b>Limitation on Liability and Indemnification of Officers and Directors</b></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Our amended and restated certificate of incorporation
provides that our officers and directors will be indemnified by us to the fullest extent authorized by Delaware law, as it now exists
or may in the future be amended. In addition, our amended and restated certificate of incorporation will provide that our directors will
not be personally liable for monetary damages to us or our stockholders for breaches of their fiduciary duty as directors, unless they
violated their duty of loyalty to us or our stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized
unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or derived an improper personal benefit from their actions
as directors.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">Our bylaws also permit us to secure insurance on
behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would
permit such indemnification. We have purchased a policy of directors’ and officers’ liability insurance that insures our officers
and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations
to indemnify our officers and directors. Except with respect to any public shares they may acquire in our initial public offering or thereafter
(in the event we do not consummate an initial business combination), our officers and directors have agreed to waive (and any other persons
who may become an officer or director prior to the initial business combination will also be required to waive) any right, title, interest
or claim of any kind in or to any monies in the trust account, and not to seek recourse against the trust account for any reason whatsoever,
including with respect to such indemnification.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">These provisions may discourage stockholders from
bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the
likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit
us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement
and damage awards against officers and directors pursuant to these indemnification provisions.</p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 8pt 0 0; text-indent: 24pt">We believe that these provisions and our directors’
and officers’ liability insurance are necessary to attract and retain talented and experienced officers and directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Section&nbsp;16(a)&nbsp;Beneficial Ownership Reporting Compliance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45in">Section&nbsp;16(a)&nbsp;of the Securities Exchange
Act of 1934, as amended, or the Exchange Act, requires our executive officers, directors, and persons who beneficially own more than 10%
of a registered class of our equity securities to file with the Securities and Exchange Commission initial reports of ownership and reports
of changes in ownership of our shares of common stock and other equity securities. These executive officers, directors, and greater than
10% beneficial owners are required by SEC regulation to furnish us with copies of all Section&nbsp;16(a)&nbsp;forms filed by such reporting
persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45in">Based solely on our review of such forms furnished
to us and written representations from certain reporting persons, we believe that, during the fiscal year ended December&nbsp;31, 2021,
our sponsor, directors, executive officer, and ten percent stockholders complied with all Section&nbsp;16(a)&nbsp;filing requirements,
except that the reports on Form 3 filed by our sponsor, directors and executive officer were inadvertently tardy and were filed on December
2, 2021 except for the Form 3 of Mr. Liu which was filed on December 6, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 71 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item&nbsp;11. Executive Compensation.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">No executive officer has received any cash compensation
for services rendered to us. No compensation or fees of any kind, including finder’s, consulting fees and other similar fees, will
be paid to our founders, members of our management team or their respective affiliates, for services rendered prior to, or in order to
effectuate the consummation of, our initial business combination (regardless of the type of transaction that it is).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Directors, officers and founders will receive reimbursement
for any out-of-pocket expenses incurred by them in connection with activities on our behalf, such as identifying potential target businesses,
performing business due diligence on suitable target businesses and business combinations as well as traveling to and from the offices,
plants or similar locations of prospective target businesses to examine their operations. There is no limit on the amount of out-of-pocket
expenses reimbursable by us. Our audit committee will review on a quarterly basis all payments that were made to the sponsor, our officers
or directors, or our or their affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">After our initial business combination, members of
our management team who remain with us may be paid employment, consulting, management or other fees from the combined company with any
and all amounts being fully disclosed to stockholders, to the extent then known, in the proxy solicitation materials furnished to our
stockholders. The amount of such compensation may not be known at the time of a stockholder meeting held to consider an initial business
combination, as it will be up to the directors of the post-combination business to determine executive and director compensation. In this
event, such compensation will be publicly disclosed at the time of its determination in an Exchange Act filing such as Current Report
on Form 8-K, as required by the SEC. The existence or terms of any such employment or consulting arrangements may influence our management’s
motivation in identifying or selecting a target business, but we do not believe that such arrangements will be a determining factor in
our decision to proceed with any potential business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item&nbsp;12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table sets forth information regarding
the beneficial ownership of our shares of common stock as of March 30, 2022 by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each of our officers and directors; and</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48pt; text-align: justify; text-indent: -24pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">all of our officers and directors as a group.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unless otherwise indicated, we believe that all persons
named in the table have sole voting and investment power with respect to all shares of common stock beneficially owned by them. The following
table does not reflect beneficial ownership of the warrants or rights included in the units offered by this Form 10-K or the private warrants
included the private placement as these warrants are not exercisable and these rights are not convertible within 60 days of the date of
this Annual Report on Form 10-K. As of March 30, 2022, there were 8,125,000 shares of Common Stock (assuming all of the shares of common
stock are separated from the units) issued and outstanding and upon which we base the information in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 72 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold"><span style="font-size: 9pt"><b>Name and Address of Beneficial Owner<sup>(1)</sup></b></span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Amount and<br> Nature of<br> Beneficial<br> Ownership<sup>(3)</sup></b></span></td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"><span style="font-size: 9pt"><b>Approximate<br> Percentage of<br> Outstanding<br> Shares<sup>(2)</sup></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 9pt; font-style: italic; text-align: left">Directors and Executive Officers</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 9pt">Jonathan Intrater <sup>(3)</sup>&nbsp;</span></td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">—&nbsp;&nbsp;</td><td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">—&nbsp;&nbsp;</td><td style="font-size: 9pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 9pt; text-align: left">Allan Liu</td><td style="width: 1%; font-size: 9pt">&nbsp;</td>
    <td style="width: 1%; font-size: 9pt; text-align: left">&nbsp;</td><td style="width: 14%; font-size: 9pt; text-align: right">30,000</td><td style="width: 1%; font-size: 9pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 9pt">&nbsp;</td>
    <td style="width: 1%; font-size: 9pt; text-align: left">&nbsp;</td><td style="width: 14%; font-size: 9pt; text-align: right"><span style="font-size: 9pt">&nbsp;&nbsp;*</span></td><td style="width: 1%; font-size: 9pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 9pt; text-align: left">Loren Mortman</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">30,000</td><td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right"><span style="font-size: 9pt">*</span></td><td style="font-size: 9pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; text-align: left">All directors and officers as a group (3 individuals)</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">60,000</td><td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">0.74</td><td style="font-size: 9pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; font-style: italic; text-align: left">5% or greater beneficial owners</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 9pt">&nbsp;</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">&nbsp;</td><td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">&nbsp;</td><td style="font-size: 9pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 9pt">Mana Capital LLC <sup>(4)</sup>&nbsp;</span></td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">1,565,000</td><td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">19.26</td><td style="font-size: 9pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 9pt">Weiss Asset Management LP<sup>(5)</sup></span></td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">589,000</td><td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">7.25</td><td style="font-size: 9pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 9pt">Space Summit Capital LLC<sup>(6)</sup></span></td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">415,689</td><td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">5.1</td><td style="font-size: 9pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 9pt">Feis Equities LLC<sup>(7)</sup></span></td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">583,612</td><td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">7.18</td><td style="font-size: 9pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 9pt; text-align: left"><span style="font-size: 9pt">Saba Capital Management, L.P. <sup>(8)</sup></span></td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">471,299</td><td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt">&nbsp;</td>
    <td style="font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; text-align: right">5.8</td><td style="font-size: 9pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 9pt; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 9pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&nbsp;</td><td style="font-size: 9pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 9pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less than
one percent.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 9pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Unless otherwise indicated, the business address of each of our officers, directors and sponsor is 8 The Green, Suite #12490, Dover, Delaware 19901.</span></td></tr>
  </tbody></table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 9pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt">Based on an aggregate of 8,125,000 shares of common stock issued and outstanding.</span></td></tr>
  </tbody></table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 9pt">(3)</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Excludes 150,000 shares of common stock and 100,000 private warrants to be transferred to the listed holder by our Sponsor upon, or subsequent to, the closing of our initial business combination.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 9pt">(4)</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Excludes 2,500,000 private warrants purchased by our sponsor
    simultaneously with the consummation of our IPO. Such warrants are not exercisable within the next 60 days. Tong Mao is the owner of
    substantially all of the voting interests of Mana Capital LLC and has the power to direct its affairs, including the voting and sale
    of all securities of the Company owned by Mana Capital LLC.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 9pt">(5)</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Based on information contained in the Schedule 13G filed by Weiss Asset Management, WAM GP, and Andrew Weiss. Each reporting person has shared power to vote 589,000 shares of common stock and shared the power to dispose of such shares. The business address for each reporting person is 222 Berkeley St., 16<sup>th</sup> Floor, Boston, Massachusetts 02116.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 9pt">(6)</span></td>
    <td style="font: 10pt/107% Courier New, Courier, Monospace"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt; line-height: 107%">Based on information contained in the Schedule 13G/A filed by Space Summit Capital LLC, the reporting entity has sole power to vote 415,689 share and sole power to dispose of such shares. The business address for the reporting person is 15455 Albright Street, Pacific Palisades, CA 90272.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 9pt">(7)</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Based on information contained in the Schedule 13G/A filed by Feis Equities LLC and Mr. Lawrence M. Feis. Each reporting person has sole power to vote 583,612 shares and sole power to dispose of such shares. The business address for the reporting persons is 20 North Wacker Drive, Suite 2115, Chicago, Illinois &nbsp;60606.</span></td></tr>
  </tbody></table>
<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-indent: -24pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 9pt">(8)</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">Based on information contained in the Schedule 13G filed by Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein, the reporting persons have the shared power to vote 471,299 shares and the shared power to dispose of such shares. The business address for the reporting person is 405 Lexington Avenue,&nbsp;&nbsp;58<sup>th</sup> Floor, New York, New York, 10174.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45in">Our sponsor and members of our board of directors
beneficially own approximately 20% of the issued and outstanding shares of our common stock. Because of the ownership block held by our
sponsor and directors, such individuals may be able to effectively exercise influence over all matters requiring approval by our stockholders,
including the election of directors and approval of significant corporate transactions other than approval of our initial business combination.
Our sponsor, officers and directors are deemed to be our “promoters” as such term is defined under the federal securities
laws.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 73 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item&nbsp;13. Certain Relationships, and Related Transactions and Director
Independence</b>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 24pt">On&nbsp;June 22, 2021, our sponsor purchased 1,437,500
shares of common stock for an aggregate purchase price of $25,000. In September 2021, we amended the terms of the subscription agreement
to issue our sponsor an additional 62,500 shares of common stock, resulting in our sponsor holding an aggregate of 1,500,000 shares of
common stock so that the shares of common stock held by our sponsor will account for, in the aggregate, 20% of our issued and outstanding
shares following our initial public offering.&nbsp;In November 2021, we entered into a second amended and restated subscription agreement
with the sponsor pursuant to which we issued the sponsor an additional 50,000 shares, resulting in the sponsor holding an aggregate of
1,550,000 shares (so that the sponsor shares will account for 20% of our issued and outstanding shares after the initial public offering)
and also agreed that, if the underwriters exercise the over-allotment option, we will issue to our sponsor such number of additional shares
of common stock (up to 232,500 shares)&nbsp;as to maintain our sponsor’s ownership at 20% or our issued and outstanding common stock
upon the consummation of our initial public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6.5pt 0 0; text-indent: 24pt">The sponsor shares are identical to the shares
of common stock included in the units offered and sold in our initial public offering. However, the holders of sponsor shares have agreed
(A) to vote their sponsor shares (as well as any public shares acquired in or after our initial public offering) in favor of any proposed
business combination, (B) not to propose an amendment to the Certificate of Incorporation, prior to a business combination, to affect
the substance or timing of the Company’s obligation to redeem all public shares if it cannot complete an business combination within
nine months (or up to 21 months) of the closing of our initial public offering, unless the Company provides public stockholders an opportunity
to redeem their public shares, (C) not to redeem any shares in connection with a stockholder vote to approve a proposed initial business
combination or any amendment to our charter documents prior to consummation of an initial business combination or sell any shares to us
in a tender offer in connection with a proposed initial business combination and (D) that the sponsor shares shall not participate in
any liquidating distribution from the trust account upon winding up if a business combination is not consummated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-indent: 24pt">All of the sponsor shares held by our sponsor
and our directors have been placed in escrow with Continental Stock Transfer &amp; Trust Company, as escrow agent, until the earlier of
six months after the date of the consummation of our initial business combination and the date on which the closing price of our shares
of common stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations and recapitalizations)
for any 20 trading days within any 30-trading day period commencing after our initial business combination, or earlier, if, subsequent
to our initial business combination, we consummate a liquidation, merger, stock exchange or other similar transaction which results in
all of our stockholders having the right to exchange their shares for cash, securities or other property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">During the escrow period, the holders of these
shares will not be able to sell or transfer their securities except for transfers, assignments or sales (i)&nbsp;to our officers or directors,
any affiliate or family member of any of our officers or directors, any of the sponsor’s members, officers, directors, consultants,
or affiliates of the sponsor or any of their affiliates or any other pecuniary interest holders in the sponsor at the time of our initial
public offering or family members of the foregoing&nbsp;, (ii) to an initial holder’s stockholders or members upon its liquidation,
(iii) by gift to a member of an individual stockholder’s family or to a trust, the beneficiary of which is a member of such individual’s
immediate family, an affiliate of such individual or to a charitable organization, (iv) by virtue of the laws of descent and distribution
upon death, (v) pursuant to a qualified domestic relations order, (vi) to us for no value for cancellation in connection with the consummation
of our initial business combination, (vii) in connection with the consummation of our initial business combination, by private sales at
prices no greater than the price at which the shares were originally purchased, (viii) in the event of our liquidation prior to our consummation
of an initial business combination, (ix) by virtue of the laws of the State of Delaware or the sponsor’s limited liability company
agreement upon dissolution of the sponsor, or (x)&nbsp;in the event that, subsequent to the consummation of an initial business combination,
we complete a liquidation, merger, capital stock exchange or other similar transaction which results in all of our stockholders having
the right to exchange their common stock for cash, securities or other property&nbsp;in each case (except for clauses (vi), (viii), (ix)
or (x) or with our prior consent) where the transferee agrees to the terms of the escrow agreement and to be bound by these transfer restrictions.
The holders will retain all other rights as our stockholders, including, without limitation, the right to vote their shares of common
stock and the right to receive cash dividends, if declared. If dividends are declared and payable in shares of common stock, such dividends
will also be placed in escrow. If we are unable to effect a business combination and liquidate, there will be no liquidation distribution
with respect to the sponsor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6.5pt 0 0; text-indent: 24pt">On June 11, 2021, our sponsor agreed to loan
us up to $200,000 pursuant to a note which was due and payable by the later of December 11, 2021 in the event that our initial public
offering was not successfully completed by such date or the date on which we complete our initial&nbsp;<span style="font-family: TimesNewRomanPSMT,serif">business
combination. We had borrowed $45,000 under this note and such amount was repaid at the closing of our initial public offering. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6.5pt 0 0; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 74 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6.5pt 0 0; text-indent: 24pt">Our sponsor purchased 2,500,000 warrants at
the closing of our initial public offering in a private placement, for an aggregate price of $2,500,000. This purchase of the additional
2,500,000 warrants took place on a private placement basis simultaneously with the consummation of our initial public offering. These
private warrants have an exercise price of $11.50 per share, are identical to the public warrants contained in the public units sold in
our initial public offering, and the terms of the private warrants will remain the same irrespective of the holder thereof.&nbsp;In the
event of a liquidation prior to our initial business combination, the private warrants will expire worthless. The purchasers of the private
warrants have also agreed not to transfer, assign or sell any of the private warrants or underlying securities (except to the same permitted
transferees as the sponsor and provided the transferees agree to the same terms and restrictions as the permitted transferees of the sponsor
must agree to, each as described above) until the completion of our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24pt; background-color: white">Our Sponsor has agreed
to transfer to Mr.&nbsp;Intrater, our Chief Executive Officer, an aggregate of 150,000 of its sponsor shares upon, or subsequent to, the
consummation of our initial business combination. In addition, our Sponsor agreed to transfer to Mr. Intrater 100,000 of the private warrants
following the consummation of our initial business combination if the closing price of our common stock is greater than $12.50 per share
for twenty (20) consecutive trading days prior to the consummation of our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24pt; background-color: white">In addition, upon the
completion of our initial public offering, our sponsor transferred 30,000 sponsor shares to each of Mr. Liu and Ms.&nbsp;Mortman in consideration
of future services to us as a director of the Company.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt; background-color: white">Other than the foregoing and
as described in this paragraph, no compensation or fees of any kind, including finder’s, consulting fees and other similar fees,
will be paid to our Sponsor, members of our management team or their respective affiliates, for services rendered prior to or in connection
with the consummation of our initial business combination (regardless of the type of transaction that it is). However, such individuals
will receive the repayment of any loans from our Sponsor, officers and directors (i)&nbsp;in connection with the extension of the time
period to complete a business combination or&nbsp;(ii) for working capital purposes and reimbursement for any&nbsp;out-of-pocket&nbsp;expenses
incurred by them in connection with activities on our behalf, such as identifying potential target businesses, performing business due
diligence on suitable target businesses and business combinations as well as traveling to and from the offices, plants or similar locations
of prospective target businesses to examine their operations. There is no limit on the amount of&nbsp;out-of-pocket&nbsp;expenses reimbursable
by us. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers, directors or our or
their affiliates and will determine which expenses and the amount of expenses that will be reimbursed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24pt">If we anticipate that we may not be able to consummate
our initial business combination within nine months, we may, but are not obligated to, extend the period for up to twelve (12) additional
one-month periods to consummate a business combination. In order to extend the time available for us to consummate our initial business
combination, our board of directors would adopt a resolution authorizing such extension and our founders or their affiliates or designees
must deposit into the trust account $216,667 ($0.0333 per share) on or prior to the date of the applicable deadline for each one-month
extension (or up to an aggregate of $2,600,004, or $0.40 per share if we extend for the full twelve months). The providers of such additional
funds will receive a non-interest bearing, unsecured promissory note equal to the amount of any such deposit that will not be repaid in
the event that we are unable to close a business combination unless there are funds available outside the trust account to do so. Such
notes would either be paid upon consummation of our initial business combination, or, at the lender’s discretion, converted upon
consummation of our business combination into additional private warrants at a price of $1.00 per warrant for each dollar amount deposited.
These warrants would have an exercise price of $11.50 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24pt">In order to meet our working capital needs following
the consummation of our initial public offering, our founders, officers and directors or their affiliates or designees may, but are not
obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion. Each
working capital loan would be evidenced by a promissory note. The working capital notes would either be paid upon consummation of our
initial business combination, without interest, or, at holder’s discretion, up to $2,400,000 of the notes may be converted into
working capital warrants at a price of $1.00 per warrant. The working capital warrants would be identical to the private warrants held
by the sponsor, including an exercise price of $11.50 per share. In the event that the initial business combination does not close, we
may use a portion of the working capital held outside the trust account to repay such loaned amounts, but no proceeds from our trust account
would be used for such repayment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 75 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24pt">We have entered into a registration rights agreement
with our sponsor, officers, and directors pursuant to which we agreed to register any shares of common stock, warrants (including working
capital and extension warrants), and shares underlying such warrants, that are not then covered by an effective registration statement.
The holders of a majority of these securities are entitled to make up to two demands that we register such securities. The holders of
a majority of these securities can elect to exercise these registration rights at any time after we consummate a business combination.
In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent
to our consummation of a business combination. We will bear the expenses incurred in connection with the filing of any such registration
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24pt">Other than the repayment of up non-interest bearing
extension loans or working capital loans, the reimbursement of expenses, and the other matters described above, no compensation or fees
of any kind, including finder’s, consulting fees and other similar fees, will be paid to our founders, members of our management
team or their respective affiliates, for services rendered prior to, or in order to effectuate the consummation of, our initial business
combination (regardless of the type of transaction that it is). However, such individuals will receive reimbursement for any out-of-pocket
expenses incurred by them in connection with activities on our behalf, such as identifying potential target businesses, performing business
due diligence on suitable target businesses and business combinations as well as traveling to and from the offices, plants or similar
locations of prospective target businesses to examine their operations. There is no limit on the amount of out-of-pocket expenses reimbursable
by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">&nbsp;After our initial business combination,
members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any
and all amounts being fully disclosed to stockholders, to the extent then known, in the proxy solicitation materials furnished to our
stockholders. It is unlikely the amount of such compensation will be known at the time of a stockholder meeting held to consider an initial
business combination, as it will be up to the directors of the post-combination business to determine executive and director compensation.
In this event, such compensation will be publicly disclosed at the time of its determination in a Current Report on Form 8-K, as required
by the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><b>Related Party Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">Our Code of Ethics requires us to avoid, wherever
possible, all related party transactions that could result in actual or potential conflicts of interests, except under guidelines approved
by the board of directors (or the audit committee). Related-party transactions are defined as transactions in which (1) the aggregate
amount involved will or may be expected to exceed $120,000 in any calendar year, (2) we or any of our subsidiaries is a participant, and
(3) any (a) executive officer, director or nominee for election as a director, (b) greater than 5% beneficial owner of our shares of common
stock, or (c) immediate family member, of the persons referred to in clauses (a) and (b), has or will have a direct or indirect material
interest (other than solely as a result of being a director or a less than 10% beneficial owner of another entity). A conflict of interest
situation can arise when a person takes actions or has interests that may make it difficult to perform his or her work objectively and
effectively. Conflicts of interest may also arise if a person, or a member of his or her family, receives improper personal benefits as
a result of his or her position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">Our audit committee, pursuant to its written charter,
will be responsible for reviewing and approving related-party transactions to the extent we enter into such transactions. The audit committee
will consider all relevant factors when determining whether to approve a related party transaction, including whether the related party
transaction is on terms no less favorable to us than terms generally available from an unaffiliated third-party under the same or similar
circumstances and the extent of the related party’s interest in the transaction. No director may participate in the approval of
any transaction in which he or she is a related party, but that director is required to provide the audit committee with all material
information concerning the transaction. We also require each of our directors and executive officers to complete a directors’ and
officers’ questionnaire that elicits information about related party transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">These procedures are intended to determine whether
any such related party transaction impairs the independence of a director or presents a conflict of interest on the part of a director,
employee or officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">To further minimize conflicts of interest, we
have agreed not to consummate an initial business combination with an entity that is affiliated with any of our founders, officers or
directors unless we have obtained an opinion from an independent investment banking firm, or another independent entity that commonly
renders valuation opinions, and the approval of a majority of our disinterested independent directors that the business combination is
fair to our unaffiliated stockholders from a financial point of view.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 76 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 24pt">All ongoing and future transactions between us
and any of our officers and directors or their respective affiliates will be on terms believed by us to be no less favorable to us than
are available from unaffiliated third parties. Such transactions will require prior approval by a majority of our uninterested “independent”
directors or the members of our board who do not have an interest in the transaction, in either case who had access, at our expense, to
our attorneys or independent legal counsel. We will not enter into any such transaction unless our disinterested “independent”
directors determine that the terms of such transaction are no less favorable to us than those that would be available to us with respect
to such a transaction from unaffiliated third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item&nbsp;14. Principal Accounting Fees and Services.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We had engaged the firm Marcum, Bernstein &amp; Pinchuk,
LLP as our independent registered public accounting firm from the period May 19, 2021 (inception) through January 19, 2022. On January
19, 2022 we engaged MaloneBailey, LLP as our independent registered public accounting firm to audit our financial statements for the year
ended December 31, 2021 as included in this Annual Report on Form 10-K. Fees for professional services provided by our independent registered
public accounting firms since inception were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td colspan="5" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>MaloneBailey, LLP</b></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>For the<br> Year Ended<br> December&nbsp;31, 2021</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>For the period of May 19, 2021 (inception) through<br> November 26, 2021</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Audit Fees&nbsp;<sup>(1)</sup></span></td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">25,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left"></td><td style="font-size: 10pt; width: 14%; text-align: right">—&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Audit-Related Fees&nbsp;<sup>(2)</sup></span></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Tax Fees&nbsp;<sup>(3)</sup></span></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">All Other Fees&nbsp;<sup>(4)</sup></span></td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">25,000</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td colspan="5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>Marcum, Bernstein &amp; Pinchuk, LLP</b></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>For the<br> Year Ended<br> December&nbsp;31, 2021</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>For the period of May 19, 2021 (inception) through<br> November 26, 2021</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Audit Fees&nbsp;<sup>(1)</sup></span></td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 14%; font-size: 10pt; text-align: right">39,655</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Audit-Related Fees&nbsp;<sup>(2)</sup></span></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Tax Fees&nbsp;<sup>(3)</sup></span></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">All Other Fees&nbsp;<sup>(4)</sup></span></td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">39,655</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 3%; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">Audit Fees. Audit fees consist of fees billed for professional services rendered for the audit of our year-end financial statements, reviews of our quarterly interim financial statements, and services that are normally provided by our independent registered public accounting firm in connection with statutory and regulatory filings. As noted above, we engaged MaloneBailey, LLP to conduct the audit of our financial statements for the year ended December 31, 2021. Although Marcum, Bernstein &amp; Pinchuck, LLP performed an audit of our financial statements from the period from inception through June 30, 2021 and provided subsequent review services through November 26, 2021, they did not perform any audit services for the full fiscal year ended December 31, 2021. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Audit-Related Fees. Audit-related fees consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of our year-end consolidated financial statements and are not reported under “Audit Fees.” These services include attest services that are not required by statute or regulation and consultation concerning financial accounting and reporting standards. We did not pay our independent registered public accounts for other services for the periods shown in the table above.</span></td></tr>
</tbody></table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 77 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: justify; width: 3%">&nbsp;</td>
    <td style="text-align: justify; width: 97%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tax Fees. Tax fees consist of fees billed for professional services relating to tax compliance, tax planning and tax advice. We did not pay our independent registered public accounts for tax services for the periods shown in the table above.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td><span style="font-size: 10pt">All Other Fees. All other fees consist of fees billed for all other services including permitted due diligence services related potential business combinations. We did not pay our independent registered public accounts for other services for the periods shown in the table above.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Pre-Approval Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our audit committee was formed upon the consummation of our initial public
offering. As a result, the audit committee did not pre-approve all of the foregoing services, although any services rendered prior to
the formation of our audit committee were approved by our board of directors. Since the formation of our audit committee, and on a going-forward
basis, the audit committee has and will pre-approve all auditing services and permitted non-audit services to be performed for us by our
auditors, including the fees and terms thereof (subject to the de minimis exceptions for non-audit services described in the Exchange
Act which are approved by the audit committee prior to the completion of the audit).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 15. Exhibits, Financial Statement Schedules.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The following documents are filed as part of this Form 10-K:</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial Statements:</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 90%">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 10%; text-align: center"><span style="font-size: 10pt">Page</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Report of MaloneBailey, LLP, Houston TX, Independent Registered Public Accounting Firm (PCAOB ID
    <span id="xdx_90E_edei--AuditorFirmId_c20210519__20211231_zjVKGzb2kWma"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:AuditorFirmId" inside-table="true" id="fact-identifier-43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">206</ix:nonnumeric></span></span>) </span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Balance sheet</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Statement of Operations</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Statement of Changes in Shareholders’ (Deficit) Equity</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Statement of Cash Flows</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Notes to Financial Statements</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-6 - F-14</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial Statement Schedules:</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 78 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td><span style="font-size: 10pt">Exhibits</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We hereby file as part of this Report the exhibits
listed in the attached Exhibit Index. Exhibits which are incorporated herein by reference can be inspected and copied at the public reference
facilities maintained by the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Copies of such material can also be obtained
from the Public Reference Section of the SEC, 100 F Street, N.E., Washington, D.C. 20549, at prescribed rates or on the SEC website at
www.sec.gov.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%"><span style="font-size: 10pt">Exhibit No.</span></td>
    <td style="white-space: nowrap; vertical-align: top; width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 89%; text-align: center"><span style="font-size: 10pt">Description</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">1.1</span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex1z1.htm" style="-sec-extract: exhibit" tabindex="18">Underwriting Agreement, dated November 22, 2021, by and among the Company and Ladenburg Thalmann &amp; Co., Inc. as representative of the underwriters, and I-Bankers Securities, Inc.**</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">1.2</span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex1z2.htm" style="-sec-extract: exhibit" tabindex="18">Business Combination Marketing Agreement, dated November 22, 2021, by and among the Company, Ladenburg Thalmann, and I-Bankers Securities, Inc.**</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">3.1</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001119/ex3x2.htm" style="-sec-extract: exhibit" tabindex="18">Amended
and Restated Certificate of Incorporation.** </a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">3.2</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001049/ex3x3.htm" style="-sec-extract: exhibit" tabindex="18">By-laws***</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">4.1</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001049/ex4x1.htm" style="-sec-extract: exhibit" tabindex="18">Specimen Unit Certificate***</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">4.2</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001049/ex4x2.htm" style="-sec-extract: exhibit" tabindex="18">Specimen Common Stock Certificate***</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">4.3</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001049/ex4x4.htm" style="-sec-extract: exhibit" tabindex="18">Specimen Warrant Certificate**&nbsp;(contained in Exhibit 4.4)</a>&nbsp;</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">4.4</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001049/ex4x4.htm" style="-sec-extract: exhibit" tabindex="18">&nbsp;Warrant Agreement, dated November 22, 2021, by and between the Company and Continental Stock Transfer &amp; Trust Company, as warrant agent.**</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">4.5</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001049/ex4x6.htm" style="-sec-extract: exhibit" tabindex="18">Rights Agreement, dated November 22, 2021, by and between the Company and Continental Stock Transfer &amp; Trust Company, as rights agent.**</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">4.6</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1870144/000107997322000372/ex4x6.htm" tabindex="18">Description of Securities *</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">10.1</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex10z1.htm" style="-sec-extract: exhibit" tabindex="18">Letter Agreement, dated November 22, 2021, by and among the Company, its independent directors and the Sponsor.**</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">10.2</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex10z2.htm" style="-sec-extract: exhibit" tabindex="18">Letter Agreement, dated November 22, 2021, by and between the Company and its chief executive officer. **</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">10.3</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex10z3.htm" style="-sec-extract: exhibit" tabindex="18">Investment Management Trust Agreement, dated November 22, 2021, by and between the Company and Continental Stock Transfer &amp; Trust Company, as trustee.**</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">10.4</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex10z4.htm" style="-sec-extract: exhibit" tabindex="18">Registration Rights Agreement, dated November 22, 2021, by and among the Company, the Sponsor and the other holders party thereto.**</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">10.5</span></td>
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex10z5.htm" style="-sec-extract: exhibit" tabindex="18">Stock Escrow Agreement, dated November 22, 2021, by and among the Company, the Sponsor, Continental Stock Transfer &amp; Trust Company, and the other holders party thereto.**</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">10.6</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000155335021001109/mana_ex10z6.htm" style="-sec-extract: exhibit" tabindex="18">Private Placement Warrant Purchase Agreement, dated November 19, 2021, by and between the Company and the Sponsor.**</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">10.7</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001119/ex10x5.htm" style="-sec-extract: exhibit" tabindex="18">Promissory
Note in the principal amount of $200,000 held by Mana Capital LLC.§</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">10.8</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001119/ex10x8.htm" style="-sec-extract: exhibit" tabindex="18">Securities
Subscription Agreement dated June 22, 2021.§</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">10.9</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001119/ex10x9.htm" style="-sec-extract: exhibit" tabindex="18">Amended
and Restated Subscription Agreement dated September 22, 2021.§</a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">10.10</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001119/ex10x10.htm" style="-sec-extract: exhibit" tabindex="18">Second
Amended and Restated Subscription Agreement.§</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 10pt; text-align: justify; text-indent: -10pt"><span style="font-size: 10pt">14</span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1870144/000107997321001119/ex14x1.htm" style="-sec-extract: exhibit" tabindex="18">Code
of Ethics.§</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">31.1*</span></td>
    <td style="padding-right: 0.8pt; text-align: justify">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1870144/000107997322000372/ex31x1.htm" tabindex="18">Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules&nbsp;13a-14(a)&nbsp;and 15(d)-14(a), as adopted Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">31.2*</span></td>
    <td style="padding-right: 0.8pt; text-align: justify">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1870144/000107997322000372/ex31x2.htm" tabindex="18">Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules&nbsp;13a-14(a)&nbsp;and 15(d)-14(a), as adopted Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">32.1*<span style="color: #0D0D0D">‡</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p></td>
    <td style="padding-right: 0.8pt; text-align: justify">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1870144/000107997322000372/ex32x1.htm" tabindex="18">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section&nbsp;1350, as adopted Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">32.2*<span style="color: #0D0D0D">‡</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p></td>
    <td style="padding-right: 0.8pt; text-align: justify">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1870144/000107997322000372/ex32x2.htm" tabindex="18">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section&nbsp;1350, as adopted Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">101.INS</span></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt">XBRL Instance Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">101.SCH</span></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">101.CAL</span></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">101.DEF</span></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">101.LAB</span></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">101.PRE</span></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">104</span></td>
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Incline
    XBRL and contained in Exhibit 101).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; padding-right: 0.8pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">*</span></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt">Filed with this Annual Report Form 10-K</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">**</span></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Previously filed with that certain Current Report on Form 8-K filed with the Securities and Exchange Commission on November 26, 2021, and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">***</span></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-left: 1pt; text-align: justify"><span style="font-size: 10pt">Previously filed with the Securities and Exchange
    Commission as an exhibit to our Registration Statement on Form S-1 as filed on October 19, 2021 and declared effective on November
    22, 2021 and incorporated herein by reference.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">§</span></td>
    <td style="padding-right: 0.8pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="padding-left: 1pt; text-align: justify"><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Previously
                                            filed with the Securities and Exchange Commission as an exhibit to our Registration Statement
                                            on Form S-1/A as filed on November 10, 2021 and declared effective on November 22, 2021 and
                                            incorporated herein by reference.</span></p></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0D0D0D">‡</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td><span style="font-size: 10pt">This certification is deemed not filed for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 16. Form 10-K Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<!-- Field: Page; Sequence: 79 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Signatures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>MANA CAPITAL &nbsp;ACQUISITION CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 46%">&nbsp;</td>
    <td style="width: 4%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; width: 50%"><span style="font-size: 10pt">/s/ Jonathan Intrater</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Jonathan Intrater</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer and Principal Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer and Principal Accounting Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dated: March 31, 2022</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the
capacities and on the dates indicated:&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 27%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Signature</span></b></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 50%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Title and Capacity</span></b></span></td>
    <td style="width: 22%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Date</span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/ Jonathan Intrater</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Chief Executive Officer, Principal Financial Officer and Chairman</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Jonathan Intrater</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">(Principal Executive Office and Principal Accounting Officer)</span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Allan Liu</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Allan Liu</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Loren Mortman</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Loren Mortman</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<!-- Field: Page; Sequence: 80 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 36.2pt 8pt 0.5in; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">To the Shareholders and Board of Directors of</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 36.2pt 8pt 0.5in">Mana Capital Acquisition Corp</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 36.2pt 0 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 36.2pt 0 0.5in"><b><i>Opinion on the Financial Statements</i></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 36.2pt 0 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">We have audited the accompanying balance
sheet of Mana Capital Acquisition Corp (the “Company”) as of December 31, 2021, and the related statements of operations,
stockholders’ equity, and cash flows for the period from May 19, 2021 (inception) through December 31, 2021, and the related notes
(collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all
material respects, the financial position of the Company as of December 31, 2021, and the results of its operations and its cash flows
for the period from May 19, 2021 through December 31, 2021, in conformity with accounting principles generally accepted in the United
States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b><i>Basis for Opinion</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB")
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">We conducted our audit in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Our audit included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><i>/s/ <span id="xdx_904_edei--AuditorName_c20210519__20211231_zFgBhDo1LHMk"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:AuditorName" inside-table="false" id="fact-identifier-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">MaloneBailey, LLP</ix:nonnumeric></span></span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">www.malonebailey.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">We have served as the Company's auditor
since 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span id="xdx_905_edei--AuditorLocation_c20210519__20211231_zo214ppwQ3z1"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="dei:AuditorLocation" inside-table="false" id="fact-identifier-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Houston, Texas</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">March 31, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 81; Options: NewSection -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>MANA CAPITAL ACQUISITION
CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>BALANCE SHEET</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_111_zTMZst1eIo9" summary="xdx: Statement - BALANCE SHEET" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" id="xdx_49E_20211231_zuA780Fy2uXf" style="text-align: center; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsAbstract_iB_zc0soG2IQdBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_iB_z452XQgghaL" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maACznE9_zqk9tJHjvBzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; padding-left: 10pt">Cash</td><td style="width: 10%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">526,625</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseCurrent_iI_maACznE9_zf3wBBw0m2c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid expenses</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">280,057</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrent_iTI_mtACznE9_maAzUwO_zqlyfzvCOvLg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">806,682</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsHeldInTrustCurrent_iI_maAzUwO_zHOcVWlB1wM8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Investments held in Trust Account</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AssetsHeldInTrustCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,000,484</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--Assets_iTI_mtAzUwO_ziNhjOSiQxGk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,807,166</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zOWxCa3eoF94" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Liabilities, Temporary Equity, and Stockholders’ Equity</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrentAbstract_iB_zHPwQt3matA9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--TaxesPayableCurrent_iI_maLCzxeW_z6cOBcQNReg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Franchise tax payable</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:TaxesPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124,434</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_iTI_mtLCzxeW_maLzLgP_zcJ6J33wyyN4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124,434</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--Liabilities_iTI_mtLzLgP_maLASEzbmQ_zmPjo1sKc7gf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124,434</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommitmentsAndContingencies_iI_zKojd30NH3Pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Commitments and Contingencies</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_maLASEzbmQ_zlKcU8Tcpjf1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock subject to possible redemption, <span id="xdx_900_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20211231_zBMMkDJu8sU4" title="Temporary equity shares authorized"><span><ix:nonfraction name="us-gaap:TemporaryEquitySharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,500,000</ix:nonfraction></span></span> shares at conversion value of $<span id="xdx_90A_eus-gaap--TemporaryEquityRedemptionPricePerShare_iI_c20211231_zw2FaRwFcZJ3" title="Temporary equity, per share"><span><ix:nonfraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-55" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.00</ix:nonfraction></span></span> per share</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,000,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB_zDPOoUDQN7P4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Stockholders’ Equity:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--PreferredStockValue_iI_maSEzOo8_zAl3GBd89Zvb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Preferred stock, $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zke3Rg0ARTUe" title="Preferred stock, par value"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00001</ix:nonfraction></span></span> par value; <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zJdctdg47m2l" title="Preferred stock, shares authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000,000</ix:nonfraction></span></span> shares authorized; <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_dn_c20211231_zl8rVldLdQZe" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_zEDoNdCSIC3i" title="Preferred stock, shares outstanding"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">none</ix:nonfraction></span></ix:nonfraction></span></span></span> issued and outstanding</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0089"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-12-31" id="fact-identifier-61" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0089" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockValue_iI_maSEzOo8_zs7F4clPWXQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Common stock, $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_z2NMzFqNqeok" title="Common stock, par value"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00001</ix:nonfraction></span></span> par value; <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zfBgQ0aokoba" title="Common stock, shares authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000,000</ix:nonfraction></span></span> shares authorized; <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20211231_zcqI683JujUb" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zAjZREesPxLb" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,625,000</ix:nonfraction></span></ix:nonfraction></span></span></span> issued
    and outstanding as of December 31, 2021 (excluding 6,500,000 shares subject to possible redemption)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--AdditionalPaidInCapital_iI_maSEzOo8_zPL5xLLIqK8g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Additional paid-in capital</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">827,553</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maSEzOo8_zx04DKYuBPF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,837</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_iTI_mtSEzOo8_maLASEzbmQ_zuFJPhWu4ugc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Stockholders' Equity</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">682,732</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzbmQ_zGFTCOq1VuMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities, Temporary Equity, and Stockholders' Equity</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,807,166</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The accompany notes are an integral part of these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 82 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>MANA CAPITAL ACQUISITION
CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>STATEMENT OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_113_zSzq3WlbWxNg" summary="xdx: Statement - STATEMENT OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" id="xdx_496_20210519__20211231_z4X0lG2kgDne" style="font-weight: bold; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">For the Period</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">From May 19,2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">(inception) through</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: right">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingCostsAndExpenses_msOILzsUC_zKvgwpHa9a0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Formation and operating costs</td><td style="width: 10%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingCostsAndExpenses" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,887</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_ecustom--FranchiseTaxExpense_msOILzsUC_z3eH4d2eJMsc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Franchise tax expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="MAAQ:FranchiseTaxExpense" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">124,434</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_iT_mtOILzsUC_maILFCOz2zy_zDmU6f3fMfBb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from Operations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">145,321</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherIncomeAndExpensesAbstract_iB_zrM1O3avbcN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--MarketableSecuritiesGainLoss_maILFCOz2zy_zFsAmgEzNJra" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Investment income on investment held in Trust Account</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:MarketableSecuritiesGainLoss" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">484</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz2zy_maNILzozc_z0Cryn6kQK01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss before income taxes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,837</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzozc_zPhvrkO66YIi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income taxes provision</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0129"><span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2021-05-19to2021-12-31" id="fact-identifier-76" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtNILzozc_zMag0szVWpK9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,837</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_zlWA5HnriH6a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted weighted average shares outstanding, common stock subject to possible redemption</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="MAAQ:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,001,327</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_ecustom--EarningsPerSharesBasicAndDiluted_zOU47ALgR8Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share, common stock subject to possible redemption</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="MAAQ:EarningsPerSharesBasicAndDiluted" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.14</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)&nbsp;</td></tr>
  <tr id="xdx_403_ecustom--BasicAndDilutedWeightedAverageSharesOutstandingCommonStockAttributableToManaCapitalAcquisitionCorp._z5oXbGpIiIX8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted weighted average shares outstanding, common stock attributable to Mana Capital Acquisition Corp.</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="MAAQ:BasicAndDilutedWeightedAverageSharesOutstandingCommonStockAttributableToManaCapitalAcquisitionCorp." contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,560,288</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_ecustom--BasicAndDilutedNetLossPerShareCommonStockAttributableToManaCapitalAcquisionCorp._z83RFeHcQS0c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share, common stock attributable To Mana Capital
    Acquisition Corp.</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="MAAQ:BasicAndDilutedNetLossPerShareCommonStockAttributableToManaCapitalAcquisionCorp." contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.09</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The accompany notes are an integral part of these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 83 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>MANA CAPITAL ACQUISITION
CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_114_z0NEqbTQHHf9" summary="xdx: Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zaQJNcBbWr9h" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zqWaymROTXIc" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zAb8hE57EXW5" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z8PDgJhzwQZb" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_4B3_z5KpHYvsBe03" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred stock</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common stock</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Paid-in</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Stockholders'</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td></tr>
  <tr id="xdx_438_c20210519__20211231_eus-gaap--StockholdersEquity_iS_zIfVudjd5GTj" style="vertical-align: bottom">
    <td style="font-weight: bold">Balance as of May 19, 2021 (inception)</td><td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20210519__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFLGhea7dHKk" title="Beginning balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0147"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-05-18_us-gaap_PreferredStockMember" id="fact-identifier-82" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0141"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-05-18_us-gaap_PreferredStockMember" id="fact-identifier-83" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td>
    <td style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20210519__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuxMshD8ALfi" title="Beginning balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0149"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-05-18_us-gaap_CommonStockMember" id="fact-identifier-84" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td>
    <td style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0142"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-05-18_us-gaap_CommonStockMember" id="fact-identifier-85" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0142" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td>
    <td style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0143"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-05-18_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-86" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td>
    <td style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-05-18_us-gaap_RetainedEarningsMember" id="fact-identifier-87" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td>
    <td style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0145"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-05-18" id="fact-identifier-88" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0145" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zNPJq0HJoIA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 43%; text-align: left">Founders shares issued to the Sponsor</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">—&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0151"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-89" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210519__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2mgWfIH4BBk" title="Founders shares issued to the Sponsor, shares" style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,550,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,984</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0154"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-93" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_ecustom--SaleOfPublicUnitsThroughPublicOffering_z9TEU4nPYZs5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sale of public units through public offering</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0159"><span><ix:nonfraction name="MAAQ:SaleOfPublicUnitsThroughPublicOffering" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-95" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98D_ecustom--SaleOfPublicUnitsThroughPublicOfferingShares_c20210519__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs9Hw3SK0uag" title="Sale of public units through public offering, shares" style="text-align: right"><span><ix:nonfraction name="MAAQ:SaleOfPublicUnitsThroughPublicOfferingShares" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,200,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="MAAQ:SaleOfPublicUnitsThroughPublicOffering" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">62</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="MAAQ:SaleOfPublicUnitsThroughPublicOffering" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">61,999,938</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0162"><span><ix:nonfraction name="MAAQ:SaleOfPublicUnitsThroughPublicOffering" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-99" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="MAAQ:SaleOfPublicUnitsThroughPublicOffering" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">62,000,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_ecustom--SaleOfPrivatePlacementShares_zKil9TaWiOca" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Sale of private placement warrants</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0167"><span><ix:nonfraction name="MAAQ:SaleOfPrivatePlacementShares" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-101" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_ecustom--SaleOfPrivatePlacementSharesShares_c20210519__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaqo8f2iZ0Vh" title="Sale of private placement shares, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0173"><span><ix:nonfraction name="MAAQ:SaleOfPrivatePlacementSharesShares" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" id="fact-identifier-102" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0173" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0168"><span><ix:nonfraction name="MAAQ:SaleOfPrivatePlacementShares" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" id="fact-identifier-103" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="MAAQ:SaleOfPrivatePlacementShares" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,500,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0170"><span><ix:nonfraction name="MAAQ:SaleOfPrivatePlacementShares" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-105" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="MAAQ:SaleOfPrivatePlacementShares" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,500,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_ecustom--UnderwritersDiscount_zjJUb9emrANe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Underwriters' discount</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0175"><span><ix:nonfraction name="MAAQ:UnderwritersDiscount" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-107" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0175" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0176"><span><ix:nonfraction name="MAAQ:UnderwritersDiscount" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" id="fact-identifier-108" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="MAAQ:UnderwritersDiscount" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,240,000</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0178"><span><ix:nonfraction name="MAAQ:UnderwritersDiscount" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-110" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="MAAQ:UnderwritersDiscount" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,240,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--UnderwritingIncomeLoss_zf7YzEiwyMB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Underwriters' reimbursement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0181"><span><ix:nonfraction name="us-gaap:UnderwritingIncomeLoss" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-112" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0182"><span><ix:nonfraction name="us-gaap:UnderwritingIncomeLoss" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" id="fact-identifier-113" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:UnderwritingIncomeLoss" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,000</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0184"><span><ix:nonfraction name="us-gaap:UnderwritingIncomeLoss" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-115" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:UnderwritingIncomeLoss" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zQDBxVlNfC15" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise of the over-allotment option by underwriters</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0187"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-117" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210519__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgVmSHrps5v8" title="Exercise of the over-allotment option by underwriters, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,999,997</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0190"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-121" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,000,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_ecustom--UnderwritersDiscountOverallotmentOptionExercised_zGTxbgYjP5h6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Underwriters' discount - over-allotment option exercised</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0195"><span><ix:nonfraction name="MAAQ:UnderwritersDiscountOverallotmentOptionExercised" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-123" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="MAAQ:UnderwritersDiscountOverallotmentOptionExercised" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60,000</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198"><span><ix:nonfraction name="MAAQ:UnderwritersDiscountOverallotmentOptionExercised" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-125" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="MAAQ:UnderwritersDiscountOverallotmentOptionExercised" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--AdditionalFoundersSharesIssuedToSponsorInConnectionWithUnderwritersOverallotmentOption_zTOMkLHxmPPb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional founders shares issued to the Sponsor in connection with underwriters' over-allotment option</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0201"><span><ix:nonfraction name="MAAQ:AdditionalFoundersSharesIssuedToSponsorInConnectionWithUnderwritersOverallotmentOption" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-127" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_ecustom--AdditionalFoundersSharesIssuedToSponsorInConnectionWithUnderwritersOverallotmentOptionShares_c20210519__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7bMqwTh6oK8" title="Additional founders shares issued to the Sponsor in connection with underwriters' over-allotment option, shares" style="text-align: right"><span><ix:nonfraction name="MAAQ:AdditionalFoundersSharesIssuedToSponsorInConnectionWithUnderwritersOverallotmentOptionShares" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0202"><span><ix:nonfraction name="MAAQ:AdditionalFoundersSharesIssuedToSponsorInConnectionWithUnderwritersOverallotmentOption" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" id="fact-identifier-129" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0203"><span><ix:nonfraction name="MAAQ:AdditionalFoundersSharesIssuedToSponsorInConnectionWithUnderwritersOverallotmentOption" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-130" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left"></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0204"><span><ix:nonfraction name="MAAQ:AdditionalFoundersSharesIssuedToSponsorInConnectionWithUnderwritersOverallotmentOption" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-131" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0205"><span><ix:nonfraction name="MAAQ:AdditionalFoundersSharesIssuedToSponsorInConnectionWithUnderwritersOverallotmentOption" contextref="From2021-05-19to2021-12-31" id="fact-identifier-132" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_ecustom--OtherOfferingExpenses_zuuBRBxDIqsa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other offering expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0209"><span><ix:nonfraction name="MAAQ:OtherOfferingExpenses" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-133" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210"><span><ix:nonfraction name="MAAQ:OtherOfferingExpenses" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" id="fact-identifier-134" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="MAAQ:OtherOfferingExpenses" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">307,431</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0212"><span><ix:nonfraction name="MAAQ:OtherOfferingExpenses" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-136" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="MAAQ:OtherOfferingExpenses" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">307,431</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--ReclassificationOfCommonStockSubjectToRedemption_iN_di_z46qgWSuQw8h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassification of common stock subject to redemption</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0215"><span><ix:nonfraction name="MAAQ:ReclassificationOfCommonStockSubjectToRedemption" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-138" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98F_ecustom--ReclassificationOfCommonStockSubjectToRedemptionShares_c20210519__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziarNlorXIWb" title="Reclassification of common stock subject to redemption, shares" style="text-align: right">(<span><ix:nonfraction name="MAAQ:ReclassificationOfCommonStockSubjectToRedemptionShares" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="Shares" inside-table="true" id="fact-identifier-139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,500,000</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="MAAQ:ReclassificationOfCommonStockSubjectToRedemption" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">65</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="MAAQ:ReclassificationOfCommonStockSubjectToRedemption" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">64,999,935</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218"><span><ix:nonfraction name="MAAQ:ReclassificationOfCommonStockSubjectToRedemption" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-142" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="MAAQ:ReclassificationOfCommonStockSubjectToRedemption" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">65,000,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_z3isBcBci8Xe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0223"><span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-05-192021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-144" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0224"><span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-05-192021-12-31_us-gaap_CommonStockMember" id="fact-identifier-145" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225"><span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-05-192021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-146" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0225" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-05-192021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,837</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-148" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,837</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20210519__20211231_eus-gaap--StockholdersEquity_iE_zqqWET5VFCk3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20210519__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQsCEC1oKKAk" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-149" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0229"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_PreferredStockMember" id="fact-identifier-150" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20210519__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhfQJjOK9brf" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,625,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-153" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">827,553</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,837</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">682,732</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The accompany notes are an integral part of these financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 84 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>MANA CAPITAL ACQUISITION
CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>STATEMENT OF CASH FLOWS</b></p>
<table cellpadding="0" cellspacing="0" id="xdx_307_112_zo098e9zFwai" summary="xdx: Statement - STATEMENT OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" id="xdx_493_20210519__20211231_zNALkO5RaKWh" style="font-weight: bold; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">From May 19, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">(inception) through</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zRPFSX4td0R9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Operating Activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_maNCPBUzGQw_zx0SoK5IHZI4" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 10%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,837</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zmNv2PDdQcX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--MarketableSecuritiesGainLoss_iN_di_msNCPBUzGQw_zwbUyQfOiKRj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Interest earned on investment held in Trust Account</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:MarketableSecuritiesGainLoss" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">484</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zlPyD05gTbU1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Changes in operating assets and liabilities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidExpense_iN_di_msNCPBUzGQw_zNTDS7lBsHUi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Prepaid expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-158" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">280,057</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInIncomeTaxes_maNCPBUzGQw_z4dWhyRvDe1g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Franchise tax payable</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInIncomeTaxes" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124,434</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtNCPBUzGQw_maCCERCzb3L_z8lBhLHgGVy4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 30pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,944</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zrbyxJs47TVi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows from Investing Activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquireInvestments_iN_di_msNCPBUzm9k_zRWN2c7K7ife" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Purchase of investment held in trust account</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:PaymentsToAcquireInvestments" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-161" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,000,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtNCPBUzm9k_maCCERCzb3L_zZeGUKWCROZg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,000,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zARZlPteBnY1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows from Financing Activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfCommonStock_maNCPBUzwJU_zq1elTD8yhjd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Proceeds from issuance of shares of Common Stock to the Sponsor</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-163" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_maNCPBUzwJU_zidTGDbH62w4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Proceeds from sale of public units through public offering</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,000,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_maNCPBUzwJU_zOzx7i6TGUZd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Proceeds from sale of private placement shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-165" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,500,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsForUnderwritingExpense_iN_di_msNCPBUzwJU_zh7xnFzH4Xk9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Payment of underwriters' discount</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:PaymentsForUnderwritingExpense" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,300,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--PaymentOfOfferingCosts_iN_di_msNCPBUzwJU_zqUQm35yKM94" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Payment of offering costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="MAAQ:PaymentOfOfferingCosts" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">397,431</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_maNCPBUzwJU_zDDYdNK1kFLk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Proceeds from issuance of promissory note to related party</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,547</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_msNCPBUzwJU_zYg4rNorxkI" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Repayment on promissory note to related party</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,547</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtNCPBUzwJU_maCCERCzb3L_zzQ0NHpd5ff" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net cash provided in financing activities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,827,569</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_mtCCERCzb3L_znxChuFfX7e1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Change in Cash</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">526,625</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zWZYH028MGul" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1pt">Cash at beginning of period</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="AsOf2021-05-18" id="fact-identifier-172" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zbfOcjbVS8Qf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Cash at end of period</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-173" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">526,625</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zDRPyU6tK4o3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental Disclosure of Non-cash Financing Activities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_ecustom--ReclassificationsOfCommonStockSubjectToRedemption_zXpS4gXQKJpa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Reclassification of common stock subject to redemption</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="MAAQ:ReclassificationsOfCommonStockSubjectToRedemption" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-174" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">65,000,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">The accompany notes are an integral part of these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 85 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-175" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z3C4kkVYK9e4" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><b>NOTE 1 — <span id="xdx_825_zaBbyoSt4xL">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</span>
</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><b><i>Organization and General </i></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Mana Capital Acquisition Corp. (the “Company”)
was incorporated in Delaware on May 19, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset
acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”).
The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early
stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth
companies.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of December 31, 2021, the Company had
not commenced any operations. All activity for the period from May 19, 2021 (inception) through December 31, 2021 relates to the Company’s
formation and the initial public offering (“Initial Public Offering”), which is described below. The Company will not generate
any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating
income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31
as its fiscal year end.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><i>Financing</i></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The registration statement for the Company’s
Initial Public Offering (the “Registration Statement”) was declared effective on November 22, 2021. On November 26, 2021,
the Company consummated the Initial Public Offering (“IPO”) of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211101__20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zZcDcVRajomc" title="Sale of units in initial public offering"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2021-11-012021-11-26_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,200,000</ix:nonfraction></span></span> units at $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zahNGod1HnVh" title="Sale of units per share"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2021-11-26_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.00</ix:nonfraction></span></span> per unit (“Units” and,
with respect to the common stock included in the Units being offered, the “Public Shares”), generating gross proceeds of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211101__20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5Zq3OUSlIE5" title="Sale of units in initial public offering aggregate amount"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2021-11-012021-11-26_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,000,000</ix:nonfraction></span></span>,
which is described in Note 3.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Simultaneously with the closing of the
Initial Public Offering, the Company consummated the sale of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211101__20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zf79FlHjhqYl" title="Sale of units in initial public offering"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2021-11-012021-11-26_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,500,000</ix:nonfraction></span></span> warrants (the “Private Placement Warrants”) at a price
of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHaVHOrLkn2e" title="Warrant Price per share"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-11-26_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-180" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.00</ix:nonfraction></span></span> per Private Placement Warrant for gross proceeds of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211101__20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zJUd2pZkPrJg" title="Sale of units in initial public offering aggregate amount"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2021-11-012021-11-26_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,500,000</ix:nonfraction></span></span> in a private placement transaction to Mana Capital, LLC (the “Sponsor”),
which is described in Note 4.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In connection with the Initial Public Offering,
the underwriters were granted a 45-day option from the date of the prospectus (the “Over-Allotment Option”) to purchase up
to <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210519__20211231__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zcNMkMBhnzk" title="Purchase of additional units"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextref="From2021-05-192021-12-31_custom_UnderwritingAgreementMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">930,000</ix:nonfraction></span></span> additional units to cover over-allotments (the “Option Units”), if any. On November 30, 2021, the underwriters
purchased an additional <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesOther_c20211101__20211130__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zTTQStkk9x39"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextref="From2021-11-012021-11-30_custom_UnderwritingAgreementMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000</ix:nonfraction></span></span> Option Units pursuant to the partial exercise of the Over-Allotment Option. The Option Units were sold
at an offering price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20211130_zMS8YVPSPLA7" title="Offering price"><span><ix:nonfraction name="us-gaap:SharesIssuedPricePerShare" contextref="AsOf2021-11-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.00</ix:nonfraction></span></span> per Unit, generating additional gross proceeds to the Company of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211101__20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zec0aQR94VM8"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2021-11-012021-11-26_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-185" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,000,000</ix:nonfraction></span></span>. Pursuant to the Second Amended
and Restated Subscription Agreement between the Sponsor and the Company, the Company issued the Sponsor a total of <span id="xdx_905_ecustom--AdditionalSharesIssuedToSponsorInConnectionWithUnderwritersOverallotmentOption_c20210519__20211231_zj8fjTsPQ5rk" title="Additional shares issued to the Sponsor in connection with underwriters' over-allotment option"><span><ix:nonfraction name="MAAQ:AdditionalSharesIssuedToSponsorInConnectionWithUnderwritersOverallotmentOption" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-186" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75,000</ix:nonfraction></span></span> shares of Common
Stock in connection with the partial exercise by the underwriters of the Over-Allotment Option.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><i>Trust account</i></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Following the closing of the Initial Public
Offering on December 31, 2021, an amount of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20210519__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6OVjWASVY92" title="Net proceeds from sale of units"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextref="From2021-05-192021-12-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,000,000</ix:nonfraction></span></span> ($<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zk6cE6p6ae86"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2021-12-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.00</ix:nonfraction></span></span> per Unit) from the net proceeds of the sale of the Units in the Initial
Public Offering and the sale of the Private Placement Warrants in the Private Placement (as defined in Note 4) was placed in the Trust
Account. Following the closing of underwriters’ exercise of over-allotment option on November 30, 2021, an additional $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211101__20211130__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z04tZkhivDYk" title="Proceeds from issuance initial public offering"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextref="From2021-11-012021-11-30_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-189" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,000,000</ix:nonfraction></span></span>
of net proceeds was place in the Trust Account, bringing the aggregate proceeds hold in the Trust Account to $<span id="xdx_90E_ecustom--AggregateProceedsHeldInTrustAccount_pp0p0_c20211101__20211130_z6QPRQpRLOF7" title="Aggregate proceeds held in trust account"><span><ix:nonfraction name="MAAQ:AggregateProceedsHeldInTrustAccount" contextref="From2021-11-012021-11-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">65,000,000</ix:nonfraction></span></span>.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The funds held in the Trust Account may
be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as
amended (the “Investment Company Act”), with a maturity of 185 days or less or in any open-ended investment company that holds
itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined
by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the Trust Account, as described
below.</p>

<ix:exclude><p id="xdx_23A_zfZT9KWecdZ8" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 86 -->
    <div id="xdx_236_zLrHULiFBbq6" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zmaNDoCTHWLk" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div id="xdx_230_zR0190fhkMee" style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_230_zSOtwKPHQIM3" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zsC8DQBQWyOi" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zXKHzdAOzFua" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zhEYRY4IeLtg" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_239_zMoI72TXduH7" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_237_zol8g78RqjXg" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_233_zC6IDFHmQPqi" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><i>Business Combination</i></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company’s management has broad
discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement
Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.
There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or
more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the
net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest
earned on the Trust Account). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50%
or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient
for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment
Company Act”). Upon the closing of the Initial Public Offering, management has agreed that an amount equal to at least $10.00 per
Unit sold in the Initial Public Offering, including proceeds of the Private Placement Warrants, will be held in a trust account (“Trust
Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section
2(a)(16) of the Investment Company Act, with a maturity of 180 days or less or in any open-ended investment company that holds itself
out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined
by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the
Trust Account, as described below.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company will provide the holders of
the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public
Shares either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer
in connection with the Business Combination. The decision as to whether the Company will seek stockholder approval of a Business Combination
or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro
rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest
then in the Trust Account, net of taxes payable). There will be no redemption rights upon the completion of a Business Combination with
respect to the Company’s warrants or rights.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">All of the Public Shares contain a redemption
feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder
vote or tender offer in connection with the Company’s Business Combination and in connection with certain amendments to the Company’s
amended and restated certificate of incorporation (the “Certificate of Incorporation”). In accordance with the rules of the
U.S. Securities and Exchange Commission (the “SEC”) and its guidance on redeemable equity instruments, which has been codified
in ASC 480-10-S99, redemption provisions not solely within the control of a company require common stock subject to redemption to be classified
outside of permanent equity. While redemptions cannot cause the Company’s net tangible assets to fall
below $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferredOther1_c20210519__20211231_zKEoJ1Hbjim8" title="Business combination net tangible asset"><span><ix:nonfraction name="us-gaap:BusinessCombinationConsiderationTransferredOther1" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-191" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000,001</ix:nonfraction></span></span>, the Public Shares are redeemable and will be classified as such on the balance sheet until such date that a redemption
event takes place.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</p>

<ix:exclude><p id="xdx_23B_zUr0h8iLrZ1e" style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 87 -->
    <div id="xdx_23A_zi87x4p9xbMl" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zhZs4HgjVZI8" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div id="xdx_23D_z2TioRG3FjUl" style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_233_ztwIUegALy3e" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zPYk426Hcxs2" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zw7dMhSOMMEc" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_236_z0F2sfKHofch" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_237_z8h3WE5GVQU3" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_233_zQfW7p32soX7" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</p></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">If the Company seeks stockholder approval
of the Business Combination, the Company will proceed with a Business Combination if a majority of the outstanding shares voted are voted
in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a stockholder vote is not required
by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other
reasons, the Company will, pursuant to its second amended and restated certificate of incorporation (the “Certificate of Incorporation”),
conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file
tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is
required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business
or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not
pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has
agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in
favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting,
and if they do vote, irrespective of whether they vote for or against the proposed transaction.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Notwithstanding the foregoing, if the Company
seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Certificate
of Incorporation will provide that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom
such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15%
of the Public Shares, without the prior consent of the Company.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The holders of the Founder Shares have
agreed (a) to waive their redemption rights with respect to the Founder Shares and Public Shares held by them in connection with the completion
of a Business Combination and (b) not to propose an amendment to the Certificate of Incorporation (i) to modify the substance or timing
of the Company’s obligation to allow redemptions in connection with a Business Combination or to redeem 100% of its Public Shares
if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other
provision relating to stockholders’ rights or pre-business combination activity, unless the Company provides the Public Stockholders
with the opportunity to redeem their Public Shares in conjunction with any such amendment.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">If the Company has not completed a Business
Combination within nine months from the closing of the Initial Public Offering, or up to 21 months in accordance with the terms of the
Company’s Amended and Restated Certificate of Incorporation (the “Combination Period”), the Company will (i) cease all
operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter,
redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including
interest earned on the funds held in the Trust Account and not previously released to pay taxes (less up to $100,000 of interest to pay
dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’
rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably
possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board
of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims
of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect
to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination
Period.</p>

<ix:exclude><p id="xdx_23E_zDRSOsiTwVCf" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 88 -->
    <div id="xdx_238_z24U4fBf8qN4" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zNMCUuz6lTK8" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_23E_zkOXAD6Hj0S1" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zAcZESESXBJ8" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"></p>

<ix:exclude><p id="xdx_23F_zQ8UIe0ZnPK7" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zeoTsP5L2ya4" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_23C_z4BiKmvbXnph" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_238_zkC0ch62P0wi" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</p></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The holders of the Founders Shares have
agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within
the Combination Period. However, if the holders of Founder Shares acquire Public Shares in or after the Proposed Public Offering, such
Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination
within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note
6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such
event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the
Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution
will be less than the Proposed Public Offering price per Unit ($10.00).</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In order to protect the amounts held in
the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered
or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement,
reduce the amount of funds in the Trust Account to below (i) $10.00 per Public Share or (ii) such lesser amount per Public Share held
in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in
the value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims
by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the
Company’s indemnity of the underwriters of the Proposed Public Offering against certain liabilities, including liabilities under
the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to
be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims.
The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by
endeavoring to have all vendors, service providers (except for the Company’s independent registered accounting firm), prospective
target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title,
interest or claim of any kind in or to monies held in the Trust Account.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><i>Liquidity and Capital Resource</i></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">As of December 31, 2021, the Company had
$<span id="xdx_90A_eus-gaap--Cash_c20211231_pp0p0" title="Cash"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-192" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">526,625</ix:nonfraction></span></span> in cash held outside its Trust Account available for the Company’s payment of expenses related to working capital purposes
subsequent to the Initial Public Offering.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Prior to the Initial Public Offering, the
Company’s liquidity needs had been satisfied through a loan under an unsecured promissory note from the Sponsor of up to $<span id="xdx_901_eus-gaap--UnsecuredDebt_iI_c20211231_zf2s9UpCrqng" title="Unsecured promissory note"><span><ix:nonfraction name="us-gaap:UnsecuredDebt" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-193" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span></span>.
The Company had an outstanding loan balance of $<span id="xdx_900_eus-gaap--LoansPayable_iI_c20211231_zfCwAB6q76ma" title="Repayment of loan"><span><ix:nonfraction name="us-gaap:LoansPayable" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-194" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,547</ix:nonfraction></span></span> which was repaid in full as of December 31, 2021.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Upon the closing of the Initial Public
Offering on November 26, 2021, an amount of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20211101__20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z8c7LYwYu9L1" title="Net proceeds from sale of units"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextref="From2021-11-012021-11-26_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,000,000</ix:nonfraction></span></span> from the net proceeds of the sale of the Units in the Initial Public Offering
and the sale of the Private Placement Warrants in the Private Placement was placed in the Trust Account. In addition, on November 30,
2021, the underwriters purchased an additional <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesOther_c20211101__20211130__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zJuG08udQMIb" title="Purchase of additional units"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextref="From2021-11-012021-11-30_custom_UnderwritingAgreementMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000</ix:nonfraction></span></span> Option Units pursuant to the partial exercise of the Over-Allotment Option. The
Option Units were sold at an offering price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20211130_zA6JjsIR6rob" title="Offering price"><span><ix:nonfraction name="us-gaap:SharesIssuedPricePerShare" contextref="AsOf2021-11-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-197" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.00</ix:nonfraction></span></span> per Unit, generating additional gross proceeds to the Company of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211101__20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pp0p0" title="Sale of units in initial public offering aggregate amount"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2021-11-012021-11-26_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,000,000</ix:nonfraction></span></span> which
was placed in the Trust Account.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In order to finance transaction costs in
connection with a Business Combination, the initial shareholders or affiliates of the initial shareholders or certain of the Company’s
officers and directors may, but are not obligated to, provide the Company working capital loans, as defined below (see Note 5). To date,
there were no amounts outstanding under any working capital loans.</p>

<ix:exclude><p id="xdx_237_z4w86Y3MIS1j" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 89 -->
    <div id="xdx_237_zfoPW54dk4T" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zJmJzwQLw7hi" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_23F_zlZcXhY1T2k5" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td id="xdx_230_zuYVVoDYKLJ1" style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zRMNfM8s0vkg" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_231_zxXvIR8A5SKj" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_237_zQhWxdw5tlhl" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_239_zt8i1KtvJfDl" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Based on the foregoing, management believes
that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation
of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing
accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective
target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating
and consummating the Business Combination.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><i>Risks and Uncertainties</i></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Management is currently evaluating the
impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on
the Company’s financial position, results of its operations, close of the Proposed Public Offering and/or search for a target company,
the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_z7xTk7ge48p2" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><b>NOTE 2 — <span id="xdx_825_zujdQMnO9VPf">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zvMHpFgUxjui" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><b><span id="xdx_86D_zsp3DZpbdHF8">Basis of Presentation</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The accompanying audited financial statement
is presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant
to the rules and regulations of the SEC.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="MAAQ:EmergingGrowthCompanyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_84B_ecustom--EmergingGrowthCompanyPolicyTextBlock_z21GL0SEoft6" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><b><span id="xdx_861_zzDX1Y74wEOj">Emerging Growth Company</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company is an “emerging growth
company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by
the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but
not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section
404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden
parachute payments not previously approved.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:UseOfEstimates" inside-table="false" id="fact-identifier-202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84E_eus-gaap--UseOfEstimates_zImWyh0HfNu4" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><span id="xdx_86A_z65aG86tUFX5">Use of Estimates</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The preparation of financial statements
in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least
reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the
financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future
confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>

<ix:exclude><p id="xdx_23B_z56gBZOmwzna" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 90 -->
    <div id="xdx_23A_zo9ruk4jHHDc" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zUZ1ap5zQMoh" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_23D_zDSQwWsJzMpi" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zN4JOHytnXzk" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_z5msxGxSpUf4" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zsaDXwratush" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zdW045KDnGr9" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_234_z9ZOoKPPo9D7" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>
<ix:exclude><p id="xdx_23B_zttffMuuakJ6" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4fRxKB8IX54" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><span id="xdx_86C_zgt3EqiDcK1a">Cash</span> </b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. The Company had cash of $<span id="xdx_907_eus-gaap--Cash_iI_pp0p0_c20211231_zJ3Acd7KG4A6" title="Cash"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">526,625</ix:nonfraction></span></span> and <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20211231_zMxu0flUfzui" title="Cash equivalents"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></span> cash
equivalents as of December 31, 2021.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="MAAQ:CashheldInTrustAccountPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_848_ecustom--CashheldInTrustAccountPolicyTextBlock_zaqqCqohgvA5" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><span id="xdx_86F_zCAwT1cBQv97">Cash held in Trust Account</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">At December 31, 2021, the Company had $<span id="xdx_906_eus-gaap--AssetsHeldInTrustCurrent_iI_pp0p0_c20211231_zU4LMdQskDSh" title="cash held in Trust Account"><span><ix:nonfraction name="us-gaap:AssetsHeldInTrustCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,000,484</ix:nonfraction></span></span>
in cash held in the Trust Account. The assets held in the Trust Account were held in money market funds, which are invested in U.S. Treasury
securities.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company classifies its U.S. Treasury
and equivalent securities as held-to-maturity in accordance with ASC Topic 320 “Investments — Debt and Equity Securities.”
Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity
treasury securities are recorded at amortized cost on the accompanying balance sheet and adjusted for the amortization or accretion of
premiums or discounts.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="MAAQ:OfferingCostsAssociatedWithPublicOfferingPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-208" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_841_ecustom--OfferingCostsAssociatedWithPublicOfferingPolicyTextBlock_zmGGcA3nbSdh" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><span id="xdx_86E_zIZz5ZRIrJWh">Offering Costs associated with a Public
Offering</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company complies with the requirements
of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “Expenses of Offering.” Offering
costs of $397,431 consist principally of costs such as legal, accounting and other advisory fees incurred in connection with the Initial
Public Offering. Such, costs were charged to stockholders’ equity upon completion of the Initial Public Offering.</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:ExtendedProductWarrantyPolicy" inside-table="false" id="fact-identifier-209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_840_eus-gaap--ExtendedProductWarrantyPolicy_zvaK2qQyJfM2" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><i><span id="xdx_86A_zjz7zo4wUFSe">Warrants</span></i></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company accounts for warrants as either
equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative
guidance in Financial Accounting Standards Board (“FASB”) ASC 480 “Distinguishing Liabilities from Equity” (“ASC
480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding
financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants
meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s
own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside
of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">For issued or modified warrants that meet
all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance.
For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded
as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair
value of the warrants are recognized as a non-cash gain or loss on the statements of operations. (See Note 9).</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="MAAQ:CommonStockSubjectToPossibleRedemptionPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_84B_ecustom--CommonStockSubjectToPossibleRedemptionPolicyTextBlock_zMbPlSk7InTj" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><span id="xdx_86C_zwNeBC1rTTQ2">Common stock subject to possible redemption</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company accounts for its shares subject
to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing
Liabilities from Equity.” Shares subject to mandatory redemption (if any) is classified as a liability instrument and is measured
at fair value. Conditionally redeemable shares of common stock (including shares of common stock that feature redemption rights that are
either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s
control) is classified as temporary equity. At all other times, shares are classified as stockholders’ equity. The Company’s
shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of
uncertain future events. Accordingly, as of December 31, 2021, common stock subject to possible redemption are presented at redemption
value of $10.00&nbsp;per share as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet.
The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock
to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common
stock are affected by charges against additional paid in capital or accumulated deficit if additional paid in capital equals to zero.</p>

<ix:exclude><p id="xdx_232_zVn7rhffYYja" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 91 -->
    <div id="xdx_23B_z1WqiIyggik5" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_230_z18Inaji4L9l" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_234_zqP1ZtZBFtu6" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td id="xdx_239_znzbiSsTQzw7" style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_z29BELIvfqQ5" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_233_zRv0XeUscfKb" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_234_ziJ2PcDp2xCj" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zmBUQJq7sjTa" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_z2K6BqAHrdW2" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><span id="xdx_86D_zGa21qlgQbik">Income Taxes</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company accounts for income taxes under
ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected
impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit
to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when
it is more likely than not that all or a portion of deferred tax assets will not be realized.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">ASC 740 also clarifies the accounting for
uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement
process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those
benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740
also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company recognizes accrued interest
and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued
for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in
significant payments, accruals or material deviation from its position.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company has identified the United States
as its only “major” tax jurisdiction.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company may be subject to potential
examination by federal and state taxing authorities in the areas of income taxes. These potential examinations may include questioning
the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws.
The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next
twelve months.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company is incorporated in the State
of Delaware and is required to pay franchise taxes to the State of Delaware on an annual basis. The franchise tax of $<span id="xdx_907_ecustom--FranchiseTax_c20210519__20211231_zyXnGUbYUGs" title="Franchise tax"><span><ix:nonfraction name="MAAQ:FranchiseTax" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">124,434</ix:nonfraction></span> </span>was expensed as of December 31, 2021.</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" inside-table="false" id="fact-identifier-213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zroXgFmSRV7f" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><span id="xdx_865_zsOBJDrfsBh2">Concentration of Credit Risk</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed
the Federal Depository Insurance Coverage of $<span id="xdx_907_ecustom--FederalDepositoryInsuranceCoverage_iI_c20211231_z9rqR8xA5NJ7"><span><ix:nonfraction name="MAAQ:FederalDepositoryInsuranceCoverage" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-214" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">250,000</ix:nonfraction></span></span>.
The Company has not experienced losses on this account. </p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zRZ4osc1nZz" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><span id="xdx_86A_zhI11qXEc6pk">Fair value of financial instruments</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The fair value of the Company’s assets
and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurements” approximates the carrying
amounts represented in the balance sheet, partially due to their short-term nature.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Fair value is defined as the price that
would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the
measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The
hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">•	Level 1, defined as observable
inputs such as quoted prices (unadjusted) for identical instruments in active markets;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">•	Level 2, defined as inputs
other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments
in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">•	Level 3, defined as unobservable
inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived
from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p>

<ix:exclude><p id="xdx_230_zB9igsUtDSPf" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 92 -->
    <div id="xdx_237_zzd4GLADH4A3" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_238_zkoLUPfo23i2" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_23F_zwMCqg81HO3" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td id="xdx_23E_ztHMo1PfZi24" style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_z0KQbVPeMUg1" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_232_zMBknEps2CT" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zqK2xwCdI1S5" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>


<ix:exclude><p id="xdx_238_zVnR9ouABXdj" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zUYS4FS149Ub" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><span id="xdx_866_z9R9BGdXpKYj">Net Income (Loss) per Share</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company complies with accounting and
disclosure requirements of FASB ASC 260, Earnings Per Share. In order to determine the net income (loss) attributable to both the redeemable
shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable common
stock and non-redeemable common stock and the undistributed income (loss) is calculated using the total net loss less any dividends paid.
The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between
the redeemable and non-redeemable common stock.  As of December 31, 2021, the Company has not considered
the effect of the warrants sold in the Initial Public Offering in the calculation of diluted net income (loss) per share, since the exercise
of the warrants is contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive and the Company
did not have any other dilutive securities and other contracts that could, potentially, be exercised or converted into common stock and
then share in the earnings of the Company. As a result, diluted income (loss) per share is the same as basic (income) loss per share for
the period presented.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zq4MDhsuAGQg" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b><span id="xdx_86A_zZCUPVmJfSB1">Recent Accounting Standards</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Management does not believe that any recently
issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial
statements.</p>

</ix:nonnumeric></span></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="MAAQ:InitialPublicOfferingTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_808_ecustom--InitialPublicOfferingTextBlock_zaQo0Fw0v7b5" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 3 — <span id="xdx_821_zYm1Sc7CZ235">INITIAL PUBLIC OFFERING</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Pursuant to the Initial Public Offering
on November 26, 2021, the Company sold <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211101__20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of units in initial public offering"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2021-11-012021-11-26_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-219" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,200,000</ix:nonfraction></span></span> Units at a price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_c20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of units per share"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2021-11-26_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-220" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.00</ix:nonfraction></span></span> per Unit, which does not include the 45-day option of the
exercise of the underwriters’ <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210519__20211231__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zqpn7hiTkl8l" title="Purchase of additional units"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextref="From2021-05-192021-12-31_custom_UnderwritingAgreementMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-221" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">930,000</ix:nonfraction></span></span> over-allotment option. On November 30, 2021, the underwriters purchased an additional <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_c20211101__20211130__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pdd" title="Purchase of additional units"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextref="From2021-11-012021-11-30_custom_UnderwritingAgreementMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000</ix:nonfraction></span></span>
Option Units pursuant to the partial exercise of the Over-Allotment Option. The Option Units were sold at an offering price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_c20211130_pdd" title="Offering price"><span><ix:nonfraction name="us-gaap:SharesIssuedPricePerShare" contextref="AsOf2021-11-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.00</ix:nonfraction></span></span>
per Unit, generating additional gross proceeds to the Company of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211101__20211130__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pp0p0" title="Proceeds from issuance initial public offering"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextref="From2021-11-012021-11-30_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,000,000</ix:nonfraction></span></span>. Each Unit consists of one share of Common stock, one-half
of one redeemable warrant (“Public Warrant”), and one right entitling the holder thereof to receive one-seventh (1/7) of a
share of common stock upon consummation of our initial business combination (“Public Right”). Each whole Public Warrant entitles
the holder to purchase one share of Common stock at a price of $11.50 per share, subject to adjustment (see Note 8).</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The remaining <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20211101__20211130_z2REfASAgGvd" title="Option unit expired"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextref="From2021-11-012021-11-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-225" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">630,000</ix:nonfraction></span></span> Option Units were
expired on November 30, 2021. Transaction costs in connection with the Initial Public Offering and the issuance and sale of Option Units
amounted to $<span id="xdx_90D_ecustom--TransactionCosts_c20211101__20211130_zJkDH23Hdp75" title="Transaction costs"><span><ix:nonfraction name="MAAQ:TransactionCosts" contextref="From2021-11-012021-11-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-226" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,697,431</ix:nonfraction></span></span>, consisting of $<span id="xdx_905_eus-gaap--OtherUnderwritingExpense_c20211101__20211130_zsPsCZYCrTU4" title="Underwriting fees"><span><ix:nonfraction name="us-gaap:OtherUnderwritingExpense" contextref="From2021-11-012021-11-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-227" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,300,000</ix:nonfraction></span></span> of underwriting fees, and $<span id="xdx_90A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c20211101__20211130_zgcG7AFR2Ku2" title="Other offering costs"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextref="From2021-11-012021-11-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-228" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">397,431</ix:nonfraction></span></span> of other offering costs.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Each unit has an offering price of $10.00
and consists of one share of the Company’s common stock and one-half of one redeemable warrant and one right entitling the holder
thereof to receive one-seventh (1/7) of a share of common stock upon consummation of the initial business combination. The Company will
not issue fractional shares. As a result, the warrants must be exercised in multiples of one whole warrant. Each whole warrant entitles
the holder thereof to purchase one share of the Company’s common stock at a price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zkTeW6Y6ciW3" title="Share price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-12-31_us-gaap_CommonStockMember1582076484" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.50</ix:nonfraction></span></span> per share, and only whole warrants are
exercisable. The warrants will become exercisable on the later of 30 days after the completion of the Company’s initial Business
Combination or 12 months from the closing of the Initial Public Offering, and will expire five years after the completion of the Company’s
initial Business Combination or earlier upon redemption or liquidation.</p>

<ix:exclude><p id="xdx_23F_zFFaoswDkh0a" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 93 -->
    <div id="xdx_23F_z1JJcTcqoIpe" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_238_zh6xjDBjPdQg" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_23B_zXKK1VvqoB52" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td id="xdx_239_zChbwkqdAzaf" style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zrJ3HplBnLx8" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zY5zLmoTNVt4" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zBi3D1EVIyE1" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>


<ix:exclude><p id="xdx_23A_znOFZAXpeeTe" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">All of the <span id="xdx_90D_ecustom--SaleOfCommonStockSubjectToRedemption_c20210519__20211231_zPcLkYhprLf7" title="Sale of common stock subject to redemption"><span><ix:nonfraction name="MAAQ:SaleOfCommonStockSubjectToRedemption" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-230" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,500,000</ix:nonfraction></span></span> public shares sold as
part of the Public Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such public shares
if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to
the Company’s amended and restated certificate of incorporation, or in connection with the Company’s liquidation. In accordance
with the Securities and Exchange Commission (the “SEC”) and its staff’s guidance on redeemable equity instruments, which
has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to
redemption to be classified outside of permanent equity.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="MAAQ:PrivatePlacementsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_803_ecustom--PrivatePlacementsDisclosureTextBlock_zkgLHJsE40e9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><b>NOTE 4 — <span id="xdx_823_zaJqwveRiyqc">PRIVATE
PLACEMENTS</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Simultaneously with the closing of the
Initial Public Offering, the Company consummated the private sale (the “Private Placement”) to the Sponsor of an aggregate
of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211101__20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2021-11-012021-11-26_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-232" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,500,000</ix:nonfraction></span>
</span>Private Placement Warrants at a price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-11-26_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-233" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.00</ix:nonfraction></span>
</span>per Private Placement Warrant ($<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211101__20211126__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp0p0"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2021-11-012021-11-26_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,500,000</ix:nonfraction></span></span>).
Each Private Placement Warrant is exercisable to purchase one share of common stock at a price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z6EPdU9Arf3g"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-12-31_us-gaap_CommonStockMember1582076484" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.50</ix:nonfraction></span>
</span>per share, subject to adjustment.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">A portion of the proceeds from the Private
Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete
a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants held in the Trust Account
will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants
will be worthless.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Sponsor and the Company’s officers
and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30
days after the completion of the initial Business Combination.</p>

<ix:exclude><p id="xdx_234_zbpr5bo2gDcl" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 94 -->
    <div id="xdx_23D_z49MZL18qxY6" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_239_zCw6DFR1zpua" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div id="xdx_23A_zebsFIO7cZuh" style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_235_zwoE3whZcpHi" style="width: 100%"><tbody><tr><td id="xdx_239_zRCgegRX9UZc" style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_z8EAPYJycsbc" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zS3XkQArU6v9" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zC1VZfxURK58" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>


<ix:exclude><p id="xdx_237_zIBFMbwcCtj8" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z40KWHlKWq8c" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 5 — <span id="xdx_829_z8jdUsRnM96a">RELATED PARTIES</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>Founder Shares</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On June 22, 2021, the Sponsor received
<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20210622__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember_zqZRMHUpKl45" title="Number of shares issued"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-06-012021-06-22_custom_FounderSharesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-237" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,437,500</ix:nonfraction></span></span> shares of the Company’s Common stock (the “Founder Shares”) for $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210601__20210622__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember_zn1p0yfx4EE7" title="Number of shares issued value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-06-012021-06-22_custom_FounderSharesMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-238" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,000</ix:nonfraction></span></span>. Subsequently, in September 2021,
the Company amended the terms of this subscription agreement to issue the Sponsor an additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210901__20210930__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember_zcq9wGJySSH3"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-09-012021-09-30_custom_FounderSharesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-239" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,500</ix:nonfraction></span></span> Founder Shares. In November 2021,
the Company issued the Sponsor an additional <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211101__20211130__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember_zRdJE8JaKckj"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-11-012021-11-30_custom_FounderSharesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-240" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span> shares of Common stock for no additional consideration, following which the Sponsor
held <span id="xdx_904_ecustom--FoundersSharesIssuedToSponsor_c20210519__20211231_z4Xic2DgL1K9" title="Founders shares issued to the Sponsor"><span><ix:nonfraction name="MAAQ:FoundersSharesIssuedToSponsor" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-241" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,550,000</ix:nonfraction></span></span> Founder Shares so that the Founder Shares will account for, in the aggregate, 20% of the issued and outstanding shares
after the Initial Public Offering. All share amounts have been retroactively restated to reflect this adjustment. In November 2021, the
Company amended the terms of the subscription agreement and agreed to issue the Sponsor up to an additional <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211101__20211130_zwR03e602mHi"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-11-012021-11-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">232,500</ix:nonfraction></span></span> Founder Shares, in
the event the over-allotment is exercised in full. On November 30, 2021 the Company issued the founder a total of <span id="xdx_902_ecustom--AdditionalFoundersSharesIssuedToSponsor_c20211101__20211130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zC0pqOAe9FGc" title="Additional founders shares issued to the Sponsor"><span><ix:nonfraction name="MAAQ:AdditionalFoundersSharesIssuedToSponsor" contextref="From2021-11-012021-11-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-243" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75,000</ix:nonfraction></span></span> shares of Common
Stock in connection with the partial exercise by the underwriters of the Over-Allotment Option. The remaining 157,500 shares of common
stock issuable pursuant to the Second Amended and Restated Subscription Agreement were not issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white">As of December 31,
2021, there were&nbsp;<span id="xdx_90B_ecustom--FounderShareIssued_iI_c20211231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember_zRljeC1c08Ta" title="Founder share issued"><span id="xdx_909_ecustom--FounderShareOutstanding_iI_c20211231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember_zZa2MvsLZFcg" title="Founder share outstanding"><span><ix:nonfraction name="MAAQ:FounderShareIssued" contextref="AsOf2021-12-31_custom_FounderSharesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-244" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:nonfraction name="MAAQ:FounderShareOutstanding" contextref="AsOf2021-12-31_custom_FounderSharesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-245" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,625,000</ix:nonfraction></span></ix:nonfraction></span></span></span>&nbsp;Founder Shares&nbsp;issued&nbsp;and outstanding. The aggregate capital contribution was $<span id="xdx_909_eus-gaap--ProceedsFromContributionsFromAffiliates_c20210519__20211231__us-gaap--RelatedPartyTransactionAxis__custom--FounderSharesMember_ziMUdCgsDNFd" title="Capital contribution"><span><ix:nonfraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextref="From2021-05-192021-12-31_custom_FounderSharesMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,000</ix:nonfraction></span></span>,
or approximately $0.02&nbsp;per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; background-color: white">The number of Founder
Shares issued was determined based on the expectation that such Founder Shares would represent&nbsp;20% of the outstanding shares upon
completion of the Initial Public Offering.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The holders of the Founder Shares have
agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) six
months after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the last reported sale price
of the Common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations
and the like) for any 20 trading days within any 30-trading day period commencing after a Business Combination, or (y) the date on which
the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Stockholders
having the right to exchange their shares of common stock for cash, securities or other property.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>Promissory Note — Related Party</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On June 11, 2021, the Sponsor issued an
unsecured promissory note to the Company (the “Promissory Note”), pursuant to which the Company may borrow up to an aggregate
principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20210611__us-gaap--RelatedPartyTransactionAxis__custom--SponsorMember_zjAclWv6ACLh" title="Principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-06-11_custom_SponsorMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span></span>. The Promissory Note was non-interest bearing and payable on the earlier of (i) December 11, 2021 or (ii)
the consummation of the Proposed Public Offering. The Company had an outstanding loan balance of $<span id="xdx_904_eus-gaap--RepaymentsOfLongtermLoansFromVendors_c20210519__20211231_zXvPdOYuFdW9" title="Repayment of loans"><span><ix:nonfraction name="us-gaap:RepaymentsOfLongtermLoansFromVendors" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,547</ix:nonfraction></span></span>, which was
repaid in full as of December 31, 2021. As of December 31, 2021, there was no amount outstanding under the Promissory Note.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>Related Party Loans</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">In order to finance transaction costs in
connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors
may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans
would be evidenced by promissory notes. <span id="xdx_903_ecustom--RelatedPartyLoansDescription_c20210519__20211231_zoP8qj0lKwQ6" title="Related Party Loans Description"><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" name="MAAQ:RelatedPartyLoansDescription" inside-table="false" id="fact-identifier-249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">The notes may be repaid upon completion of a Business Combination, without interest, or, at the
lender’s discretion, up to $2,400,000 of the notes may be converted upon completion of a Business Combination into warrants at a
price of $1.00 per warrant.</ix:nonnumeric></span></span> Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination
does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds
held in the Trust Account would be used to repay the Working Capital Loans. As of December 31, 2021, there was no amount outstanding under
the Working Capital Loans.</p>

<ix:exclude><p id="xdx_234_zLWNvmhSP2fa" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 95 -->
    <div id="xdx_238_zdNrz5iz6vn9" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zmayhrk8xhD4" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div id="xdx_231_zyViyz2YESOe" style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_235_zn8HyAE60Ptg" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zkmur37FjNr9" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zHg5M1kkki88" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zyhuO3XhpI8c" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_23F_z2WiTgQw0Rn4" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_236_zwRUPfinRZ39" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>


<ix:exclude><p id="xdx_234_zAzMiQvfSiel" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:InvestmentTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-250" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80F_eus-gaap--InvestmentTextBlock_zx9kZ4hzncmj" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 6 — <span id="xdx_82C_zVItpKeoKeg1">INVESTMENTS HELD IN TRUST
ACCOUNT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As of December 31, 2021, assets held in the
Trust Account were comprised of $<span id="xdx_90C_eus-gaap--AssetsHeldInTrustCurrent_c20211231_pp0p0" title="Investments held in Trust Account"><span><ix:nonfraction name="us-gaap:AssetsHeldInTrustCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,000,484</ix:nonfraction></span></span> in mutual funds which are invested in U.S. Treasury Securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents information about the
Company’s assets that are measured at fair value on a recurring basis at December 31, 2021 and indicates the fair value hierarchy
of the valuation inputs the Company utilized to determine such fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zoNFKJEIFIJd" summary="xdx: Disclosure - INVESTMENTS HELD IN TRUST ACCOUNT (Details)" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font: bold 8pt Times New Roman, Times, Serif"><span id="xdx_8B7_zvfRLIlYmcW" style="display: none">Schedule of Fair value assets measured on recurring basis</span></td><td style="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td><td style="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif">Description</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Level</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">December 31,&nbsp;2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%">Assets:</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Trust Account – U.S. Treasury Securities Mutual funds</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsHeldInTrustCurrent_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zlmrSw7ExDna" title="Investments held in Trust Account" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:AssetsHeldInTrustCurrent" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,000,484</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>&nbsp;</b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zjh6G7bqRh8a" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 7— <span id="xdx_829_z67LWhRNENWk">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>Registration Rights</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company entered into a registration
rights agreement with its founders, officers, directors or their affiliates upon the effective date of the Initial Public Offering pursuant
to which the Company is required to register any shares of common stock, warrants (including working capital warrants), and shares underlying
such warrants, that are not then covered by an effective registration statement. The holders of these securities will be entitled to make
up to two demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have
certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business
Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The
Company will bear the expenses incurred in connection with the filing of any such registration statements.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>Underwriting Agreement</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company granted the underwriters a
45-day option from the date of the Initial Public Offering to purchase up to <span id="xdx_907_ecustom--NumberOfOverallotmentUnits_c20210519__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z30MfK9aTazj" title="Number of Over-Allotment Units"><span><ix:nonfraction name="MAAQ:NumberOfOverallotmentUnits" contextref="From2021-05-192021-12-31_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-255" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">930,000</ix:nonfraction></span></span> additional Units to cover over-allotments, if any,
at the Initial Public Offering price less the underwriting discounts and commissions to the extent provided for in the underwriting agreement.
On November 30, 2021, the underwriters purchased an additional <span id="xdx_90F_ecustom--NumberOfOverallotmentUnits_c20211101__20211130__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z0qJ7RzYMVe9" title="Number of Over-Allotment Units"><span><ix:nonfraction name="MAAQ:NumberOfOverallotmentUnits" contextref="From2021-11-012021-11-30_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-256" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">300,000</ix:nonfraction></span></span> Option Units pursuant to the partial exercise of the Over-Allotment
Option. The Company paid an underwriting discount of <span id="xdx_909_ecustom--UnderwritingDiscount_dp_c20211101__20211130_zEzXpLjEmUHj" title="Underwriting discount"><span><ix:nonfraction name="MAAQ:UnderwritingDiscount" contextref="From2021-11-012021-11-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.00</ix:nonfraction></span></span>% of the gross proceeds of the Initial Public Offering and the sale of Option
Units or $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211101__20211130__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember_zcfTGsQkgRUe" title="Proceeds from initial public offering"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextref="From2021-11-012021-11-30_custom_UnderwritingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-258" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,300,000</ix:nonfraction></span></span> to the underwriters at the closing of the Initial Public Offering and the sale of Option Units.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zMDya5XYtX9k" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 8 — <span id="xdx_825_z5nOyew6pLU">STOCKHOLDERS’ EQUITY</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>Preferred Stock</b> — The Company
is authorized to issue <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_c20211231_pdd" title="Preferred stock, shares authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000,000</ix:nonfraction></span></span> shares of preferred stock with a par value of $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_c20211231_pdd" title="Preferred stock, par value"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-261" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00001</ix:nonfraction></span></span> per share. As of December 31, 2021, there were
<span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231_zdnrZrKgFxU2" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_z98mJw0Ap9g6" title="Preferred stock, shares outstanding"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></span></span> shares of preferred stock issued or outstanding.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>Common Stock</b> — The Company
is authorized to issue <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20211231_pdd" title="Common stock, shares authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-264" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000,000</ix:nonfraction></span></span> shares of Common stock with a par value of $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pdd" title="Common stock, par value"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00001</ix:nonfraction></span></span> per share. Holders of Common stock are entitled
to one vote for each share. As of December 31, 2021 there were 1,625,000 (excluding <span id="xdx_901_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20211231_zZIh7oekAFXb" title="Temporary equity shares authorized"><span><ix:nonfraction name="us-gaap:TemporaryEquitySharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-266" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,500,000</ix:nonfraction></span></span> shares subject to possible redemption) shares
of common stock issued and outstanding.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>Rights </b>— Except in cases where
the Company is not the surviving company in a Business Combination, each holder of a Public Right will automatically receive one-seventh
(1/7) of one share of common stock upon consummation of a Business Combination, even if the holder of a Public Right converted all shares
held by him, her or it in connection with a Business Combination or an amendment to the Company’s Amended and Restated Certificate
of Incorporation with respect to its pre-business combination activities. In the event that the Company will not be the surviving company
upon completion of a Business Combination, each holder of a Public Right will be required to affirmatively convert his, her or its rights
in order to receive the one-seventh (1/7) of a share underlying each Public Right upon consummation of the Business Combination. The Company
will not issue fractional shares in connection with an exchange of Public Rights. Fractional shares will either be rounded down to the
nearest whole share or otherwise addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a
result, the holders of the Public Rights must hold rights in multiples of seven in order to receive shares for all of the holders’
rights upon closing of a Business Combination.</p>

<ix:exclude><p id="xdx_237_zvcOXbMbEm0b" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zyPVVVmcLoL8" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 96 -->
    <div id="xdx_23C_zn8Cxsz81Ei7" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zWGAQ52sGI8g" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_233_zsebV62LVjbk" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zGpzESA3ZU2k" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zpwmODBcSHy4" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_23E_z11KkNHjmvek" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_232_zUe3gQjgd6Q5" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>


<ix:exclude><p id="xdx_23C_zvGwYaHsASmj" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>Warrants</b> — Public Warrants
may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole
warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination
and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of
a Business Combination or earlier upon redemption or liquidation.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company will not be obligated to deliver
any shares of Common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a
registration statement under the Securities Act covering the issuance of the shares of Common stock issuable upon exercise of the warrants
is then effective and a current prospectus relating to those shares of Common stock is available, subject to the Company satisfying its
obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash
or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless
the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising
holder, or an exemption from registration is available.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company has agreed that as soon as
practicable, but in no event later than 30 days after the closing of a Business Combination, the Company will use its commercially reasonable
efforts to file, and within 90 days following a Business Combination to have declared effective, a registration statement covering the
issuance of the shares of Common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares
of Common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Common stock is at the time of any exercise
of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under
Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants
to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects,
the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts
to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Redemption of Warrants When the Price per
Share of Common stock Equals or Exceeds $<span id="xdx_90B_ecustom--ShareRedemptionPricePerShare_c20210519__20211231_ztjFNUZSZDM5" title="Share redemption price per share"><span><ix:nonfraction name="MAAQ:ShareRedemptionPricePerShare" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-267" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">18.00</ix:nonfraction></span></span> — Once the warrants become exercisable, the Company may redeem the outstanding Public
Warrants:</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in"><span style="font-family: Symbol; font-size: 10pt">·</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in whole and not in part;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in"><span style="font-family: Symbol; font-size: 10pt">·</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon a minimum of 30 days’
prior written notice of redemption, or the 30-day redemption period to each warrant holder; and</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in"><span style="font-family: Symbol; font-size: 10pt">·</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if, and only if, the last reported
sale price of the Common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganization, recapitalizations
and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company
sends the notice of redemption to warrant holders.</span></td></tr></tbody></table>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The redemption price for the warrants shall
be either (i) if the holder of a warrant has followed the procedures specified in our notice of redemption and surrendered the warrant,
the number of shares of common stock as determined in accordance with the “cashless exercise” provisions of the warrant agreement
or (ii) if the holder of a warrant has not followed such procedures specified in our notice of redemption, the price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zI3ingvLoQCg" title="Warrant Price per share"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.01</ix:nonfraction></span></span> per warrant.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">If the Company calls the warrants for redemption,
all holders that wish to exercise warrants can do so by paying the cash exercise price or on a “cashless” basis. If a holder
elects to exercise the warrant on a “cashless” basis, such a holder would pay the exercise price by surrendering the warrants
for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common
stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value”
(defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of our
common stock for the 5 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the
holders of warrants. Alternatively, a warrant holder may request that we redeem his, her or its warrants by surrendering such warrants
and receiving the redemption price of such number of shares of common stock determined as if the warrants were exercised on a “cashless”
basis. If the holder neither exercises his, her or its warrants nor requests redemption on a “cashless” basis, then on or
after the redemption date, a record holder of a warrant will have no further rights except to receive the cash redemption price of $0.01
for such holder’s warrant upon surrender of such warrant. The right to exercise the warrant will be forfeited unless the warrants
are exercised prior to the date specified in the notice of redemption.</p>

<ix:exclude><p id="xdx_232_zgyC1BWO2y72" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 97 -->
    <div id="xdx_23F_ziNK1VumKVJ1" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_235_z96C3uh3pacj" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_234_zsLS8ncxNpC" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td id="xdx_23E_zfaydzeuVj7g" style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zIQtAc1BqS8h" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_239_zsgzTrsemeTj" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_236_zkBpPATMRDTh" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>


<ix:exclude><p id="xdx_237_zcSgvaeI73wc" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The exercise price and number of common
stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend,
extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants
will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be
required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period
and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect
to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with
respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Private Placement Warrants are be identical
to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Common
stock issuable upon the exercise of the Private Placement Warrants are not transferable, assignable or saleable until 30 days after the
completion of a Business Combination, subject to certain limited exceptions.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company accounts for the <span id="xdx_900_ecustom--WarrantsIssued_c20210519__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSWKqT5dGULh" title="Warrants issued"><span><ix:nonfraction name="MAAQ:WarrantsIssued" contextref="From2021-05-192021-12-31_us-gaap_IPOMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,750,000</ix:nonfraction></span></span>
warrants issued in connection with the Initial Public Offering (including <span id="xdx_90E_ecustom--WarrantsIssued_c20210519__20211231__us-gaap--AwardTypeAxis__custom--PublicWarrantMember_z3K1lKdYy0Ta"><span><ix:nonfraction name="MAAQ:WarrantsIssued" contextref="From2021-05-192021-12-31_custom_PublicWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-270" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,250,000</ix:nonfraction></span></span> Public Warrants and <span id="xdx_904_ecustom--WarrantsIssued_c20210519__20211231__us-gaap--AwardTypeAxis__custom--PrivateWarrantMember_z4J3VCOYEkE7"><span><ix:nonfraction name="MAAQ:WarrantsIssued" contextref="From2021-05-192021-12-31_custom_PrivateWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,500,000</ix:nonfraction></span></span> Private Placement Warrants)
in accordance with the guidance contained in ASC 815-40. The Company’s management has examined the public warrants and private warrants
and determined that these warrants qualify for equity treatment in the Company’s financial statements. The Company accounted for
the warrant as an expense of the Initial Public Offering resulting in a charge directly to stockholders’ equity.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zQosieHq63C9" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 9 — <span id="xdx_825_zvtI8oAboHC5">INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company’s taxable income primarily
consists of interest earned on investments held in the Trust Account. There was no income tax expense for the period from May 19, 2021
(inception) through December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The income tax provision (benefit) consists of the
following for the period from May 19, 2021 (inception) through December 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zeHCuSWfEOsk" summary="xdx: Disclosure - INCOME TAXES (Details)" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zguS2NrG24A3" style="display: none">Schedule of   Income tax provision</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" id="xdx_495_20210519__20211231_zQtUwEiSr5Mj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Period from</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">May 19, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(inception) through</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,&nbsp;2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Current</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--CurrentFederalTaxExpenseBenefit_zvFlWb1SpCRj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 6pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538"><span><ix:nonfraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextref="From2021-05-19to2021-12-31" id="fact-identifier-274" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0538" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_zHKIkuDl5ysd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; padding-left: 6pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span><ix:nonfraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-275" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124,434</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxesAbstract_iB_zq84yepXEoRj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Deferred</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_zVlT4dwHKmg6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 6pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,416</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_zWp5a8uqGX65" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 6pt">State</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0546"><span><ix:nonfraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextref="From2021-05-19to2021-12-31" id="fact-identifier-277" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_zH3ro94cUqVi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-278" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,416</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxProvision_pp0p0_z0XvILOmXc1k" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="MAAQ:IncomeTaxProvision" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">124,434</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A2_zT0D2hdVwikf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of the statutory federal income tax
rate to the Company’s effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z20H9fXVCgAi" summary="xdx: Disclosure - INCOME TAXES (Details 1)" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td><span id="xdx_8B7_zYxTYVbIauIf" style="display: none">Schedule of Effective income tax rate reconciliation</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Period from</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">May 19, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(inception) through</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,&nbsp;2021</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">U.S. statutory rate	</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210519__20211231_zvAEFFR1mmE9"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20210519__20211231_zJNBV3IR6BKi" title="Change in valuation allowance"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2021-05-19to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A6_z4xkcaHEgW25" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 98 -->
    <div id="xdx_237_zV73CCowHCPf" style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_z0gdIDBcu2va" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div id="xdx_234_zaoT3zPp2UBg" style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td id="xdx_236_z40LgvwPjXna" style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zl7LBKoBlJlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zq1WWqG5viDk" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">MANA CAPITAL ACQUISITION CORP.</p></ix:exclude>

<ix:exclude><p id="xdx_232_zpqgc7TmGac3" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTES TO FINANCIAL STATEMENTS</p></ix:exclude>

<ix:exclude><p id="xdx_238_ztyGqX0ltmg7" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the period from May 19, 2021 (Inception) through
December 31, 2021</p></ix:exclude>


<ix:exclude><p id="xdx_23A_zayoQWOfrHOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zCSdKAwuW331" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s net deferred tax assets were as
follows as of December 31, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxalLigrK1ld" summary="xdx: Disclosure - INCOME TAXES (Details 2)" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B0_z5Ff5TdsJvk5" style="display: none">Schedule of deferred income tax assets</span></td><td>&nbsp;</td>
    <td colspan="3" id="xdx_49D_20211231_zR1ZvY36jNYc" style="text-align: center">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zCAUwAT0BDb4" style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets:</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_z9L4Vz5jFjXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left; padding-bottom: 1pt; padding-left: 6pt">Net operating loss carryover</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,416</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsGross_iI_zvZiDTKfAkr3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,416</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zYKaIX7C7l56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,416</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsNet_iI_zCVrETB336j4" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Deferred tax asset, net of allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2021-12-31" id="fact-identifier-287" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0573" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A2_zBHHD9d1L0th" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">As of December 31, 2021, the Company had $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zJJlw5vELwHh" title="Net operating loss carryovers"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-288" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,837</ix:nonfraction></span></span>
of U.S. federal net operating loss carryovers available to offset future taxable income which do not expire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In assessing the realization of deferred tax assets,
management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The
ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary
differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax
assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information
available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has
therefore established a full valuation allowance.</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>&nbsp;</b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:EarningsPerShareTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80B_eus-gaap--EarningsPerShareTextBlock_zf64IBo1Oqn1" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 10 — <span id="xdx_824_zzEXjt9hZBGi">NET INCOME (LOSS) PER
SHARE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The net income (loss) per
share presented in the audited statement of operations is based on the following:</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-290" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zTAFCAH6Kcx" summary="xdx: Disclosure - NET INCOME (LOSS) PER SHARE (Details 1)" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_ztXOr7jsH5Dh" style="display: none">Schedule of basic and diluted net loss per share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" id="xdx_493_20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zbX8s3VCc4W4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" id="xdx_49D_20210519__20211231__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableCommonStockMember_zfHfbrtoj3zd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For&nbsp;the&nbsp;Period&nbsp;From</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">May 19, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(inception) through</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,&nbsp;2021</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common</td><td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zjKH9mWjktzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 66%">&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted net income/(loss) per share:</td><td style="width: 1%">&nbsp;</td>
    <td style="text-align: left; width: 1%">&nbsp;</td><td style="text-align: right; width: 14%">&nbsp;</td><td style="text-align: left; width: 1%">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="text-align: left; width: 1%">&nbsp;</td><td style="text-align: right; width: 14%">&nbsp;</td><td style="text-align: left; width: 1%">&nbsp;</td></tr>
  <tr id="xdx_40F_ecustom--Numerators_zJBI5Or80a3k" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;Numerators:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--TemporaryEquityNetIncome_zo3okCHtdBm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;&nbsp;&nbsp;&nbsp;Net
    income/(loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction name="us-gaap:TemporaryEquityNetIncome" contextref="From2021-05-192021-12-31_custom_RedeemableCommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-291" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,837</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction name="us-gaap:TemporaryEquityNetIncome" contextref="From2021-05-192021-12-31_custom_NonRedeemableCommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-292" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,837</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--Denominators_zeynY4JZuBI5" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;Denominators:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zNL3A8xVwmb6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;&nbsp;&nbsp;&nbsp;Weighted-average shares&nbsp;outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextref="From2021-05-192021-12-31_custom_RedeemableCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,001,327</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextref="From2021-05-192021-12-31_custom_NonRedeemableCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,560,288</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_ecustom--EarningsPerSharesBasicAndDiluted_zSD0ONbOK2Fe" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted net income/(loss) per share</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction name="MAAQ:EarningsPerSharesBasicAndDiluted" contextref="From2021-05-192021-12-31_custom_RedeemableCommonStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.14</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction name="MAAQ:EarningsPerSharesBasicAndDiluted" contextref="From2021-05-192021-12-31_custom_NonRedeemableCommonStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.09</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A5_z1ewr2WNVRwl" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-05-19to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-297" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zR33EIkXgfij" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><b>NOTE 11 — <span id="xdx_82A_zCnALIJ1R9Qe">SUBSEQUENT
EVENTS</span></b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company evaluated subsequent events
and transactions that occurred after the balance sheet date through the date that the financial statement was available to be issued.
Based upon this review, except as noted above, the Company did not identify any other subsequent events that would have required adjustment
or disclosure in the financial statements.</p>

</ix:nonnumeric></span><p id="xdx_815_zf7shjcqMwCk" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 99 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font-size: 9pt; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Gray 2pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></p>

<p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->

</body>
</html>